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Foreword
Cocaine is currently the drug of greatest national concern, from a
public health point of view, and of particularly high interest from
the research and scientific point of view.
The public health concern derives from the following sources: It
has shown the highest continuing rate of increase in DAWN mentions
(emergency room visits), overdose deaths, and serious clinical
problems, despite a leveling of national prevalence since 1980.
Animal studies show it to be one of the most potent reinforcers
available. It is the one drug most easily and universally accepted
in animal self-administration studies without prior induction
training, and is widely used to shape animal behavior for the
self-administration of other reinforcing drugs. It has one of the
highest reinforcing potentials as measured by breaking point
studies, and is the drug which animals, with unlimited access, are
most likely to select repeatedly in preference to food and water to
the point of death. These preclinical observations and related
clinical data lead to the conclusion that the prospect of
substantial increases in available supply and decreases in price
constitutes a major and growing public health danger.
We are still uncertain as to whether the leveling off in overall
national prevalence, which as shown by our two major national
surveys occurred for cocaine between 1979 and 1982, has continued
since then. If so, the increase in medical complications,
addiction, and clinical problems described above would represent a
higher percentage of a constant total pool of users running into
serious problems. This interpretation is consistent with studies
showing that an average of 4 to 5 years elapses between first use of
cocaine and the need for treatment, and other studies showing that
the best predictor of cocaine use is heavy, early marijuana use.
The current upsurge in public health related cocaine problems would
then be the predictable second stage of the peak of marijuana use
which we saw in this country in the late 1970s. An alternative
possibility is that greatly increased availability of this most
reinforcing illicit drug has broken through powerful cultural and
demographic barriers and begun to lead to a substantial increase in
the number of users and/or intensified patterns of use. Evidence
for this latter alternative may only become evident in future
national surveys.
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In any event, while we await further clarification of the exact
nature of current trends in cocaine use, there is an urgent need for
a rapid increase in information on mechanisms of brain action,
treatment methods, health consequences, and prevention strategies.
This monograph makes an important contribution towards planning
future research by reviewing our knowledge base.
Charles R. Schuster, Ph.D.
Director
National Institute on Drug Abuse
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Cocaine 1984: Introduction
and Overview
John Grabowski
INTRODUCTION
Diverse aspects of cocaine pharmacology, use, and effects
have been discussed at length in both the lay press and the
scientific literature. Research involving cocaine has a
long, interesting history which has been described at
intervals, and this volume provides a current review of
present knowledge concerning the drug. Dramatic increases
in use in the past decade, increasing evidence of untoward
consequences of use, and resultant public health concerns
also set the stage for a timely and thorough review of
scientific and clinical issues concerning cocaine.
Cocaine is an alkaloidal agent and is derived from the plant
Erythroxylon coca and other Erythroxylon species in South
America. Its multiple behavioral effects constitute those
of the prototypic "stimulant" (with all the caveats
pertaining to such loose categorizations). The drug is,
thus, viewed in the context of amphetamines, caffeine, khat,
and a variety of more recently developed synthetic agents.
Cocaine, in the leaf form or as the extracted substance, has
been used for different purposes, with varying restrictions,
in different cultures. Paralleling the accepted medical and
cultural uses has been a history of abuse of the drug.
There is, as a result, ample evidence that cocaine abuse can
have debilitating physical and behavioral-psychological
consequences. Since not all users exhibit these symptoms,
however, some have assumed that it is inherently safe. As
with all drugs, this is an unwarranted assumption, since
definable dose-related hazards exist. Thus, there is
considerable interest in delineating the drug's
characteristics in terms of abuse. Investigation of this
and related drugs is also extremely important because of
fundamental scientific issues concerning its neurochemical,
pharmacological, and behavioral spectra of action.
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OVERVIEW OF MONOGRAPH
This monograph was developed with emphasis on major areas of
scientific and clinical interest. Thus, the topics range
from postulated neurochemical mechanisms of action, through
analysis of behavioral effects and patterns of use, to
review of therapeutic strategies.
There has been a dramatic resurgence of cocaine use in the
last decade. Adams and Durell address this issue and
provide a brief overview of the epidemiological sources by
which trends have been followed. In particular, they note
substantial increases in medical examiner and emergency room
"mentions" of cocaine use which strongly indicate a change
to patterns of use with more hazardous consequences. In the
past, cocaine use among so called "street" heroin users was
not common, but was observed. More publicity concerning use
has accrued to upper socioeconomic status users. However,
as Adams and Durell note, the drug is now used, and untoward
consequences of use have been observed in individuals across
all socioeconomic groups. It is in this context of a major
public health concern and important area of scientific and
therapeutic inquiry that the present monograph arises.
A cogent and timely review of one perspective on cocaine s
neurochemical mechanisms of action is provided by Wise. In
the last decade, inroads have been made in delineating
chemical and structural foci at which drugs have their
effects. Major breakthroughs were made in identifying the
mechanisms by which opiates act at specific "receptors."
This, in turn, led to the search for specific sites at which
benzodiazepines and other agents including cocaine act.
There was, and is, a need to identify integrated neuronal
pathways mediating the complex interacting events of
behavior, drug action, neural function itself, and
environmental conditions. Since drugs constitute but one of
many items serving to reinforce and strengthen behavior,
there is a further need to relate the mechanisms of their
reinforcing properties to those of other events and
conditions (food, water, etc.).
Wise and many other scientists have pursued this line of
inquiry, and these efforts are reviewed. Differing
viewpoints on the specifics of both the relative
contribution of various neurochemical systems and/or neural
pathways do exist in the scientific literature. Wise notes
the interactions in areas of scientific research which have
contributed to our enhanced understanding of brain function
and reinforcement, including that derived from reports over
several decades describing the effects of electrical brain
stimulation. This research, integrated with the work of
others on neurochemical functions, generated current efforts
to define the mechanisms of drug reinforcement. The
questions which must be pursued are those related to
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examining commonalities and differences in the neural
substrates of reinforcement. As Wise notes, these data will
contribute to vastly improved understanding of behavior and
reinforcement generally, and drug abuse behavior in
particular. The great need for further research in this and
related areas is evident and advances will be forthcoming.
These, in turn, must be related to and integrated with the
data which have accumulated concerning complex
behavioral-psychological and clinical issues. The need for
substantial interdisciplinary research is apparent.
All chapters in this volume refer in one way or another to
the pharmacology of cocaine. Thus, the thrust of the
chapter entitled "The Pharmacology of Cocaine" simply refers
more specifically to issues of absorption, drug onset,
distribution of the drug in the body, metabolism, and
excretion. Jones has provided an overview of the cocaine
literature in the discipline of pharmacology, including
discussions of central nervous system (in this case, EEG)
effects and physiological function. The need to understand
fully how drugs alter physiological functions, are absorbed,
distributed, metabolized, and excreted by the body is
clear. Other important pharmacological issues are
addressed, including those concerning both theoretical and
practical questions on tolerance and dependence. Tolerance
has been clearly demonstrated and, as Jones notes,
dependence with respect to physiological systems may well be
related to dosing and duration of action. In any case,
presence or absence of physiological dependence is
irrelevant in terms of potential hazards of compulsive
administration. While the issue is of great scientific
interest, many of the discussions which have arisen involve
definitional problems rather than scientific questions.
From a scientific perspective, it is important to note that
many of the related questions are similar or identical to
those concerning other drugs. In addition to tolerance and
dependence, questions concerning toxicity and route of
administration can be discussed reasonably based on Jones'
review and presentation of data.
An important bridge between understanding the specific
neurochemical and general pharmacologic characteristics of
an abused agent and the observation of use in the "real
world" emanates from tightly controlled laboratory
experiments of behavioral effects. Without such efforts
linking the specifics of action within the body and
behavioral effects, it would be impossible to describe
accurately mechanisms of the therapeutic effects of a drug
or the basis for compulsive drug use. Depending on specific
scientific questions, the research may proceed with either
nonhuman or human subjects. The results of a decade or more
of research to determine precisely the behavioral
pharmacology of cocaine in the animal laboratory are
reviewed by Johanson. Attention is given to those questions
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which can only be reasonably and objectively examined using
nonhuman subjects. The model described permits precise
specification of features of the reinforcing effectiveness
and inferred "abuse liability" of cocaine. The mechanisms
and character of behaviorally toxic effects are similarly
examined. Data on toxicity resulting from this model point
to an important distinction: Pharmacologic studies can
provide clear indications of physiologic effect as a
consequence of increasing doses. It has become apparent
through research on effects of drugs of abuse, however, that
collateral untoward behavioral consequences (or trends
suggesting their impending emergence) may appear long before
physiologic damage is evident. Indeed, behavioral
disruption may be evident at doses below those which would
lead to physiologic toxicity.
Based on the data reviewed by Johanson which describe the
nature and generality of cocaine administration across
species and disparate environmental conditions, general
statements can be made about likely patterns and
consequences of chronic human use, but always with
appropriate scientific caution and awareness of their
limitations. The dose-related toxic behavioral consequences
observed in research with nonhuman subjects are well
summarized, ranging from stereotypic behavior to anorexia
characteristic of stimulant drugs. Also reviewed are the
necessary comparisons with other drugs which are always
essential in placing in perspective the behavioral effects
of an agent.
Some scientific questions concerning behavioral-pharmacolo-
gical issues are better resolved using human subjects in
laboratory settings. The complexities are numerous, but
these efforts provide unique information which would not
otherwise be obtained, They help to bridge the gaps between
studies founded in neurochemistry, pharmacology,
behavioral pharmacologic or clinical research, and
observations in the natural environment.
Fischman has reviewed the spectrum of available data on
cocaine administration in humans under controlled
conditions. In the human laboratory, the opportunity exists
to study the pharmacologic characteristics, physiologic
effects, basic behavioral indicants of reinforcing
effectiveness, and other drug response and related these to
both results of animal laboratory research and patterns of
use and abuse in the natural environment. Thus, as Fischman
notes, reports of cardiovascular responses to cocaine and
the evolution of tolerance are similar in nonhuman primates
and in humans. Such cross-validation and determinations of
generalizability of effects are important.
Measuring these responses in relation to subjective effects
is likewise important, In particular, specifically relating
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these subjective effects to the route of administration in a
laboratory setting provides clearer understanding of the
effects which are likely to be observed in the natural
environment. Thus, this review of the work of numerous
Investigators permits reasonable statements about the
probability and character of abuse and the subjective
effects of cocaine as a consequence of different
administration routes. Precision can also be observed in
defining the character of tolerance and dependence.
Similarly, analysis of the effects of drugs on human
performance is clearly important. These effects depend on
complex interactions between dosage, environmental
conditions and the task at hand.
The relationship between effects of cocaine and other drugs
commonly self-administered by humans is likewise of
considerable interest. The similarities as well as
differences between a range of "stimulants" and other local
anesthetics are, thus, discussed. The significance of these
issues resides not only in the determination of behavioral
and pharmacologic mechanisms of action, but in the practical
public health issue that "substances" obtained illegally are
often composites of various drugs with differing actions.
An extensive laboratory literature on effects of cocaine is
evolving, as are epidemiological data bases and clinical
efforts. Siegel reviews an area in which limited data are
available and relates this to other issues surrounding
cocaine use. Reports of use obtained through careful
repeated interviews can be related to both specific
laboratory research as described by Jones, Johanson, and
Fischman, and clinical research reviewed by Kleber and
Gawin. Thus, Siegel cites the limited number of reports
concerning perceptions about cocaine and reported effects in
chronic, but moderate users. More important, Siegel
describes patterns of use, abuse, and abstinence by a group
of individuals over time. These unique data provide
important insights into the evolution of both problematic
use and cessation along with symptomatology that emerges at
different points among users in the natural environment. In
particular, the information supports laboratory-based
predictions concerning dosage and routes of administration.
These data also provide a basis from which the clinician can
retrospectively interpret or evaluate the patterns of use
resulting in a patient's entering treatment.
Of considerable importance are the data indicating that
differing dosages are likely to be self-administered via
different routes. Reports indicating that, over extended
periods, users might not only increase dosage but might have
periods of abstinence, point to the importance of long-term
followups when evaluating treatment. That is, cessation
during treatment may be temporary, just as it would be if
initiated independently of formal treatment. This
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observation coincides with much that is known about other
drug use ranging from tobacco to opiates. That different
users explicitly use the drug for different purposes (e.g.,
social vs. work), suggests that when a cocaine user appears
for treatment, rather different stategies may be required in
reestablishing nondrug-oriented behavioral repertoires.
Data presented on both chronic effects and toxic responses
clearly enhance our understanding of these phenomena and, in
this case, do so in the context of regular users of the
drug. Equally important has been the fact that the review
suggests the possibility of predictively separating the
probability of dysfunction in relation to conditions
correlated with use.
One response of treatment of drug abuse, including cocaine
(Crowley 1983) and its correlated problems, has been
extensively discussed in another recent NIDA monograph
(Grabowski et al. 1983). In the present monograph, Kleber
and Gawin provide a thorough review of both the literature
and concepts underlying potential therapeutic approaches.
The authors provide important clinical background
information on both diagnostics and symptomatology. In
addition, they discuss, from a somewhat different
perspective, the severity of consequences of different forms
and patterns of use. Severity of problems is also viewed in
the extended framework ranging from neurochemical to
socioeconomic issues. The importance of this wide-ranging
perspective in drug abuse treatment is clear, and the
authors provide cogent indications of the need. Kleber and
Gawin note the long history of efforts to treat cocaine
abuse and, in so doing, provide a background for the diverse
strategies currently available. Again, the need for
integrated behavioral-psychiatric and pharmacological
strategies is emphasized. They note the importance of
emphasizing basic treatment components and, thereby, point
to the fact that cocaine abuse has elements in common with
other drug abuse. In particular, it is explicitly noted
that, as with other drugs, the user must, because of
behavioral environmental interactions, spend "drug-free"
time in the environment in which drug abuse occurs or
relapse is probable. They also point to the advantages and
disadvantages of various currently available treatment
approaches.
Perhaps most important in the review is attention to the
possibility of different generative conditions leading to
patterns of abuse. While attending to a range of social and
environmental features, reports are cited suggesting a
quasi-therapeutic, albeit ineffective, element which may be
inherent in some cases of escalating cocaine use. That is,
some users may be pursuing self-medication of depression
predating cocaine use which is, in turn, exacerbated by the
cycles of use. Plausible neurochemical bases for this view
are proffered. In addition, the authors provide salient
6
reviews of pertinent literature on pharmacological adjuncts
in the treatment of cocaine abuse. Again, the important
focus of this review is its emphasis on the need for
integrated therapeutic approaches and, of perhaps greater
importance, the need for integrated interdisciplinary
perspectives on clinical research in the area.
ISSUES AND QUESTIONS OF SPECIAL INTEREST
Two superordinate categories of questions arise concerning
cocaine. One is defined in terms of use, abuse, and
correlated social and clinical issues. The other involves
numerous scientific, theoretical and technical issues not
directly linked to the issue of abuse. Overlap necessarily
exists and, in some cases, it is simply the framing of the
question which contributes to an apparent difference. In
fact, the scientific issues concerning mechanisms of action
ultimately have relevance to the clinical concerns.
Similarly, the questions raised in the clinical environment
often contribute to the formulation of questions addressed
in laboratory research. Issues of both categories are
discussed in this volume, and it is apparent that there is a
wealth of knowledge concerning cocaine. There are,
nevertheless, numerous questions which remain to be
answered.
Dominant issues of public interest are addressed throughout
this volume and in the abundant scientific literature.
Specific discussion of these issues can be found elsewhere
(e.g., Van Dyke and Byck 1982; Grabowski and Dworkin 1984).
It is, thus, sufficient to note here that the most commonly
raised questions of public interest are those concerning
routes of administration (e.g., nasal vs. inhalation),
dosage forms or related issues (e.g., cocaine base vs.
hydrochloride), dosage administered acutely and chronically,
risks, drug interactions (e.g., cocaine and heroin),
predisposition to use the drug, and treatment. One issue
not raised in the lay press, but of potential public health
interest, is that concerning coca paste. This product,
while not used in the United States, is widely used in South
American countries where coca is prevalent. Coca paste is a
contaminated intermediate product of the cocaine extraction
process which has specific health hazards associated with
its inhalation through smoking (Jeri 1980: Hawks, personal
communication).
A reasonable comparative perspective indicates that our
knowledge of cocaine and its effects is considerable. Some
questions raised in the past globally, the research issues
of significance with respect to cocaine specifically and
stimulants generally include: (1) analysis of relationships
between neurochemical mechanisms, behavioral mechanisms, and
interactions with environmental determinants of effects;
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(2) delineation of subjective effects and human performance
with emphasis on interactions with other drugs;
development of optimal combined pharmacological-behavioral
treatment strategies; and, (4) developing epidemiological
techniques for examining drug use trends and patterns which
reside outside the current drug treatment and medical
networks. Finally, given that much is known about this
agent and much data will result from ongoing research,
cocaine is an important pharmacological tool and metric for
analysis of other complex psychopharmacologic and
sociopharmacologic phenomena.
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Cocaine: A Growing Public
Health Problem
Edgar H. Adams and Jack Durell
This monograph, reviewing the pharmacology, behavioral effects, and
the treatment of cocaine abuse, appears at a time of intensifying
concern regarding what appears to be an epidemic of serious adverse
consequences. This chapter outlines some of the epidemiologic data
which describe the rise in cocaine use over the past several years.
These issues will be further elaborated in a future monograph which
will be based on a NIDA-sponsored scientific review held in July
1984.
Cocaine abuse has grown from a relatively minor problem 15 years ago
to a major public health threat today. Oral ingestion of cocaine
was widespread in the late 19th and early 20th centuries when it was
an ingredient in many patent medicines, tonics, and soft drinks.
Following the passage of the Harrison Narcotic Act in 1914 and the
Narcotic Drugs Import and Export Act in 1922, its use began to
decline; between the 1930s and the late 196Os, cocaine had all but
disappeared from the American scene. The second report from the
National Commission on Marihuana and Drug Abuse in 1973 stated that
little social cost related to cocaine had been verified in this
country (National Commission 1973). At the same time, the Strategy
Council on Drug Abuse stated that the morbidity associated with
cocaine use did not appear to be great. They further stated that
there virtually were no confirmed cocaine overdose deaths and that a
negligible number of users seek medical help or seek the kinds of
treatment offered by specialized drug treatment programs (Strategy
Council 1973).
Unfortunately, these low rates of actual abuse led the general
public, as well as many drug experts, to conclude that cocaine was a
safe drug. It was not generally recognized that cocaine has a high
abuse potential and that under conditions of greater accessibility
of cocaine, much more serious patterns of abuse would become
evident. This possibility was recognized by a few clinicians and
was clearly enunciated by Drs. Donald R. Wesson and David E. Smith
who in the 1977 NIDA monograph on cocaine concluded:
However, if the drug were more readily available at a
substantially lower cost, or if certain socio-cultural
rituals endorsed and supported the higher dose patterns,
more destructive patterns of abuse could develop. (p. 150)
Their conclusion was prophetic.
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The situation now is vastly different. The adverse consequences of
cocaine abuse are abundantly evident, both as reflected in the
popular media and in those statistical data sets that are
available. Both the print media and television are replete with
reported cases of compulsive use which have resulted in wrecked
lives and fortunes. Many cocaine victims have been rich and
famous--many have not! The statistical data sets, on the other
hand, provide us with some aspect of the overall dimensions of the
problem. Unfortunately, there are gaps in our data which make it
impossible to make precise statements about the full extent of
cocaine abuse and dependence.
The data from the National Household Survey indicate that the
prevalence of cocaine use rose dramatically during the middle and
late seventies. This change is exemplified by the following:
1. The number of people who had tried cocaine at least once
had increased from 5.4 million in 1974 to 21.6 million in
1982 (NIDA 1983).
2. The number of current users of cocaine rose from 1.6
million in 1977 to 4.2 million in 1982 (Blanken et al. in
press).
While the most recent surveys of prevalence of use indicate that
trends have leveled off, at least among those under 26, the impact
of the dramatic increases of the late 1970s is becoming more and
more visible as both demand for treatment of dependence and medical
crises associated with cocaine use increase. For example, "There
was more than a threefold increase in the rate of cocaine-related
(medical) emergencies (from 0.7 to 2.3/10,000 emergencies) and the
rate of cocaine-related deaths per 10,000 medical examiner reports
(from 4.5 to 19.1/10,000 deaths) between 1976 and 1980-1981" (Kozel
et al. 1982). Over the same time period, the proportion of drug
treatment program admissions with cocaine as their primary drug
problem increased from 1.2 percent to 5.8 percent. More recent data
indicate that these increasing trends have continued unabated. For
example, cocaine accounted for almost 9 percent of the treatment
admissions reported to NIDA in 1983.
Data on adverse health consequences are reflected by hospital
emergency room visits and medical examiner cases as collected by
NIDA through the Drug Abuse Warning Network (DAWN). Data on
admissions to treatment were collected through the Client Oriented
Data Acquisition Process (CODAP) which was the national reporting
system through 1981 and during most of 1982.
Previous reports have indicated that emergency room admissions
associated with cocaine use increased approximately three and
one-half times between 1976 and 1981. More recent data, based on a
subset of DAWN emergency rooms that have reported consistently since
1981, indicate that this upward trend continues. Since 1981 through
the fourth quarter of 1983, emergency room mentions for cocaine have
increased by 75 percent. Early data for 1984 indicate that
approximately 2,000 cocaine mentions were recorded for the first
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quarter of 1984. This is remarkable in that it equals the cocaine
mentions for the entire year of 1978.
Other changes that have occurred between 1978 and 1982 are
consistent with the aging of the abusing population. In 1978, 21
percent of the emergency room admissions were over 30, while in
1982, 41 percent were age 30 or over (Blanken et al. in press).
Perhaps indicating more chronic use, 52 percent of emergency room
admissions for cocaine in 1982 indicated dependence vs. 44 percent
in 1978. There has also been an increase in the intravenous use of
cocaine and the use of cocaine in combination with other drugs. For
example, in 1978, 57 percent of the cocaine mentions were in
combination with other drugs, while in 1982, 71 percent were in
combination (Blanken et al. in press). As cocaine has become more
available, the practice of speedballing, the combination of heroin
and cocaine, has increased. In 1979, speedballing mentions
accounted for approximately 17 percent of the cocaine mentions in
DAWN, whereas in 1983, speedballing accounted for more than 25
percent of the mentions.
Similar to the DAWN trends, CODAP admissions have also shown marked
increases over the past several years. In 1977, primary cocaine
admissions accounted for 1.8 percent of all admissions to CODAP.
while in 1981 they accounted for 5.8 percent (NIDA 1978,1982).
This further increased to 7 percent of admissions in 1982 and, as
previously mentioned, to 9 percent in 1983. The increase in cocaine
admissions is even more striking if admissions for other than for
primary use are included. For example, admissions for speedballing
generally record heroin as primary and cocaine as secondary. When
both primary and secondary admissions are included, cocaine was
abused by over 17 percent of all admissions in 1981. This
represents in excess of 42,000 people admitted for some problem with
cocaine. We know that this is an underestimate, since there are
many admissions of cocaine abusers to private drug treatment units
and to alcoholism treatment units that are not reflected in CODAP
data. Since cocaine is used extensively by the higher
socio-economic group, seriously undersampled in the CODAP data, the
extent of the underestimate may be quite large. The more recent
situation is even worse in estimating the demand for treatment in
that CODAP data are no longer collected on a national basis.
As with the DAWN statistics, CODAP admissions presented multiple
drug problems; 82 percent of all primary cocaine admissions in 1982
reported having at least a secondary drug problem. The order of
frequency in the secondary drug problems was marijuana, alcohol, and
heroin. This is the reverse of the order of the frequency of
combinations reported in DAWN, where heroin, alcohol, and marijuana
were the most cited combinations with cocaine. Of course, DAWN data
would be expected to reflect combinations that are more likely to
eventuate in acute medical crisis.
Of particular concern has been the tendency of users to shift from
snorting cocaine to other routes of administration. In several
reports, an increase in the intravenous administration of cocaine,
as well as free basing (smoking) has been noted (Kozel et al. 1982;
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Adams 1982a; Blanken et al. in press). The 1982 CODAP data indicate
a dramatic increase in free basing of cocaine from 1 percent of
admissions in 1979 to almost 7 percent in 1982. These changes are
important because of the reports that either free basing or
intravenous injection of cocaine may lead more readily to intensive
use and compulsive drug-seeking behavior (Van Dyke and Byck 1982).
An analysis of CODAP data by frequency of use and route of
administration does, in fact, indicate that both intravenous
administration and free basing or smoking of cocaine more frequently
lead to daily use than does inhalation (Adams 1982b). In
recognizing this pattern, however, it should not be forgotten that
inhalation (snorting) still accounts for almost 60 percent of all
admissions for cocaine problems and that compulsive use has been
reported among those who limit their use to the intranasal route.
Furthermore, recent evidence suggests that intranasal administration
is not without its medical consequences. Recently, a case of
myocardial infarction in an otherwise healthy 21-year-old male was
reported after intranasal administration of 0.25 gram of cocaine
(Schachne et al. 1984). This raises the possibility that cocaine,
which has a direct effect on catecholamines, may in fact be a
cardiovascular risk factor in some individuals.
In May 1983, a private treatment unit opened a toll-free telephone
hotline offering advice to cocaine abusers. The number of callers
was a surprise. In the 18 months since the service began, over
450,000 calls, sometimes as many as 1,000 per day, have been
received. Hotline staff have conducted 20-40 minute telephone
interviews on several samples of the callers. Though there is much
uncertainty regarding the representativeness of the sample and the
validity of the telephone interview, the technique has provided a
rich data source regarding self-reported cocaine abusers. Several
findings (Gold and Washington 1984) are of particular interest:
(1) Sixty-one percent of callers used primarily the intranasal
route and they reported patterns and consequences of cocaine
use comparable to those free-basing (21%) and using IV (18%).
(2) From 66% to 83% reported addictive patterns of use including
loss of control over use (75%) and inability to stop using in
spite of repeated attempts (67%).
(3) Over 90% reported adverse physical, psychological and
consequences associated with its use.
In summary, a wealth of data based on mortality statistics,
emergency room admissions, treatment admissions, and calls to the
national toll-free cocaine hotline indicate that we are in the midst
of an epidemic of adverse consequences of cocaine abuse with no
indication of any abatement in the rising tide. Moreover, there is
evidence that the cost of cocaine is diminishing and the supply is
increasing. This was first seen at the wholesale level and is now
being seen on the retail level. Since the high cost of cocaine has
been a barrier that helped to prevent many users from compulsive,
uncontrolled use, the decrease in cost increases the possibility
12
that compulsive use will increase. Indeed, there is reason to be
concerned about the possibility of increased use by adolescents and
young adults, age groups that have not as yet developed a widespread
problem with cocaine.
One example of the spread of cocaine use in a population in which it
is not thought to be predominant is reflected by a study of arrest-
ees in a police initiative aimed at drug-related offenses in East
Harlem (Wish et al. 1984). Urine samples, obtained from 84 percent
of a sample of arrestees, were 87 percent drug positive. Of the
positive urines, 79 percent were positive for cocaine vs. 58 percent
for opiates. In this street population, cocaine use was prevalent
over opiate use in all age groups. Furthermore, 46 percent of the
sample reported that they had been dependent on cocaine for some
time vs. 24 percent for heroin. These findings, while they are a
small sample, suggest that cocaine is prevalent among street drug
users and is not the sole preserve of the affluent.
Though previous upsurges in stimulant use have tended to be passing
fads, the current epidemic is unprecedented. Increased production
and profits have resulted in a growing illicit industry with a
vested interest in sustaining, and even increasing, cocaine use.
The one hopeful fact is that prevalence of use appears to have
leveled off. If that is so, the current continuing increase in
adverse consequences may be the result of the reported lag,
averaging about 4 years, between the onset of cocaine use and
entrance into treatment and also of an increase in the occurrence of
intensified patterns of use. Thus, the residual effects of the
epidemic and continuing effects of endemic levels of use may be seen
for some time. Perhaps increased public knowledge of cocaine's
dangers will contribute to a decrease in its use. For the moment,
however, if prices continue to decline, there is ample reason to
fear even more widespread use of cocaine.
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Neural Mechanisms of the
Reinforcing Action of Cocaine
Roy A. Wise
Cocaine shares with a number of drugs the property of strong abuse
potential. In attempting to understand abuse potential it is use-
ful to consider the factors in common and the factors not in common
between cocaine and other abused drugs; every drug has multiple
effects, and only those effects shared by the variety of abused
drugs are likely to account for abuse liability. Cocaine is, over
most of its effective dose range, a psychomotor stimulant; it
shares this property with amphetamine but not, over most of their
effective dose ranges, with opiates, barbiturates, benzodiazepines,
or ethanol. Cocaine does not share the physical dependence-produc-
ing property of the sedative hypnotics. Cocaine has local anes-
thetic properties which are not shared with the other major classes
of drugs of abuse; other local anesthetics, while sometimes self-
administered, are not significantly or knowingly abused by man.
These drug actions, then, would not seem to provide likely explana-
tions for the development of compulsive drug intake which can de-
velop across the variety of abused agents.
What cocaine does share with opiates, barbiturates, benzodiaze-
pines, and ethanol is a rewarding or "reinforcing" property. When
behavioral acts are regularly followed by intravenous, or, in some
cases, oral, administration of drugs in these classes, such behav-
ioral acts become more and more frequently repeated. Of the habit-
forming drugs, cocaine and heroin stand out as perhaps the most
powerful reinforcers as defined by the rapidity of acquisition of
self-administration. Thus the property shared by cocaine, a stim-
ulant, and other drugs of abuse, primarily depressants, is the
quality of reinforcement. In the attempt to understand the neural
mechanisms underlying the abuse liability of cocaine and other
drugs one important place to start is with brain structures impli-
cated in the process of reinforcement.
For a number of reasons it is believed, first, that the brain has
specialized neural circuits that are activated by the various rein-
forcers capable of influencing behavior (Olds 1962), and, second,
that the activation of these circuits is necessary for natural re-
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inforcers to be effective (Wise 1982). Just as it proved reason-
able to assume that opiate receptors did not evolve only to serve
the need of modern man for synthetic analgesics, so is it reason-
able to assume that the neural substrates of drugs of abuse did not
evolve only to serve our nonmedical impulses. Analgesics suppress
pain by centrally activating endogenous pain control circuits
(Mayer and Price 1976; Basbaum and Fields 1978); similarly, we
might expect drugs of abuse to be reinforcing by centrally activat-
ing endogenous reward circuits (Olds and Travis 1960; C.D. Wise
and Stein 1970; Belluzzi and Stein 1977). It is from this per-
spective that students of drug abuse might hope to benefit from the
study of reward circuits in the brain.
The notion that cocaine and amphetamine can centrally activate nat-
ural reward mechanisms and that they owe their reinforcing action
to such activation (C.D. Wise and Stein 1970) is consistent with
the fact that these agents have the traditional properties of con-
ventional reinforcers (Johanson 1978). If animals are reinforced
with amphetamine or cocaine on fixed or variable ratio schedules or
fixed or variable interval schedules, the patterns of responding
seen are similar to those characteristic patterns which would be
established with the same reinforcement schedules in an operant
chamber delivering food or at a slot machine delivering silver
dollars. Amphetamine reinforcement also shares several of the
characteristics of reinforcement by electrical stimulation of the
brain (Pickens and Harris 1968). In both cases responding is sus-
tained for long periods of time, with occasional periods of abstin-
ence that are unpredictable as to onset and duration. In both cases
the rate of responding is regular, depending on the parameters of
reinforcement and on the response demands of the task, but not
depending on the length of preceding abstinence periods. In both
cases voluntary abstinence periods can be terminated by the experi-
menter if unearned reinforcement or "priming" is given. In both
cases the central reinforcer can be more powerful than more "natural"
reinforcers, even in cases of acute need; access to psychomotor
stimulant reinforcement (Pickens and Harris 1968) or to electrical
brain stimulation reinforcement (Routtenberg 1964) can cause self-
starvation to the point of severe weight loss.
Our present understanding of neural mechanisms of reinforcement
began with the discovery that rats would work for electrical stim-
ulation of some but not all portions of their own brains (Olds and
Milner 1954). Early studies followed two major directions: anatom-
ical mapping (Olds and Olds 1963) and pharmacological challenge
(Olds and Travis 1960). The mapping studies exploited the relative
anatomical selectivity of brain stimulation and generated hypoth-
eses as to what anatomical circuitry might participate in reward
function (Olds 1962). The pharmacological studies soon implicated
catecholamine systems as likely links in reward circuitry, and the
study of psychomotor stimulant reward became a useful adjunct to
brain stimulation (Baxter et al. 1974; Yokel and Wise 1975; Davis
and Smith 1977), since stimulants activate catecholamine systems
with a degree of neurochemical selectivity that the anatomically
selective brain stimulation lacks. Recently it has proven pos-
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sible to train animals to work for reasonably localized central
injections of drugs; with this approach it is possible to activate
reward circuits with useful degrees of both anatomical and neuro-
chemical selectivity (Bozarth 1983). Current evidence from studies
involving these techniques suggests the view that different drugs
and even drugs of different classes may activate common reward
circuitry of the brain--reward circuitry essential for the rewarding
impact not only of drugs of abuse but also of food, water, and re-
warding hypothalamic brain stimulation. This evidence on the mech-
anisms of cocaine and opiate reinforcement, evidence on their rela-
tion to the anatomical substrate of opiate physical dependence, and
the implications of this evidence for theories of drug abuse are
the subjects of the present chapter.
SUBSTRATE OF BRAIN STIMULATION REWARD
In the three decades of research on brain stimulation reward three
dozen or so distinct reward sites have been studied (German and
Bowden 1974) . Brain stimulation has been found to be rewarding at
all supra-spinal levels of the central nervous system, though not
in all portions of each level. A major goal of workers in the
field has been to find anatomical common denominators for the
diverse reward sites that have been identified. Olds’ early (1962)
theory of limbic and hypothalamic subsystems has been superseded by
the catecholamine theories of Stein and others (German and Bowden
1974; Fibiger 1978; Wise 1978), and Stein’s early (1962) noradren-
ergic hypothesis has been superseded by the various dopamine hy-
potheses (see Fibiger 1978; Wise 1980, 1981a). Current evidence
now rules out the view that either noradrenergic or dopaminergic
circuits are the primary (directly activated) fibers of brain
stimulation reward (Shizgal et al. 1980a; Gallistel et al. 1981),
and there is currently no viable theory of brain reward mechanisms
which ties together more than a few of the dozens of known reward
sites.
The most frequently studied brain stimulation reward site is the
lateral hypothalamic portion of the medial forebrain bundle. It
now seems clear that rewarding stimulation in this region depends
primarily on the direct activation of descending fibers of passage.
The refractory periods of the directly activated neurons of the
lateral hypothalamus can be estimated by stimulating with trains
of pulse pairs of different inter-pulse intervals. When the
intervals are shorter than the refractory periods of the directly
activated fibers, performance drops precipitously; the critical
interval at which this change occurs indicates the length of the
refractory period for that portion of the directly activated pop
ulation of neurons which plays a role in the behavior. In the case
of lateral hypothalamic self-stimulation, the refractory periods
are short (Yeomans 1979), suggesting that the directly activated
fibers are probably myelinated, and ruling out the possibility
that they are catecholaminergic (Gallistel et al. 1981).
The conduction velocities and direction of conduction of the
reward-relevant fibers of the medial forebrain bundle can also be
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determined. In this case it is necessary to place two electrodes
at different points on the hypothesized path of the reward-relevant
fibers. Pulse pairs are again administered, with one member of
each pair going to each of the two electrodes. When the inter-
pulse interval is long, both pulses are behaviorally effective and
performance is strong; this is usually true whether or not the two
electrodes activate the same fibers. When the second pulse loses
behavioral effectiveness as a result of decreasing the inter-pulse
interval, however, it can be concluded that the electrodes must
lie at different sites along the same continuous fibers (Shizgal
et al. 1980a). With short inter-pulse intervals, stimulation at the
more efferent electrode site effectively cancels the effects of
stimulation at the more afferent site; stimulation at the efferent
site elicits (along with the orthodromic or "normally" conducting
impulse) an antidromic or "backwards" conducting impulse. When
the inter-pulse interval is short, the antidromic impulse collides
with and inactivates the oncoming impulse from the other stimula-
tion site.
When long inter-pulse intervals are used, on the other hand, the
first impulse bypasses the site of the second electrode before the
second pulse is administered, and, if sufficient extra time is
given for membrane recovery, a normal second impulse will be elic-
ited and performance will reflect it. The critical time in this
case is equal to the sum of the time necessary for the first
impulse to travel from the tip of the first to the tip of the sec-
ond electrode (conduction time) , plus the time necessary for the
membrane to recover from the first impulse (refractory period).
In the case of lateral hypothalamic self-stimulation, the critical
fibers extend to the ventral tegmental area, and the conduction
velocities are fast (Shizgal et al. 198Oa; Bielajew and Shizgal
1982), again suggesting that the fibers are probably myelinated
and again ruling out catecholaminergic fibers as the directly
activated substrate (Shizgal et al. 1980a; Bielajew and Shizgal
1982).
The two-electrode preparation used for conduction velocity tests
can also be used to determine the direction of conduction of the
reward-relevant fibers. If stimulation is given through one elec-
trode and tissue is hyperpolarized at the other, stimulation will
be effective only when it is administered at a site efferent to
the hyperpolarization (Kuffler and Vaughan Williams 1953). In the
case of medial forebrain bundle self-stimulation, this test reveals
that at least the major portion of the directly activated reward
system projects caudally from the lateral hypothalamic area to the
ventral tegmental area (Shizgal et al. 1980b).
The descending reward fibers of the medial forebrain bundle ter-
minate in a region sharing the precise dorsal, ventral and lateral,
and the approximate caudal boundaries of the dopaminergic cell
groups of the ventral tegmental area and substantia nigra (Corbett
and Wise 1980; Wise 1981b). Since pharmacological interference with
dopaminergic transmission attenuates the rewarding impact of lat-
eral hypothalamic stimulation (Fouriezos and Wise 1976; Fouriezos
18
et al. 1978; Franklin 1978; Franklin and McCoy 1979; Gallistel et
al. 1982; Zarevics and Setler 1979), it seems likely that the de-
scending fibers make synaptic contact with either the dopaminergic
cells or the terminals of their afferents (both the reward sites
and the terminals of any dopaminergic afferents share the anatom-
ical dispersion of the dopaminergic cells). Opiates and psycho-
motor stimulants both appear to have their effect in this circuitry,
opiates at the level of the dopamine cell bodies and stimulants at
the terminals of the dopaminergic nerve fibers. It is not yet
known which of the efferents of the dopaminergic fiber projections
represent the next link in the reward circuitry, but cells of the
nucleus accumbens are most strongly implicated from studies of
psychomotor stimulant reinforcement.
MECHANISM OF REWARDING ACTION OF COCAINE AND AMPHETAMINE
Several lines of evidence suggest the dopaminergic synapse to be
the site of the rewarding actions of the psychomotor stimulants
cocaine and amphetamine. Amphetamine and cocaine share the abili-
ty to increase transmitter concentrations in both the noradrener-
gic and the dopaminergic synapse, cocaine by blocking the reuptake
mechanism (which usually terminates catecholamine synaptic action)
and amphetamine by blocking reuptake and also by directly causing
or augmenting synaptic catecholamine release (Axelrod 1970;
Carlsson 1970; Heikkila et al. 1975). The rewarding effects of
cocaine and amphetamine are attenuated by nonselective catechol-
amine synthesis and receptor blockade (Pickens et al. 1968; Wilson
and Schuster 1972), and whereas selective blockade of noradren-
ergic synapses alone does not have similar effects, selective
blockade of dopaminergic synapses does (Yokel and Wise 1975, 1976;
Risner and Jones 1976, 1980; deWit and Wise 1977). When low doses
of dopamine antagonists are given, stimulant self-administration
is maintained, but it is maintained at a higher than normal level
of hourly intake (Yokel and Wise 1975; Risner and Jones 1976, 1980;
deWit and Wise 1977). There is no question of response debilitation
from the dopamine antagonism; the animals actually respond more
under dopamine receptor blockade than they would under normal con-
ditions. Rather, it seems clear that dopaminergic antagonism
attenuates the reinforcing effectiveness of the stimulants;
higher than normal concentrations of stimulants are earned before
the animal shows signs of drug satiety.
When higher doses of dopamine antagonists are given, the animals
cease responding for stimulants (Yokel and Wise 1975, 1976; deWit
and Wise 1977). Response cessation is not imnediate, however, and
in the case of the rat, at least, responding is accelerated for an
hour or two before it ceases (Yokel and Wise 1975, 1976; deWit and
Wise 1977). The response acceleration parallels what is seen when
nonrewarding saline is substituted for rewarding amphetamine. This
has been conceptualized as reflecting the "frustration" of respond-
ing in the absence of the expected rewarding payoff (Amsel and
Roussel 1952); descriptively and procedurally it is an extinction-
induced rate increase. The period of response acceleration makes
it clear that the animals are not critically incapacitated by the
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dopaminergic antagonists (even at the time of peak antagonist ac-
tion: Yokel and Wise 1976) and suggests that response cessation re-
sults from an absence or attenuation of the usual reinforcing
impact of the stimulant. With high doses of dopamine antagonists
it appears that the reinforcing efficacy of amphetamine and cocaine
is either eliminated or reduced to levels inadequate to sustain
responding.
That activation of some dopaminergic receptor population accounts
for psychomotor stimulant reinforcement is also consistent with the
fact that apomorphine and piribedil, direct dopamine receptor
agonists, have amphetamine-like rewarding actions in rats and dogs
(Baxter et al. 1974; Risner and Jones 1976; Wise et al. 1976;
Davis and Smith 1977; Yokel and Wise 1978). Clonidine, a nor-
adrenergic receptor agonist, has reinforcing properties at very
low doses, though the behavioral side-effects are more like opiate
effects than like stimulant effects (Davis and Smith 1977). Clon-
idine and methoxamine, another noradrenergic agonist, do not have
amphetamine-like reinforcing properties, as reflected in a number
of tests (Risner and Jones 1976; Yokel and Wise 1978). The rein-
forcing action of apomorphine is not altered by dopamine synthesis
inhibition (Baxter et al. 1976), and thus it is post-synaptic dop-
amine receptors and not dopamine autoreceptors that mediate the
rewarding effect of dopamine agonists (normal dopamine function
would be needed to express effects of apomorphine that were med-
iated at the autoreceptor).
The conclusion derived from animal studies, that the reinforcing
effect of psychomotor stimulants is attenuated by dopamine antago-
nists, is confirmed by human studies. The subjectively rated eupho-
ria produced by intravenous amphetamine is reduced by nonselective
catecholamine antagonists (Jonsson et al. 1971) or by the selective
dopamine antagonist pimozide (Gunne et al. 1972), but it is en-
hanced, if anything, by the selective noradrenaline antagonists
propranolol, phentolamine and phenoxybenzamine (Gunne et al. 1972).
It thus seems clear that of the shared pharmacological actions of
amphetamine and cocaine it is the action in the dopaminergic syn-
apse that is critical to the phenomenon of reinforcement.
Which of the various dopaminergic pathways are implicated? There
are three major anatomical projections of the dopaminergic cells of
the ventral tegmentum: the striatum, the limbic system, and the
cortex. Of these the nucleus accumbens, most frequently treated as
a limbic structure, is most clearly implicated in psychomotor stim-
ulant reinforcement. Neurotoxin-induced lesions of this structure
reduce or eliminate amphetamine and cocaine reinforcement (Roberts
et al. 1977, 1980; Lyness et al. 1979), as do local injections of
dopamine antagonists (Phillips and Broekkamp 1980). Direct injec-
tions of amphetamine into nucleus accumbens are rewarding in their
own right (Monaco et al. 1980). Injections of amphetamine into
the cortex of monkeys are also reported to be reinforcing (Phillips
et al. 1981) as are injections of cocaine into the cortex of rats
(Goeders and Smith 1983); thus there may be more than one dop-
aminergic projection that participates in brain reward circuitry.
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The nucleus accumbens seems particularly important, however, at
least in the rat.
Thus the mechanism of psychomotor stimulant reinforcement and the
mechanism of lateral hypothalamic brain stimulation reinforcement
seem to share common elements. The brain stimulation reinforcement
seems to activate dopaminergic synapses indirectly, by stimulating
the fibers that make anatomical contact with the dopamine cells or
their afferents; the cocaine and amphetamine reinforcements activ-
ate the dopaminergic synapse directly, by increasing dopamine con-
centrations at the post-synaptic receptor.
DOPAMINE INVOLEVMENT IN FOOD AND WATER REINFORCEMENT
The dopaminergic synapse also seems involved in the mechanisms of
food and water reinforcement. If the dopaminergic synapse is
pharmacologically blocked, several findings suggest the reinforc-
ing impact of food and water to be compromised (Wise et al. 1978a,
b; Wise 1982; Spiraki et al. 1982; Xenakis and Sclafani 1982).
Briefly, the effects of dopaminergic blockade are as follows: food
loses the ability to establish the lever-pressing habit in untrain-
ed hungry rats; food loses the ability to sustain such habits in
trained rats; rats with experience lever-pressing for food under
dopaminergic blockade initiate responding progressively less on
subsequent test days; and food continues to be a potent elicitor
of free-feeding responses but loses much of its ability to main-
tain free feeding after food is tasted (Wise 1982). Responding
also fails to be maintained by water reinforcement under dopamine
blockade (Gerber et al. 1981) .
Attenuation of the rewarding effects of food by neuroleptics can
also be demonstrated on the day after the neuroleptic treatment,
when the animal is no longer under the influence of the blocker;
hungry animals having received food previously under pimozide
treatment do not subsequently return, as do normal animals, to
the part of the environment where food was last found (Spiraki et
al. 1982). The effects of dopaminergic blockade do not always and
do not perfectly parallel the effects of withholding reinforcement;
thus it is clear that dopamine blockers do more than simply block
reinforcement (they probably produce motoric impairment as well)
and that they usually block reinforcement only partially, at least
in the dose range most frequently tested (Wise 1982). While
they do not block responding in all paradigms at equal doses,
dopaminergic blockers decrease responding in the same manner over
a wide enough range of paradigms to make it clear that, whatever
its side effects, dopamine blockade alters the reinforcing
efficacy of both food and water.
This evidence thus relates food and water reward to an anatomical
mechanism having a critical dopaminergic link, though it is not
yet known by which anatomical pathways the reward message reaches
the dopaminergic cells. While the dopaminergic link in the mech-
anism of food reward may not be identical to the dopaminergic link
in the mechanism of brain stimulation and psychomotor stimulant
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reward, a common link does become one of the more attractive of
the obvious possibilities.
DOPAMINE INVOLVEMENT IN OPIATE REINFORCEMENT
Other drugs of abuse might be suspected to act through the same
reward mechanism, though there is no logical necessity that they
must do so. In the case of opiates, however, there is strong
recent evidence that a dopaminergic mechanism of rewarding action
is again involved. Whereas reward-relevant dopaminergic neurons
appear to be transsynaptically activated by brain stimulation
reward, they seem more likely to be directly activated by reinforc-
ing injections of morphine. This is not so clear from pharmaco-
logical challenge of intravenous opiate self-administration; while
moderate doses of dopamine blockers cause response cessation in this
paradigm (G.J. Gerber, M.A. Bozarth, and R.A. Wise, unpublished
observations), they do not cause the low-dose response acceleration
(Ettenberg et al. 1982) which helps make their effects on psycho-
motor stimulant self-administration so clearly interpretable as a
reward deficit (Yokel and Wise 1975). It is not clear why animals
do not compensate for dopaminergic blockade by increasing their
opiate intake, particularly when they do increase intake to compen-
sate for opiate receptor blockade (Ettenberg et al. 1982); however,
a similar lack of compensatory response acceleration is also seen
when apomorphine self-administration is challenged by dopamine
receptor blockade (Yokel and Wise 1978); thus the lack of compensa-
tory response acceleration in response to low dose neuroleptics can-
not be taken as reason to disregard the decreases in drug intake
caused by higher neuroleptic doses. Nor can the lack of accelerated
responding, before response cessation, following moderate doses of
neuroleptics (Ettenberg et al. 1982) be taken as reason to disregard
the response cessation. Responding for apomorphine also ceases
without response acceleration after moderate dose of neuroleptics
(Yokel and Wise 1978), and this does not rule out a role for dop
amine in apomorphine reinforcement. Additional paradigms are
needed, however, to make it clear (a) that reinforcing opiates do
activate dopaminergic neurons and (b) that such activation is
critical to their reinforcing action. Several are now available.
First, direct injections of morphine (Phillips and LePiane 1980;
Bozarth and Wise 1981a, 1982) and other opiates and opioid peptides
(van Ree and de Wied 1980; Phillips and LePiane 1982) are reinforc-
ing when administered into the region of the dopaminergic cells of
the ventral tegmentum. This is seen in a conditioned place prefer-
ence paradigm, where animals learn to return to the place where
they have experienced opiates in the past (Phillips and LePiane
1980, 1982; Bozarth and Wise 1982), and also in a lever-pressing
paradigm where responding is reinforced by direct brain injections
of morphine (Bozarth and Wise 1981a) or fentanyl (van Ree and de
Wied 1980). Injections dorsal (Phillips and LePiane 1980), ante-
rior or posterior (Bozarth and Wise 1982) to the dopaminergic
cell group are not reinforcing. Injections of morphine in other
regions, particularly the lateral hypothalamus (Stein and Olds
1977; M.E. Olds 1979), have also been reported to be reinforcing, but
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it seems most likely that such injections diffuse and have their
reinforcing action in the ventral tegmental area (Broekkamp 1975;
Wise and Bozarth 1981; Bozarth 1983). Intravenous heroin rein-
forcement is not altered by destruction of the cells of the lat-
eral hypothalamus, as it would be if there were important reward-
relevant opiate receptors in this region (Britt and Wise 1981),
and rats do not learn to lever-press for hypothalamic injections
as rapidly or as reliably as they learn to lever-press for ventral
tegmental injections (Bozarth and Wise 1982).
On the other hand, ventral tegmental microinjections of opiate an-
tagonists cause compensatory increases at  low doses and extinguish
responding for intravenous opiates at high doses (Britt and Wise
1983). Ventral tegmental microinjections of the enkephalinase in-
hibitor thiorphan produce a reinforcing state, presumably mediated
by an endogenous opioid peptide transmitter, as shown by the place
preference test (Glimcher et al. 1983). Thus the reinforcing ac-
tion of opiates seems localized to the region of the dopamine-con-
taining cells that are implicated in psychomotor stimulant reward.
That rewarding ventral tegmental morphine injections pharmacologi-
cally activate the dopaminergic cells of this region is inferred
from the fact that they cause contralateral circling (Bozarth and
Wise 1982). Such circling is known to accompany activation of the
dopaminergic projection to the striatum (Ungerstedt 1971), and dop-
aminergic antagonists block the circling elicited by morphine in
this region (Holmes et al. 1983). The fact that the circling is
directed away from the side of morphine injection indicates that
the injections excite rather than inhibit the dopaminergic cells
in question (Ungerstedt 1971), and electrophysiological evidence
confirms that there is a population of dopaminergic cells in the
ventral tegmentum which is excited by morphine (Matthews and German
1982; Ostrowski et al. 1982). That this dopaminergic activation
plays a necessary role in opiate reinforcement is confirmed in the
conditioned place preference task; if morphine is given during dop-
aminergic receptor blockade, the animals do not show learned ap-
proach to the morphine-associated portion of the environment
(Bozarth and Wise 1981b; Spiraki et al. 1983).
The emerging picture is, then, one of a reward circuit involving a
descending myelinated fiber system in the medial forebrain bundle
(activated directly in the case of brain stimulation reward), commu-
nicating with dopaminergic cell bodies of the ventral tegmental area
(where morphine initiates its reinforcing action), and ultimately
resulting in synaptic release of dopamine at terminals where the
reinforcing effects of psychomotor stimulants are pharmacologically
initiated. Food and water reward are thought to depend on at least
the dopaminergic portion of this circuitry, but it is not known by
what input fibers the message arrives at the dopaminergic cells.
DOPAMINERGIC MECHANISMS AND OTHER HABIT-FORMING DRUGS
At least two other drugs with some degree of abuse liability appear
likely to have actions at the dopaminergic link of this same re-
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inforcement system. Phencyclidine, which has amphetamine-like re-
inforcing properties (along with several non-amphetamine-like side
effects), shares amphetamine's approximate site of reinforcing ac-
tion in nucleus accumbens; phencyclidine injections in this region
cause conditioned place preference (Giovino et al. 1983). It is not
known whether phencyclidine has presynaptic or postsynaptic effects
in the dopaminergic synapse, like cocaine or apomorphine, respect-
ively, or whether it acts in other synaptic junctions to influence
the same output cells. Nicotine, which is self-administered intra-
venously in man (Henningfield et al. 1983) and in lower animals
(Dougherty et al. 1981), is also capable of activating dopaminergic
cells (Giorguieff-Chesselet et al. 1979; Lichtensteiger et al.
1982), although, again, the mechanism of interaction is not known
in any detail. Thus there is a good chance that future research
will link the reinforcing mechanisms of action of at least some
other drugs of abuse to the mechanism shared by food, water, lat-
eral hypothalamic brain stimulation, amphetamine, cocaine, and op
iates. Other neurotransmitter systems are also likely to be linked
to the mechanisms under discussion; for example, neurotensin, an
endogenous peptide transmitter, is reinforcing when injected into
the ventral tegmental area, as shown in both place preference and
self-administration tests. The rewarding effects are dopamine-
dependent, as they are blocked by neuroleptics (Glimcher et al.
1983b).
RELATION OF DRUG DEPENDENCE TO DRUG REINFORCEMENT
In considering the mechanism of cocaine's abuse liability it has
been useful to consider cocaine actions that are shared with other
drugs of abuse. It is unlikely that the peripheral autonomic ef-
fects or local anesthetic effects of cocaine are critical, since
these are not effects common to other classes of abused drugs.
Similarly, it seems clear that actions other than physical depend-
ence-producing actions such as those of opiates, ethanol, barbitu-
rates, and benzodiazepines must explain the habit-forming conse-
quences at least of cocaine; cocaine shares the habit-forming prop-
erty but not the dependence-producing property of these drugs.
Based on this conclusion, it is tempting to accept the currently
popular notion that cocaine is less dangerous (less "addicting"
or less compulsively habit-forming) than so-called "hard drugs"
that do produce physical dependence syndromes. It is widely held
that cocaine is a much safer drug for recreational use than is
heroin, for example, because heroin "addicts" the user while co-
caine does not. This unfortunate and erroneous belief is based on
two fallacies, one empirical and one logical. The empirical fal-
lacy is that humans seem usually not to endanger their health by
taking cocaine to excess; the logical fallacy is that it is the
ability to produce physiological dependence that makes drugs most
dangerous. The first fallacy is refuted by direct evidence; the
second is refuted by the fact that even opiate self-administration
can be shown to derive from opiate actions unrelated to physical
dependence.
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Studies in animals suggest that cocaine is a far more inherently
health-threatening pharmacological agent than heroin. Rats given
free access to intravenous cocaine or amphetamine take drug to the
exclusion of food. These animals lose weight and usually die in a
few weeks (Pickens and Harris 1968; Bozarth and Wise, unpublished
observations); rewarding brain stimulation can have similar effects
(Routtenberg 1964). Widespread human experience with cocaine sug-
gests that cocaine does not have such compelling effects in man;
but it must be remembered that few humans have unlimited access to
cocaine, and among those that do, compulsive and potentially lethal
cocaine abuse are increasingly reported. The seeming safety of co-
caine as used recreationally by man may be an illusion that depends
more on the intake-limiting effects of cocaine price and availabil-
ity than on any inherent safety in the drug itself. In as much as
cocaine and amphetamine have very similar effects in the reward
circuitry of the brain, the lessons learned with intravenous amphet-
amine in both man and animals are very relevant: the psychomotor
stimulants do not impose reasonable limits on their own intake;
they have a dangerous tendency to be self-administered to the
detriment of health when they are freely available in unlimited
quantity. Positive reinforcing properties alone, as shared with
rewarding brain stimulation, are enough to produce this high degree
of health risk (Routtenberg 1964).
Whatever the safety factor we attribute to cocaine, it is clear
that its habit-forming property, and thus its abuse liability, is
independent of a classic physical dependence syndrome. In consid-
ering the degree to which cocaine shares common mechanisms of rein-
forcing action with other drugs, it is important to determine how
critical the physical dependence syndrome is for the reinforcing
effects of those drugs that do produce it. Recent evidence on the
nature of opiate reinforcement suggests that physical dependence
is not a necessary condition for reinforcement even in the case of
opiates. Thus the primary mechanisms of opiate and cocaine rein-
forcement do, indeed, seem shared.
There are two major principles of reinforcement as analyzed in the
literature of experimental psychology, and each has been suggested
to underlie opiate reinforcement (Beach 1957). The first is the
principle of "positive reinforcement," in which a positive state
caused by the drug--euphoria--is seen to account for the reinforc-
ing effects of the drug. Although many of the subjective effects
are different, euphoria is a property that opiates share with co-
caine and amphetamine; stimulant euphoria and opiate euphoria are
sufficiently similar to make it appropriate to rate them on the
same mood scale (Jasinski 1973). The second principle is the prin-
ciple of "negative reinforcement," in which a negative state which
the drug reduces--withdrawal dysphoria--is seen to account for op-
iate reinforcement. Stimulants do not share with opiates the abil-
ity to block the opiate withdrawal syndrome, and there is no comp
arable withdrawal syndrome, in severity or quality, associated
with psychomotor stimulants; thus the negative reinforcement princi-
ple is not a satisfying explanation of cocaine self-administration
and is not a common denominator of drugs of abuse, despite the fact
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that it is a principle widely held to explain compulsive intake of
opiates and other sedative-hypnotics.
There is now strong and direct evidence that the primary reinforc-
ing effects of even opiates are positive and not negative rein-
forcement effects. First, no obvious signs of opiate dependence
develop in animals allowed to work for low doses of intravenous
opiates (Woods and Schuster 1968; Deneau et al. 1969) or for limit-
ed access to central (ventral tegmental) morphine injections
(Bozarth and Wise 1983). Thus opiates can be reinforcing, produc-
ing strong self-administration habits, when given in dose regimens
and by routes of administration that do not lead to obvious depend-
ence signs.
It is always possible, however, that some degree of dependence
develops, but goes undetected, in any paradigm where drug is given
more than once; dependence signs need not be obvious to outside
observers in order to play a role in drug reinforcement. However,
opiate reinforcement can also be demonstrated in a place-preference
paradigm where drug is administered only once (Bozarth and Wise
1983); here there is never any opportunity for drug to relieve with-
drawal distress. Thus opiate dependence is not a necessary condi-
tion for opiate reinforcement.
There is even clearer recent evidence, however, that morphine de-
pendence and primary morphine reinforcement are not causally link-
ed; opiate reinforcement and opiate dependence are now known to be
mediated by anatomically distinct neural mechanisms, each with its
own population of central opiate receptors. Even 72 hours of con-
tinuous infusion of morphine into the opiate reward site of the
ventral tegmental area fails to produce the opiate dependence syn-
drome as reflected in naloxone-precipitated withdrawal symptoms
(Bozarth and Wise 1983). When the same dose is infused into the
periaqueductal gray matter, on the other hand, strong dependence
signs develop (Wei and Loh 1976; Wei 1981; Bozarth and Wise 1983).
Drug-naive rats do not work for injections into this region, how-
ever (Bozarth and Wise 1981a) , nor do injections in this region
produce conditioned place preference (see the control group of
Phillips and LePiane 1980). Thus the primary reinforcing effect
of opiates involves a population of opiate receptors that inter-
acts with reward circuitry of the ventral tegmental area and that
is not involved in dependence phenomena, whereas the dependence-
producing effect of opiates involves an anatomically distinct pop
ulation of opiate receptors that interacts with circuitry of the
periaqueductal gray matter and is not involved in positive rein-
forcement phenomena. Thus opiates, along with cocaine, have habit-
forming actions involving positive reinforcement mechanisms. It
remains possible that opiates can produce, in addition, negative
reinforcement; it is not yet known whether morphine-dependent ani-
mals will work for morphine injections into the periaqueductal gray;
it seems likely that in dependent subjects both factors may come
into play (Beach 1957).
The potent reinforcing actions of opiates and cocaine which are
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common actions, however, would appear to be positive reinforcing
actions. Whatever the influence of withdrawal distress in depend-
ent subjects, it would appear that the mood elevation associated
with cocaine and opiates in nondependent subjects is sufficiently
powerful to account for the initial acquisition of drug self-admin-
istration habits and is likely to account as well for the rapid
reacquisition of such habits in detoxified subjects. This positive
reinforcement property and the mood elevation that tends to accompa-
ny it appear to result from the activation of neural systems which
evolved to serve the control of behavior by conventional reinforcers
such as food and water. The fact that drugs and rewarding brain
stimulation can activate these endogenous reward systems powerfully
and centrally may account for the fact that these reinforcers which
do not offer obvious survival value to either the individual or the
species can sometimes exert more effective behavioral control than
substances or events that do.
SUMMARY AND CONCLUSIONS
Cocaine has multiple central and peripheral pharmacological actions.
The action responsible for the rewarding property, and hence the
abuse liability, of cocaine is an action in the dopaminergic syn-
apse; in the rat the major set of critical dopaminergic synapses
appears to be in the nucleus accumbens. Cocaine prolongs the ac-
tivity of dopamine in the synapse by blocking the dopamine reuptake
mechanism (which usually inactivates the transmitter by removing it
from the proximity of its synaptic targets). This is an action
shared with amphetamine; in addition to blocking the dopamine reup-
take mechanism, amphetamine also augments dopaminergic function by
augmenting dopamine release directly into the synapse. While
amphetamine and cocaine have discriminable subjective effects,
perhaps due to differences in rate of onset and metabolism or per-
haps due to different side effects, cocaine shares its rewarding
impact and abuse liability very closely with amphetamine. When
drug access is unlimited, cocaine and amphetamine have the same
ability to dominate behavior, reducing other behaviors such as
feeding and sleeping and, in the process, reducing stress resist-
ance to life-threatening levels.
Opiates also owe their reinforcing properties to their ability to
activate dopaminergic synapses in brain reward circuitry, though
they activate the system at a different site and by a different
local mechanism than those of amphetamine and cocaine. Where
amphetamine and cocaine activate dopaminergic activity in the dop
aminergic synapse, opiates activate dopaminergic activity by acti-
vating (or disinhibiting) the dopaminergic cell bodies. The site
of rewarding action of opiates is the ventral tegmental area, where
the dopaminergic cells projecting to the nucleus accumbens (as
well as other targets) are located. Opiate actions that are re-
stricted to this mechanism do not include opiate physical depend-
ence; the dependence syndrome involves anatomically distinct sys-
tems in the brain, systems not activated by amphetamine  or cocaine.
While opiate physical dependence may contribute to the motivation
for opiate intake in dependent subjects, it is not necessary for
27
opiates to be habit-forming.
The neural circuitry involved in the rewarding actions of cocaine,
amphetamine, and the opiates is circuitry thought to be specialized
for natural reward function. The circuit activated by these drugs
is also activated by some cases of rewarding brain stimulation.
While there may be more than one reward circuit in the brain, the
rewarding effects of food and water appear to depend, along with
those of cocaine, amphetamine, opiates and lateral hypothalamic
brain stimulation, on the integrity of a dopaminergic link in such
circuitry. The rewarding effects of cocaine, however, need not
be conveyed to the central nervous system over networks of sensory
nerves, as are those of food and water; cocaine can activate, power-
fully and directly, the central circuits of goal-directed behavior.
Given this fact it should not be surprising that motivation for
cocaine can come to dominate motivation for more essential and
health-promoting substances. Survival value has resulted from the
fact that food, water, warmth, shelter, sex partners, and social and
parental interactions have been subserved by the central circuits
of reward and motivation. The refinement of substances such as
cocaine and methods such as rewarding brain stimulation which can
activate central reward circuitry directly, are unlikely to serve
the further evolution of man so long as they provide shortcuts to
the pleasures of reward and bypass the adaptive activities that
have led to these pleasures over most of our evolutionary history.
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The Pharmacology of Cocaine
Reese T. Jones
As we approach the one hundredth anniversary of the use of cocaine
in medicine, the reader might assume that scientific knowledge of
cocaine is relatively complete. It is not. Much of what is known
about cocaine, its local anesthetic properties, central nervous
system stimulant actions, general subjective and cardiovascular
effects when ingested by a variety of routes -- oral, nasal, by
chewing, by injection -- was described 50 to 100 years ago. The
"new" facts regarding the pharmacology of cocaine have mostly been
collected and reported since 1975 when NIDA funded a series of
research contracts to study the pharmacology of cocaine in humans.
Those studies and ones evolving from them provide detailed descrip
tions of acute, short-term cocaine effects and are reviewed else-
where in this volume. The studies provide better documented
information on relationship between dose and route of administra-
tion, blood levels of cocaine and limited physiologic or psycho-
logic effects (Fischman et al. 1976,1983; Resnick et al. 1977; Van
Dyke et al. 1978,1982; Fischman and Schuster 1980,1981,1982).
However, many large gaps in what we should know about the pharma-
cology of cocaine remain. This chapter touches on some of the
issues where more should be known, speculates on assumptions about
what we do know, and suggests a few areas needing attention from
researchers and from those sources that should support good
research on the pharmacology of cocaine.
COCAINE AND BRAIN FUNCTION
Some of the most impressive and predictable consequences of
cocaine are effects on brain function and the sought-after conse-
quences of altered brain function -- euphoria, relief of fatigue
and boredom, and other consequences of psychic stimulation. Hans
Berger, in one of the earliest reports describing the human elec-
troencephalogram (Berger 1931), mentioned that a 24-year-old man
given a 30 mg dose of cocaine subcutaneously showed increased EEG;
alpha frequency and amplitude 20 minutes after injection. Cocaine
given during a second test session with this young man produced
less EEG; change. A second subject demonstrated a similar alpha
amplitude and frequency increase associated with the "stimulating
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action of cocaine upon psychic processes." Berger gave a few more
volunteers cocaine (Berger 1937). His new recording equipment
allowed him also to measure EEG beta activity and he found in-
creased beta activity along with the higher amplitude and higher
frequency alpha 30 minutes after a 20 mg subcutaneous injection of
cocaine. "We are confronted here with the graphic representation
of the stimulating action exerted by cocaine upon mental proces-
ses," Berger said. Keep in mind Berger's papers were the first
demonstrations of human EEGs and involved, among other things,
comparisons of caffeine and cocaine.
Now, almost 50 years after Berger's auspicious demonstrations of
cocaine effects on the electrical activity of the human brain, no
further publications describing the effects of cocaine on the
resting EEG in humans have appeared. One small study examined
cocaine-induced sleep EEG; changes in depressed patients. Modest
doses of cocaine (30 to 200 mg daily) given orally for ten days
suppressed rapid eye movement sleep. When cocaine was stopped, a
rebound of REM sleep quantity followed as it does after withdrawal
of amphetamines and many other psychoactive drugs given for a few
days (Post et al. 1974). The depressions did not improve.
In studies in our laboratories, we find substantial cocaine-
induced changes in nonstimulated resting EEG and on the late
components of auditory event-related potentials thought to be
related to information processing. Intravenous doses of cocaine
similar to those commonly used outside of the laboratory setting
(0.2 mg/kg) produced increases in beta2 activity like those des-
cribed by Berger 50 years ago. However, no differences between
cocaine and placebo on alpha activity have been found. Cocaine
decreases the amplitude of the so-called P300 component of an
auditory-evoked response recorded during a task that required the
subject to evaluate each stimulus as to its task relevance. That
the cocaine effect seems to be maximal at a 0.2 mg/kg dose with
higher doses producing no greater decreases in amplitude suggests
that even lower doses of cocaine may have measurable effects on
brain function. Other laboratories report stimulants like methyl-
phenidate increase the P300 component amplitudes. It is generally
assumed that methylphenidate, amphetamine, and related stimulants
have actions and many mechanisms similar to cocaine. The diff-
erent pattern of evoked potential changes suggests that there may
be some differences in actions or mechanisms as well.
Generalized convulsions were among the very earliest toxic effects
of cocaine noted in the late 19th century (Van Dyke and Byck 1976;
Eidelberg et al. 1963). The convulsions were generally considered
to reflect cocaine's CNS stimulant effects. Early studies noting
that at high doses the convulsive behavior was followed by death
generally associated with respiratory depression, assumed that
cocaine acted at the cortical level with "stimulation proceeding
from above downward." When more precise neurophysiologic record-
ing techniques were developed in the 19606, it was obvious that
changes in limbic system function preceded the generalized motor
convulsions. It was suggested that cocaine seizures originating
in limbic structures might provide a useful model to investigate
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temporal lobe epilepsy and psychoses that may be associated with
psychomotor seizures (Eidelberg et al, 1963). Worth noting is
that, in contrast to cocaine's propensity to induce seizures even
after a single dose, amphetamines generally induce seizures only
after repeated administration of high doses, suggesting possible
differences between amphetamines and cocaine.
Ihe relative lack of interest in the human electrophysiology of
cocaine is even more surprising since with animals one of the more
dramatic consequences of chronic cocaine administration is a phen-
omenon referred to as 'kindling," manifest by increased sensiti-
vity and responsivity of various neural and other systems (Post
et al. 1976,1981; Stripling and Hendricks 1981; Ellinwood and
Kilbey 1980). Hypothesized mechanisms accounting for kindling
are related to enhanced propagation of electrical signals in the
nervous system. That the locus of activity seems to be in the
limbic system structures makes the phenomenon all the more inter-
esting and clinically relevant because chronic cocaine and other
stimulant administration mimics certain aspects of a schizophrenic-
like process (Post 1975; Ellinwood and Kilbey 1980). It is plaus-
ible that the electrical and behavior changes seen in animals
given cocaine repeatedly and some of the behaviors of people taking
cocaine repeatedly could result frorm similar mechanisms. Such
EEG phenomena as kindling have not been reported to occur in long-
term, frequent cocaine users. On the other hand, such populations
have not been studied systematically, if at all, in terms of this
phenomenon observed in the laboratory.
Cocaine has complex actions on the central nervous system. Many
effects on brain function are similar to those produced by other
stimulants, for example, amphetamines or caffeine. Other cocaine
effects are more similar to other local anesthetics, for example,
potent membrane stabilizing properties. Since most local anesthe-
tics do not produce the mental stimulation and other psychological
effects of cocaine (Fischman et al. 1983), its local anesthetic
properties are probably neither necessary nor sufficient explana-
tions for cocaine's sought-after effects but could account for
some of its untoward toxic effects. Cocaine alters the metabolism
of norepinephrine, dopamine, serotonin, and acetylcholine. It is
a potent convulsant, but under other circumstances has anticonvul-
sant properties. Some of the earliest studies with cocaine docu-
mented its delay in the inactivation of epinephrine and norepi-
nephrine and blockade of norepinephrine reuptake. Subsequent
neurochemical studies on the actions of cocaine on the brain
focused on the catecholamine systems and generally reported
effects similar to the more extensively studied amphetamines.
However, some evidence has accumulated that cocaine also alters
serotoninergic mechanisms, for example, blocking the synaptosomal
uptake of tryptophan (Knapp and Mandell 19721. This would slow
the conversion of tryptophan to serotonin even though tryptophan
hydroxylase activity increases (Mandell and Knapp 1977). Turnover
of 5-hydroxy tryptophan is slowed, suggesting possible differences
in cocaine and amphetamine mechanisms (Friedman et al. 1975).
Cocaine also decreases acetylcholine uptake (Liang and Questel
1969). Assuming that lithium diminishes cocaine effects (Cronson
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and Flemenbaum 1981) and that endorphinergic mechanisms may be
involved, then the whole story of cocaine mechanisms in the CNS
is still incompletely understood and is probably complex.
ABSORTION AND METABOLISM
The availability of biochemical assays sufficiently sensitive to
measure tissue levels of cocaine and its metabolites in humans now
enables researchers to better assess the significance of clinical
data and to more properly design research studies (Jatlow and
Bailey 1975; Chinn et al. 1980; Lindgren 1981; Ambre et al. 1982;
Miller et al. 1977; Johns et al. 1977; Hawks et al. 1974). In
recent years, many of the laboratory studies with cocaine report-
ing data from humans have measured plasma levels of cocaine. Some
rudimentary understanding has developed regarding relationships
between cocaine dose, route of administration, and effects, but
uncertainty remains.
Enzymes called esterases play an important role in the metabolism
of cocaine. In humans and other mammals, plasma and liver have
high levels of esterase activity. Moderate activity is present in
other organs including brain (Foldes 1978). Cholinesterases, also
referred to as plasma cholinesterase, serum cholinesterase, pseudo-
cholinesterase, nonspecific cholinesterase, play an important role
in the metabolism of cocaine (Stewart et al. 1979; Inaba et al.
1978). Individuals with low cholinesterase activity may have
slower metabolism of cocaine and some of its metabolites (Jatlow
et al. 1979). In vitro activity of these enzymes becomes an
important consideration in cocaine assay procedures (and can make
for considerable in vitro losses of cocaine unless inhibited by
the addition of fluoride, physostigmine, or other esterase inhibi-
tors) (Jatlow and Bailey 1975).
Plasma cholinesterase activity can vary greatly between indivi-
duals and between species. The genetics of plasma esterase
inheritance are relatively well understood (Neitlich 1966; Foldes
1978). The percent inhibition of the esterase activity by dibu-
caine, known as the dibucaine number, is one common clinical
measure used to screen for unusual sensitivity to the muscle
relaxant succinylcholine. People with low dibucaine numbers seem
to be not only slow metabolizers of succinylcholine but may also
be slow metabolizers of cocaine, at least as judged by in vitro
tests (Jatlow et al. 1979; Stewart et al. 1979). On the other
hand, some individuals may have genetically determined increased
cholinesterase activity and would be expected to metabolize
cocaine more rapidly. A number of disorders including liver
disease, the presence of carcinoma, and exposure to anticholin-
esterase drugs will lower cholinesterase activity (Foldes 1978).
Some inconsistencies in the cocaine literature, particularly in
issues of tolerance and dependence, may result from species varia-
tions in cholinesterase activity and resulting cocaine metabolism.
Cholinesterase activity is relatively high in humans, horses, and
certain species of monkeys (for example, chimpanzees) but not
others (for example, macaques). Cholinesterase activity is much
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lower in other mammals (for example, dogs, cats, sheep, and rats)
and very low in cows. Fourfold differences in cholinesterase
activity can occur in various strains of mice. Cholinesterase
activity is much lower in the fetus, infants, and aged males, and
decreases to a lesser degree during pregnancy.
The pharmacologic significance of such variations in determining
cocaine metabolism or toxicity is not entirely clear. Most
cocaine studies in animals, particularly behavioral studies, have
rarely even measured cocaine or cocaine metabolite levels, let
alone determined kinetics. However, there is enough evidence from
in vitro assays to indicate that variations in cholinesterase
activity in the range commonly encountered clinically can have
significant effect on the in vitro metabolism of cocaine and
cocaine metabolites. Since there is both hepatic and nonhepatic
metabolism of cocaine, the functional impact of very low or much
higher than normal cholinesterase activity might depend on route
of administration -- for example, it might be more important when
the cocaine is given intravenously or perhaps smoked than with
oral, intraperitoneal, or subcutaneous administration Rate and
dose could interact as well.
METABOLITES
Cocaine is extensively metabolized in humans to water soluble
metabolites that are mainly excreted in urine. The two major
metabolites in urine are benzoylecgonine and ecgonine methyl ester
(Fish and Wilson 1969; Inaba et al. 1978; Kogan et al. 1977).
These hydrolysis products are generally assumed to result from the
action of esterases in liver and in serum, though benzoylecgonine
may be formed nonenzymatically in vivo (Stewart et al. 1979). The
N-demethylated metabolites of each of the above may occur. Nor-
cocaine has been identified in rat, monkey, and human (Inaba
et al. 1978). Although the effects of norcocaine in humans are
yet to be determined, norcocaine is biologically active as judged
by inhibition of norepinephrine uptake in synaptosomes (Hawks
et al. 1974), local anesthetic actions (Just and Hoyer 1977), and
by effects on schedule controlled behavior (Spealman et al. 1979).
Since norcocaine may have very similar kinetics to the parent
compound, it may be less of a confounding variable than if its
kinetics differed (Misra et al. 1975)
Benzoylecgonine is generally assumed to be without significant
biological activity, though it occurs at substantial levels in
plasma (Johns et al. 1977; Kogan et al. 1977). Even though it
produces significantly less inhibition of norepinephrine uptake in
synaptosomes that does cocaine (Hawks et al. 1974), Misra has
speculated that benzoylecgonine could form molecular complexes
with calcium ion and thus participate in a number of membrane
level nerve functional changes (Misra 1976). Additional metabo-
lites, hydroxycocaine and methylecgonidine, have been identified
in the bile of a person dying of cocaine overdose (Lowry 1979).
Cocaine blood levels in that case were substantial, 3700 ng/ml.
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Assays of ecgonine methyl ester in urine (Ambre et al. 1982) or
benzoylecgonine are useful as markers of cocaine use, although the
pathways, particularly enzymatic versus nonenzymatic formation,
are not yet completely worked out (Stewart et al. 1979). When
considering the biological importance of cocaine metabolites,
attention to possible species differences is important. For
example, cocaine is a potent hepatotoxin in mice, probably due to
the hepatic tissue binding of a metabolite of N-hydroxy-norcocaine
(Rauckman et al. 1982; Smith et al. 1981). In humans and most
other species, liver damage does not seem to be specifically
associated with cocaine administration other than by speculative
comments in some human studies where the general consequences of
chronic intravenous drug use confound the issue. A relatively old
report (Yamamoto et al. 1953) suggested decreased cocaine metabo-
lism by rabbit livers after chronic administration, but the study
did not specifically measure liver damage. Given some of the
variability already alluded to in discussing plasma cholinesterase
activity, it is particularly important when studying cocaine meta-
bolites to keep in mind that there will be species selectivity and
probably dose- and route-dependent interactions.
COCAINE RECEPTORS
Although a cocaine receptor has not yet been identified, specific
binding characteristics have been suggested. In an appropriately
speculative report, three lines of evidence were cited supporting
the association of high affinity type cocaine binding in the
cerebral cortex with serotonergic nerve terminals (Reith et al.
1983). There was a correlation between cocaine binding inhibition
by various drugs and the inhibition of serotonin neuronal uptake
in mouse cerebral cortex. In mice treated with various serotonin
and catecholamine neurotoxins, only the serotonin neurotoxin
decreased the high affinity binding of tritiated cocaine in rat
cerebral cortex. Some reports have implicated serotonergic
systems as important, particularly in increases in cocaine-induced
locomotor activity that are not blocked by haloperidol or alpha
methyl paratyrosine. Reith et al. (1983) remind us that the-array
of effects produced by cocaine that include locomotor stimulation.
mood changes, stereopy, and hallucinations are not likely to be
due to a single mechanism. Thus, cocaine binding sites on sero-
tonergic nerve terminals may mediate only some effects, but it is
the mood elevating effects that are perhaps involved with these
binding sites.
KINETICS
The pharmacokinetics of cocaine and its metabolites, that is, the
mechanisms of absorption, metabolism, and excretion, have yet to
be fully worked out. Some important parameters have not been
determined in humans: for example, renal excretion pattern,
protein binding, and blood/plasma partitioning. What has been
published on the kinetics of cocaine and its metabolites reflects
great unaccounted for variability, both within and between sub-
jects in the same laboratory and between laboratories. For
example, estimates of elimination half-life after intravenous
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doses range from approximately 19 minutes (mean 41.4) (Javaid
et al. 19831 to 168 minutes (Kogan et al, 1977). Some of the
earlier studies offering kinetic data probably did not sample
bloods long enough after cocaine administration to properly
define the terminal phase of clearance, and numbers of subjects
tested often were very small. Elimination half-life may be dose
related but not to the extent that would account for the reported
variability (Barnett et al. 1981). With a sample of 40
infrequent cocaine users, we found t-1/2 to range from a mean of
61 minutes at 0.2 mg/kg intravenously to 80 minutes at a dose of
0.6 mg/kg. However, at any given dose level there was great
variability in the range of half-lives and equally great vari-
ability when subjects were tested on more than one occasion a
week or two apart. Similar variability is evident even on such
basic pharmacokinetic parameters as plasma versus time area under
the curve, peak plasma levels, and times to peak plasma levels.
It seems that one attribute of cocaine uptake, distribution, and
metabolism is that it is variable.
ROUTE OF ADMINISTRATION
The availability of sensitive assays has led to a better under-
standing of the contribution of route of cocaine administration
in determining effects. Although cocaine now is rarely taken
orally, that is by swallowing or drinking, oral ingestion as an
elixir was common in the late 19th century. Why has the nasal
route become so popular? Relative bioavailability and intensity
of many cocaine effects were similar after oral or nasal doses
(Wilkinson et al. 1980; Van Dyke et al. 1978). we found similar
patterns of effects after nasal and oral doses in a large number
of subjects given oral, nasal, and intravenous cocaine. Bio-
availability of both oral and nasal cocaine is about 30% to 40%
when compared to intravenous doses given to the same person. The
comparisons of oral, nasal, and intravenous routes suggest that
the rate of change in plasma and presumably in brain drug levels
and associated subjective effects may be very important consider-
ations in determining preferred route of administration.
Similar oral and nasal cocaine doses produce similar peak blood
levels and times to peak blood level (about 60 minutes), yet the
onset and magnitude of both subjective effects and cardiovascular
changes such as heart rate and blood pressure increase are much
more rapid after intranasal administration. Effects begin within
a minute or so after spraying the dose in the nasopharynx with a
18% cocaine solution and within a few minutes of administration
of cocaine as a crystalline material. No one has done enough
early plasma sampling after administration to properly define the
earliest phase of uptake, but initial uptake appears to be faster
when cocaine is taken nasally than when taken orally. For
example, after 2 mg/kg doses; plasma levels at 15 minutes were
5.7 ng/ml with the oral route and 17.5 no/ml after nasal adminis-
tration, yet the peak plasma levels at 1 hour were similar. It
is likely that plasma concentrations do not adequately reflect
brain levels of the drug, and that brain levels are important
determinants of the sought-after effects. Regional distribution
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and cocaine levels in various organs are not well characterized.
In an autopsy case, brain cocaine levels were surprisingly high
as compared to blood levels (Chinn et al. 1980). Given the
vasculature of the nasopharnyx, it is plausible that cocaine
brain levels at the earliest phase of nasal administration may
exceed systemic plasma levels. Brain levels in rats given radio-
labeled cocaine suggest cocaine is taken up rapidly by the brain
(Misra et al, 1975). Perhaps the best illustration of the impor-
tance of rate of uptake is the intense but very transient subjec-
tive effect after smoking cocaine (Paly et al. 1982; Perez-Reyes
et al. 1982; Siegel 1982). The initial effects after smoking seem
more intense and more rapid in onset than comparable intravenous
doses would produce.
NEUROCHEMICAL SUBSTRATES
As with most if not all psychoactive drugs, the neurochemical
substrates of action are not completely understood. More pre-
cisely, the substrates seem to become more complicated as their
interactions are better appreciated. It is important to consider
neurochemical substrates following acute administration separ-
ately from those that follow chronic administration of cocaine.
Single doses of cocaine (and other stimulants) may have quite
different consequences than does chronic repeated administration.
It traditionally has been said that the stimulating effects of
cocaine could be attributed to its ability to block the reuptake
of norepinephrine. This obviously is no longer considered to be
a sufficient explanation, since many psychoactive drugs (for
example, antidepressant drugs) in common use block the reuptake
of neurotransmitters but are not stimulants and do not produce
euphoria. Cocaine inhibits the reuptake of norepinephrine, and
also dopamine and serotonin. Cocaine alters tryptophan hydroxy-
lase and, thus, the drug-sensitive regulatory processes in the
biosynthesis of serotonin. It may have direct effects on nor-
adrenergic receptors. As do other stimulants, it interacts with
the cholinergic system as well; for example, physostigmine, an
acetylcholinesterase inhibitor, inhibits cocaine-induced hyper-
activity and stereotypy in rats (Post et al. 1976). With
repeated doses, neurochemical mechanisms can interact with con-
ditioning or learning mechanisms, electrophysiologic changes,
alterations in dopamine receptor binding sites, and possibly
pharmacokinetic mechanisms (Ellinwood and Kilbey 1980).
ABSORPTION
Cocaine, when taken as the salt, is water and fat soluble and
thus readily enters the body. When considering cocaine's pharm-
acology, particularly questions of absorption and metabolism,
broad generalizations become risky because of the varied routes of
administration available to the user or used by the scientist.
Cocaine can be taken orally, i.e., swallowed; it can be taken
nasally as a spray or a powder, much as tobacco snuff is taken; it
can be taken buccally, either by chewing coca leaves or by placing
it in the buccal pouch, much as one would do with tobacco snuff;
41
it can be smoked, injected intravenously or subcutaneously or
intramuscularly. Since it is readily absorbed through mucous
membranes or even abraded skin, those routes are available and
have been utilized. Intraperitoneal injection is commonly used in
studies with rodents.
Dose of any drug is, of course, of great importance in determining
both acute and chronic toxicity. With cocaine, route of adminis-
tration may be of equal and perhaps at times greater importance
than dose, since metabolism and disposition are relatively rapid
and involve mechanisms both in blood and liver and perhaps else-
where. Since cocaine is a potent vasoconstrictor, its rate of
absorption is altered by its effects on regional vasculature when
given subcutaneously and perhaps by other routes. Most acute
toxic reactions from cocaine are associated with the rapid onset
of high plasma levels, usually after rapid absorption. Estimates
of what is a lethal dose of cocaine vary greatly and depend very
much on route of administration. Other aspects of toxicity,
particularly chronic toxicity, may well vary with route of admin-
istration, possibly because of route-dependent metabolic differ-
ences.
ORAL INGESTION
Despite seemingly authoritative statements to the contrary,
cocaine is readily absorbed when taken orally (Van Dyke et al.
1978; Wilkinson et al. 1980). This should not be surprising,
since during the 19th century initial widespread use of cocaine
in Europe and the United States was in the form of oral elixirs
containing cocaine (Van Dyke and Byck 1982). The most common
route by which cocaine is taken is still, of course, by chewing
coca leaf  or sucking on powdered coca leaves (Holmstedt et al.
1979; Paly et al. 1979; Holmstedt and Fredga 1981). When coca
leaves are chewed, probably there is a combination of cocaine
absorption from the mucous membranes of the mouth (and thus some
avoidance of first pass liver metabolism) and also swallowing and
absorption from the gastrointestinal tract. When coca leaves are
chewed OK sucked on, measurable amounts of cocaine appear in the
blood as soon as 5 minutes after chewing begins and, when
swallowed, cocaine is measurable in blood within 15 minutes and
perhaps earlier. The bioavailability of cocaine when taken
orally has been estimated at about 20% (Mayerson and Perrier
1978). Currently in our laboratory, where more precise compari-
sons can be made to intravenous doses (thus taking into account
metabolic processes other than hepatic metabolism), we find
systemic absorption between 30% and 40% after oral doses.
The relative lack of popularity for oral dosing on the current
drug-using scene is curious. Although peak subjective effects are
slower in onset, they are not greatly different from those follow-
ing dosage by the more popular intranasal route (Van Dyke et al.
1982, 1978). It has been argued that the toxicity of cocaine might
be quite different, probably considerably less, if it were ingested
orally by chewing coca leaves rather than by currently popular
routes (Weil 1981). Most cocaine-using volunteers tested in our
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San Francisco laboratories have never heard of  or considered oral
administration. Those few who are familiar with the oral route
rarely have ever tried it. The precise sites of absorption,
stomach versus duodenum, etc., and possible differences in meta-
bolic profiles when taken by the oral route should be determined.
NASAL ADMINISTRATION
Cocaine produces excellent anesthesia and vasoconstriction of
mucous membranes. For many years, cocaine was the anesthetic of
choice for nasal surgery for that reason. When compared to oral
administration, the absorption after nasal administration has a
more rapid onset with correspondingly more rapid appearance of
subjective effects. Even so, the peak plasma levels of cocaine,
the time of peak plasma levels, and the bioavailability are simi-
lar with both nasal and oral administration Wilkinson et al.
1980; Van Dyke et al. 1982, 1978). The preference for the nasal
route suggests that rate of increase in tissue levels is an impor-
tant attribute to the cocaine user. The pattern and timing of
effects suggest that there may well be more rapid increases in
brain lwel of cocaine than in systemic levels reflected by venous
blood samples. The vasculature of the nasopharnyx would allow for
this possibility.
It should be kept in mind that plasma levels of cocaine do not
necessarily indicate organ levels -- for example, brain levels.
In an instance where cocaine blood levels were being measured in
surgical patients (Miller et al, 1977), one patient developed
restlessness, excitement, and bradycardia thought to represent
early toxic symptoms from the cocaine within 2 minutes after
cotton packs containing 5% cocaine solution were inserted in his
nose. Even though the packs were removed immediately, his peak
plasma cocaine levels 75 minutes later were 350 ng/ml, a threefold
higher level than seen in other patients at that dose. At 20
minutes after the pack was removed, levels were 100 ng/ml. This
single case illustrates that, for reasons not completely under-
stood, the systemic uptake and perhaps more importantly the brain
uptake of cocaine after nasal administration can be extremely
rapid.
The factors determining rate of absorption of cocaine from nasal
administration are not completely understood, Differences between
the inhalation of crystals OK solution are small (Wilkinson et al.
1980). Variations in blood drug levels seem to be a function of
total dose and not of the concentration of cocaine solution used
(Cambell and Adriani 1958; Miller et al. 19771. Some of the
relatively rare acute toxic reactions when cocaine is used for
anesthesia may be due to the inhalation of cocaine mist which, if
containing particles small enough to diffuse into alveoli, might
be very quickly absorbed and, because of the very rapid uptake
into brain, produce CNS levels that would otherwise not be
attained through the slower absorption from nasal  or pharyngeal
mucosa or trachea (Campbell and Adriana 19581.
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When the cocaine is instilled into the nasopharynx either as
crystalline material or as a spray, surprisingly little of the
delivered dose appears in saliva, suggesting relatively complete
absorption from the nasopharynx rather than partial swallowing,
The cocaine is very slowly cleared from nasal mucous membranes
with measurable levels remaining 3 hours after administration
(Van Dyke et al. 1982), probably due to paralysis of the cilia
on the membranes of the nasal mucous blanket (Barton and Gray
1979). Since some studies reporting terminal half-lives for
nasally administered cocaine only sample bloods for 2  or 3 hours,
the validity of such kinetic measures must be considered in the
context that absorption is still going on throughout the period
when clearance is being measured.
PARENTERAL ADMINISTRATION
Cocaine can be injected subcutaneously  or into muscle or vein.
The former routes give relatively slow onset of effects, probably
because of vasocontriction and thus relatively slowed absorption.
The effects following intravenous injection are related to both
dose and rate of administration (Javaid et al. 1978; Resnick
et al. 1977; Fischman et al. 1976; Barnett et al. 1981). When
injected rapidly, subjective and physiologic effects appear within
30 seconds, rapidly peak, and then decrease relatively rapidly
over the next 30 minutes. Absorption, of course, is 100%. Rate
of change, i.e., rapidity of injection, seems to be almost as
important in determining subjective and physiologic effects as
absolute blood levels. Rate and dose relationships have not been
studied nor are the dose effect functions for most effects well
worked out at cocaine dose levels much in excess of 0.6 mg/kg of
body weight. A dose of that level injected over 1 minute will
produce peak blood levels of between 300 and 400 ng/ml with brief
but intense subjective effects. In contrast, a volunteer subject
given four to five times that dose but distributing the injections
over 60 minutes demonstrated peak cocaine levels of 1100 ng/ml but
no greater subjective and cardiovascular measures than those pro-
duced by the much lower dose given over 1 minute (Fischman and
Schuster 1982). Although the precise relationships between dose
and rate of administration have not been investigated, one would
expect that with a rapidly metabolized and rapidly redistributed
drug like cocaine, rate might be as important as dose.
INHALATION: SMOKING
The very intense and relatively brief cocaine effects that follow
the smoking of cocaine probably reflect the fact that the smoking
of any drug is a very efficient way of delivering it in a very
concentrated bolus to the brain (Jeri et al. 1978; Paly et al.
1982; Siegel 1982). The alveoli of the lung offer an enormous
area for the absorption of the volatilized cocaine. More impor-
tant perhaps in its appeal to certain users is that the circula-
tion time from lungs to brain is about 8 seconds while from arm to
brain it is at least 16 seconds. Even then an intravenous injec-
tion in an arm vein must first pass through the left heart, lungs,
and right heart before reaching brain, with ample time for distri-
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bution and metabolism by blood cholinesterases before brain is
reached. The probable efficiency of smoking varies with the
technique used (Jeri et al. 1978; Perez-Reyes et al. 1982). Most
smoking techniques do not allow for precise temperature control,
and variations from optimal pipe temperature may either make for
low delivery or destroy most of the available cocaine.
The intense, pleasurable, and hence reinforcing, effects which
sometimes lead to surprisingly frequent, compulsively repeated use
should not be unexpected if similar patterns of tobacco use are
considered. Although taking tobacco orally by chewing or by snuff
will satisfy the nicotine craving of some tobacco-dependent indi-
viduals, most tobacco smokers would agree that the first few inha-
lations of the day are really quite different and are a special
way of delivering nicotine to the brain. There is at least a
partial analogy when comparing the various alternate routes of
administration of cocaine. For smoking, the conversion of cocaine
from its more common salt to the base is necessary because the
physical chemical characteristics of the base, stability particu-
larly, are more desirable. The toxicity that develops with smoked
high-dose use is not well understood in terms of mechanisms
(Siegel 1982).
Given that both liver and blood contain enzymes that metabolize
cocaine, one might well expect differences in metabolism depending
on route of administration. The metabolic profiles, particularly
of benzoylecgonine and ecgonine methyl ester as they may differ by
route, have not yet been determined, mainly because suitable
plasma assays have only recently become available. The terminal
half-life of cocaine, that is, the amount it takes for half of the
material to be eliminated, is about 60 to 80 minutes no matter
what the route, though there is tremendous variability both within
and between subjects at any given route.
TOXICITY
Sometimes consideration of the acute and chronic toxicity of a
drug will give insights into its modes of action. When cocaine is
used for anesthesia, toxic reactions are not common. For example,
a survey of American plastic surgeons found only five fatalities
and 34 severe reactions out of a total of over 108,000 patients
given topical cocaine. However, even under the relatively con-
trolled conditions of the operating room, the mechanism of toxic
reactions is still not well understood. Simple overdose does not
seem to be the most common determinant and factors leading to
rapid absorption may be more important (Campbell and Adriani 1958;
Pearman 1979). Various authorities have estimated maximum safe
doses of cocaine between 100 and 300 mg when administered topic-
ally (Pearman 1979). Doses in that range are in common use in
experimental situations with normal volunteers without untoward
effects, so those figures must be conservative ones.
The features of acute cocaine poisoning include profound central
nervous system stimulation progressing to preconvulsive movements,
then convulsions and cardiovascular and respiratory failure.
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Although probably a more common sequelae after intravenous admin-
istration, deaths occur after cocaine taken by virtually any route
if the dose is large enough (Bar-Or and Wahby 1982; Bednarczyk
et al. 1980; Bettinger 1980; Dimaio and Garriott 1978; Fishbain
1982). Postmortem tissue levels, particularly blood levels, vary
greatly because of cocaine metabolism postmortem, so the estab-
lishment of precise toxic doses is difficult (Fletcher and Hancock
1981; Jatlow et al. 1979; Lowry et al. 1979). The sudden death
following cocaine administration may occur so rapidly that treat-
ment is not available. In dogs (Catravas and Waters 1981) and in
primates Guinn et al. 1980) chlorpromazine, possibly because of
its antidopaminergic, antiadrenergic, sedative, and antihyper-
thermic effects, and diazepam, possibly because of anticonvulsant
and sedative effects, appear useful in the treatment of acute
cocaine intoxication. Symptomatic treatment of the respiratory
and cardiovascular depression, of course, is important as well.
Although beta blockers have been recommended in the treatment of
early cocaine toxicity (Rappolt et al. 1978) in the animal
studies, propranolol seemed to be of little use in modifying the
consequences of high doses.
Because of the potentiation of catecholamine effects by cocaine,
one might assume potentially toxic interactions with drugs or 
conditions where adrenergic activity plays a role (Smith 1973;
Coleman et al. 1982). Curiously, although neuroleptics seem to
diminish or block cocaine effects (Colpaert et al. 1978; Catravas
and Waters 1981), tricyclic antidepressants, which might be
expected to potentiate the effects of cocaine, seem to diminish
some vasoconstrictor effects (Schecter et al. 1982), and diminish
acute cardiac toxicity in rats (Antelman et al. 1981).
TOLERANCE AND DEPENDENCE
It is often said and written that tolerance to cocaine does not
occur and that dependence as manifest by "physiologic" withdrawal
signs does not occur. Both these beliefs are firmly reinforced by
authoritative reviews and are probably incorrect. Discussions of
cocaine tolerance usually start by citing the extensive evidence
of seemingly increasing sensitivity to cocaine effects (Ellinwood
and Kilbey 1980; Post 1975; Post et al. 1976, 1981; Stripling and
Hendricks 1981; and many others). There has been less emphasis on
data consistent with the development of more traditional toler-
ance, i.e., diminished effects with repeated doses (Branch and
Dearing 1982; Teeters et al. 1963). Decreases in some cocaine
effects with repeated doses are not necessarily inconsistent with
the concomitant increased intensity in other effects, for example,
kindling, indicating a sensitization to cocaine.
Tolerance must involve a variety of adaptive mechanisms and
changes. It is reasonable to assume that some of these adaptive
changes to the presence of the drug OK its metabolites might
appear as increasing effects while at the same time other effects
are decreasing. Only in the very special case where tolerance to
a drug can be accounted for mainly by more rapid  or complete
metabolism is the coexistence of disappearing acute effects and
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the gradual enhancement of other consequent effects not plausible.
In the case of cocaine, dispositional changes  or changes in the
metabolism of the drug do not seem to be sufficient explanations
for the phenomenon of tolerance when it appears.
Cocaine is a relatively short-acting drug. Optimal conditions to
produce tolerance require a Constant presence of the drug in the
body, particularly if the measures of tolerance are not sensitive
ones, as may be the case in some animal studies. It may be that
once daily or three times daily doses as have been used in animal
studies are not always sufficient to produce tolerance. From the
very earliest accounts of cocaine use in humans, in those in-
stances where it was used frequently, diminished effects are
commonly reported and are now being observed in controlled labora-
tory situations (Fischman and Schuster 1981).
In humans the progressive increases in irritability, restlessness,
hypervigilance, paranoid and suspicious behavior associated with
prolonged high-dose cocaine use may be the human correlate of the
kindling phenomenon observed in some animal experiments. The
psychoses Seen after sustained amphetamine use and after cocaine
use are similar and thought to be a useful model in the study of
naturally occurring schizophrenic psychoses (Post et al. 1976).
such a state, i.e., Concurrent increasing and decreasing sensiti-
vity to a drug, certainly does not fit the simplistic model of
what tolerance to a drug should represent, On the other hand, if
one conceives of tolerance as involving a number of mechanisms
adaptive in one sense and perhaps maladaptive in another sense (if
neurochemical changes produce a psychosis), then what is commonly
observed clinically fits. Whether people with a genetic predispo-
sition for schizophrenia are at more risk to cocaine-induced
psychoses has not been determined. Whether metabolic explanations
are relevant, likewise has not been determined. Curious inconsis-
tencies appear-for example, the sustained and, at least as
measured by plasma levels, relatively high dose yet relatively
nontoxic use of cocaine by the Quechua Indians. Animal studies
indicate that coca leaf contains constituents other than cocaine
that alter its pharmacology (Bedford et al. 1982,1981). Does the
whole leaf have something that serves as a protective device for
the Quechua? Is it bioavailability? Is it a matter of cultural
difference?
As clinical observations accumulate, the existence of a true
withdrawal syndrome following cocaine use seems compelling. The
depression, Social withdrawal, craving, tremor, muscle pain, eat-
ing disturbance, electroencephalographic changes, and changes in
Sleep patterns must be more than simply the consequence of what
traditionally has been termed "psychological dependence." When
listening to descriptions of this state by cocaine-using patients,
these dysphoric and often dramatic Symptoms must be viewed as
negative reinforcers. For many patients it appears that the
withdrawal symptoms are a major consideration that makes discon-
tinuing cocaine almost impossible so long as the drug is avail-
able. Yet continuing the drug produces unacceptable irritability,
paranoid and delusional thinking, and other unpleasant effects.
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This cocaine-induced state becomes of theoretical importance in
terms of model building as well as a practical consideration in
treatment. Many of the current models, particularly those invol-
ving explanations for stimulant drug administration, tend to con-
sider mainly positive reinforcement with only minimal attention to
negative reinforcement because of what increasingly appears to be
the inappropriate belief that tolerance does not develop and
dependence does not follow the withdrawal of stimulant drugs. The
differences between so-called physical dependence and so-called
psychological dependence may be more a matter of semantics and
sensitivity of measures than of neurochemistry. Most investiga-
tors would concede that psychological dependence certainly is a
consequence of repeated cocaine use.
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Assessment of the Dependence
Potential of Cocaine in Animals
Chris E. Johanson
INTRODUCTION
The illicit use of cocaine has increased dramatically over the last decade.
The discussions, articles, and songs about cocaine in popular literature
and the media are excessive, and few would disagree that cocaine is
the most infamous drug of abuse in the United States today. Although
actual use of other illicit drugs such as marijuana may exceed the use
of cocaine, this is most likely due to cost and availability rather than
preference. A myriad of factors are responsible for the meteoric rise
in cocaine’s popularity. One factor often cited is the association of
cocaine with glamorous and highly successful segments of society such
as movie stars, recording artists, and the ultra-rich. While such an
association without a doubt contributes significantly to the popularity
of cocaine, the drug itself, in the absence of these influences, has high
dependence potential. In this paper, the experimental evaluation of
cocaine’s dependence potential will be reviewed, and it will be concluded
that there is strong evidence demonstrating that cocaine is a drug of
extremely high dependence potential. It is understandable that this
characteristic of the drug coupled with social factors arising from its
association with success and glamour would lead to the present disturbing
level of abuse.
Two components are essential in the experimental assessment of the
dependence potential of any drug. The first is the demonstration that
the drug will be voluntarily self-administered by the experimental subject
or, in the terminology of behavior analysis, that the drug has positive
reinforcing properties. An event such as drug self-administration is
considered a positive reinforcer if it increases behavior leading to its
delivery or decreases behavior resulting in its withdrawal. More generally
speaking, behavior is controlled by its consequences, including the
administration of a drug. A variety of studies have shown that most
drugs abused by humans also increase behavior leading to their self-
administration in an experimental situation (Johanson and Balster 1978;
Griffiths et al. 1980; Johanson and Schuster 1981). The reinforcing
properties possessed by a drug are not a static pharmacological
characteristic. They are the result of a dynamic interaction between
the event and the environmental context of its administration. The
dependence potential of a drug is directly related to the range of
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conditions under which it functions as a reinforcer as well as the extent
to which it controls behavior compared to other drug or nondrug
reinforcers.
A second component in the assessment of the dependence potential of
a drug is the demonstration that at doses which are voluntarily
administered there are toxic consequences to the organism. This toxicity
could include changes in morphology, biochemistry, sensory processes,
or a vast array of behaviors, as well as the development of tolerance
or physical dependence. All drugs produce toxicity but the important
issue is the relationship and degree of overlap between reinforcing and
toxic doses. In conclusion, the dependence potential of a drug such as
cocaine can be assessed by measuring the range of conditions under
which it functions as a positive reinforcer and the strength of its
reinforcing properties relative to other drugs plus the degree of
deleterious consequences produced by the self-administered drug at both
individual and societal levels.
To assess these properties of a drug, it is essential to develop an
experimental model capable of analyzing the variables controlling both
excessive self-administration and its consequences in a simple enough
situation that functional relationships between independent and dependent
variables emerge clearly. Although more complex situations, which build
upon and combine these relationships, can then be studied in order to
understand their potential interactions, they can never reach the
complexity of nonlaboratory settings and still produce unambiguous
results. To a large degree, the experimental model which has been
most extensively developed uses animal subjects, such as rats and rhesus
monkeys, but it is desirable that the results are not species specific.
The organism selected for a model of drug abuse would not have to be
nonhuman. In fact, human self-administration studies in controlled
laboratory settings have been increasing in number and are important
for validating animal studies. However, using animals has several
advantages. The range of manipulations possible with animals allows
experiments to be done that would be impossible using human subjects.
In addition, using animals in the study of behavioral influences on drug
self-administration assists investigators in divesting themselves of
psychological preconceptions and in being less prone to use vaguely
defined hypothetical constructs as an explanation of drug self-
administration (Schuster et al. 1979).
The continued use of the animal model which has been developed over
the last 20 years is due to demonstrations of its validity (Johanson and
Schuster 1981). Most important, drugs which are self-administered by
animals in a laboratory situation are the same as those commonly abused
by humans (Johanson and Balster 1978). These include psychomotor
stimulants, opiates and opioids, sedative-hypnotics, alcohol, and some
but not all hallucinogens (e.g., phencyclidine). In addition, the effects
of environmental and pharmacological manipulations leading to changes
in the degree of self-administration are similar in infra-humans and
humans (Griffiths et al. 1980; Johanson and Schuster 1981). This
concordance has led to the acceptance of the animal model as a valid
predictor of dependence potential (Thompson and Unna 1977). In the
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present paper, the use of this animal model to assess the dependence
potential of cocaine will be reviewed.
METHODOLOGY
Prior to reviewing the experimental studies on the reinforcing properties
and toxic consequences of cocaine in animals, a brief description of the
methods is necessary. Cocaine is taken by humans by a variety of
routes, including the oral, intranasal, and intravenous, as well as by
inhalation (smoked as the base). Although cocaine is self-administered
principally by the intranasal route in humans, the intravenous injection
of cocaine is not uncommon. For technical reasons, however, this route
has been more extensively utilized in experimental studies.
Techniques for the intravenous delivery of drugs to animals were
originally described for rats by Weeks (1962) and for rhesus monkeys by
Yanagita et al. (1965). Such systems have several fundamental aspects:
(1) the chronic implantation of a venous catheter into the organism to
allow immediate delivery of a drug; (2) an experimental arrangement
that allows the organism relatively unrestricted movement, yet still
protects the catheter; and (3) an automatic programming system for the
delivery of drug, contingent upon some response by the animal. The
salient feature of this type of system is that it is possible to deliver
a drug with minimal delay into a vein without disturbing the animal.
Several designs incorporating these features have been used. In our
laboratory, for instance, rhesus monkeys are fitted with a tubular steel
harness which is connected to the wall of a large chamber by a metal
spring. This arrangement allows the monkey to move relatively freely
within the confines of the chamber. The catheter runs through the
metal spring and is connected outside the chamber to a pump. The
chamber is also equipped with response levers and lights signalling drug
availability, all of which are controlled by electronic equipment.
THE REINFORCING PROPERTIES OF INTRAVENOUS COCAINE
In this section, the range of conditions under which cocaine has been
shown to function as a positive reinforcer, i.e., to maintain responding,
will be reviewed. The purpose of this review is to demonstrate that
the number of experimental contexts where cocaine is self-administered
is far ranging. It would be difficult to quantify the extent of this range
simply by counting studies, but it is generally believed by researchers
in the area that cocaine is one of the most reinforcing drugs. Although
rigorous experimental proof of this contention is not easy to demonstrate,
there is anecdotal evidence of cocaine’s strength. For instance, most
researchers use cocaine to train experimentally naive animals to self-
administer drugs. Further, in most substitution studies, regardless of
the drug(s) being evaluated, cocaine is used as the baseline drug because
responding is so readily maintained (Johanson and Balster 1978). Finally,
researchers embarking on a new area of behavioral research often select
cocaine as the first drug to evaluate. For instance, except for alcohol,
early studies on the effects of punishment on drug-taking behavior used
cocaine (e.g., Grove and Schuster 1974).
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In addition to demonstrating the ubiquitous quality of cocaine’s
reinforcing properties, this review will also show that behavioral variables
such as schedule of presentation are exceedingly important in the way
cocaine controls performance. Responding leading to cocaine delivery
is controlled in much the same way as responding leading to the delivery
of nondrug reinforcers. This qualitative similarity has important
implications for understanding the behavioral mechanisms of action of
drug reinforcement.
One of the first studies to investigate cocaine as a reinforcer was
conducted by Wilson et al. (1971). Rhesus monkeys were given 4 hrs
of daily access to cocaine during which each lever press resulted in
drug delivery. Under these limited access conditions, animals regulated
their drug intake to a remarkable degree. After animals were trained,
they showed stability in their daily intake of cocaine over periods of
months. There were no indications of changes in sensitivity to cocaine’s
reinforcing effects as would be indicated by an increase (tolerance) or
a decrease (supersensitivity) in its rate of self-administration. Wilson
et al. (1971) also demonstated the constancy of cocaine intake by
changing the dose delivered for each lever press. As dose per delivery
was increased, the number of infusions taken by the animals decreased,
resulting in an almost constant intake of drug regardless of the dose
per infusion. Regulation was also evident in the pattern of cocaine
self-administration. Infusions were equally spaced throughout the session
almost as if the drug were being delivered under the control of a clock.
While most animals who administered cocaine showed clear signs of
stimulation (e.g., piloerection, agitation), convulsions rarely occurred
except in the beginning stages of training.
The results of this study by Wilson et al. (1971) have been replicated in
a number of ways. What is impressive is the generality of the
phenomenon. For instance, cocaine is self-administered by every species
of animal tested, including rats (Pickens and Thompson 1968), squirrel
monkeys (Goldberg 1973; Stretch 1977; Katz 1979), rhesus monkeys
(Woods and Schuster 1968), pigtail macaques (Young and Woods 1980),
and baboons (Griffiths et al. 1975), as well as dogs (Risner and Jones
1975; Risner and Silcox 1981; Risner and Goldberg 1983). This
concordance across species is one type of evidence of the robustness of
cocaine’s ability to function as a reinforcer. A second type of evidence
is that cocaine maintains responding regardless of its route of delivery.
Allthough the i.v. route has been used most commonly, cocaine also
maintains responding when delivered intragastrically (Altshuler and
Phillips 1978; Woolverton and Schuster 1983), by chewing or smoking
(Siegel et al. 1976), and even intramuscularly (Katz 1980; Goldberg et
al. 1976). The failure to demonstrate that animals will snort cocaine
is more likely a function of experimenter skills and absence of appropriate
technology than of any difference across species.
Cocaine self-administration not only occurs with a variety of species
and using several routes of administration but also under a variety of
environmental circumstances. In the terminology of behavior analysis,
this can be translated into schedule contingencies, i.e., the rule that
governs the relationship between behavior and the delivery of the
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reinforcer. As will be shown, the nature of that rule can have an
overwhelming influence on the reinforcing properties of a drug. In the
simplest schedule, continuous reinforcement (CRF), every response is
followed by a reinforcer (e.g., Wilson et al. 1971). However, the
relationship between responding and reinforcer may be more complex.
A response may be reinforced on the basis of the number of responses
emitted since the termination of the previous reinforcer delivery (a ratio
schedule), or on the basis of the time elapsed since the last reinforcer
delivery (an interval schedule). A ratio or interval schedule may either
be fixed or vary in number or time. Four basic schedules, then, are
fixed ratio (FR), variable ratio (VR), fixed interval (FI) and variable
interval (VI). In addition to these, there exist numerous other possibilities
for relating responding and the delivery of the reinforcer, i.e., schedules
of reinforcement (Ferster and Skinner 1957).
Many studies have shown that cocaine maintains responding under fixed
ratio schedules (Downs and Woods 1974; Balster and Schuster 1973a).
The pattern of responding, typical of performance maintained by other
events such as food and water (Ferster and Skinner 1957), is characterized
by an initial pause followed by a high terminal rate of responding.
Although the pattern of ratio responding maintained by cocaine is similar
to that maintained by other events, the rates of responding typically
found in drug self-administration studies have been low compared to
rates maintained by food, and increases in dose/delivery further decrease
rates (Kelleher 1975). In many studies, however, rates are higher at
the beginning of the session (Downs and Woods 1974). This generally
low or decreasing rate is most likely due to the dual actions of the
drug (see Johanson and Schuster, 1981, p 233, for a complete discussion).
On the one hand, cocaine serves as a reinforcer which increases rates
of responding, but on the other hand the drug has the ability to
temporarily disrupt ongoing behavior (Wilson and Schuster 1975; Spealman
et al. 1977; Herling et al. 1979) and thus have a rate-decreasing effect.
Since increased responding under ratio schedules results in increased
rates of drug intake, the problem is particularly striking under this
schedule. Several techniques have been used to avoid these effects
while still using response-based, rather than time-based schedules.
Goldberg and Kelleher (1976), for instance, limited the number of
infusions available each session and, as well, imposed a time-out following
infusions. These modifications resulted in much higher rates of
responding.
Cocaine has also been demonstrated to maintain responding under fixed
interval schedules. An important feature of interval schedules is that
rates of responding can change considerably without affecting rate of
reinforcement. One of the first studies using an interval schedule of
drug delivery in monkeys was done by Balster and Schuster (1973b).
They used a fixed interval 9-min schedule with responding maintained
by cocaine infusions in one component and food delivery in the other.
In addition, there was a 15-min time-out following the delivery of each
reinforcer. Responding was well maintained and the pattern with cocaine
was similar to that maintained by food. In contrast to ratio schedules,
as dose per infusion increased, rate of responding increased. Similar
results were found in a study by Goldberg and Kelleher (1976) using a
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fixed interval 5-min schedule of cocaine delivery. However, response
rates increased only up to a dose of 0.5 mg/kg and then decreased as
dose was further increased. This difference was most likely due to the
more frequent injections in the Goldberg and Kelleher (1976) study.
Again despite the powerful nature of the contingencies governing
reinforcer delivery in controlling responding, the nonspecific rate-
modifying actions of cocaine also exerted an influence.
Several studies with cocaine as well as other drugs have used second-
order schedules as a way of minimizing the direct effects of drug
administration in order to get a less confounded estimate of a drug’s
reinforcing actions. In this type of schedule, responding specified by
one particular schedule is treated as a unitary response that is itself
reinforced by another schedule (Kelleher 1966). The responding treated
as a unitary response can also be followed by the presentation of a
brief stimulus paired with the delivery of the reinforcer. Goldberg,
(1973) using squirrel monkeys, studied responding maintained by cocaine
and d-amphetamine as well as food under a fixed ratio 30 schedule of
stimulus presentations (2-sec yellow light), which itself was maintained
under a fixed interval 5-min schedule of drug or food delivery. This
schedule was designated a second-order (FI 5-min (FR 30:s)). When
either drug was used to maintain responding, rates of responding were
extremely high and performance was ratio-like between stimulus
presentations. Furthermore, early in the interval, overall response rate
was relatively low but accelerated as the interval progressed, which is
the pattern of responding typical of fixed interval performance
maintained by diverse reinforcing events. For instance, in the same
study, responding maintained by food was virtually identical in both
pattern and rate. Several additional studies have been conducted with
this schedule using both squirrel and rhesus monkeys. Typical responding
has been maintained under FI (FR) schedules by intravenous and
intramuscular cocaine as well as with fixed ratio schedules of fixed
interval components (Goldberg et al. 1981; Kelleher and Goldberg 1977;
Goldberg and Kelleher 1977; Goldberg et al. 1975). Furthermore, in
many studies, high rates of responding were maintained even when only
one cocaine reinforcer was delivered at the end of the session (Goldberg
et al. 1976; Katz 1979,198O).
Kelleher and Goldberg (1977) demonstrated the importance of the brief
stimuli in maintaining responding under second-order schedules. When
these stimuli were removed following the FR components but the drug
was still delivered, rate declined and patterning was disrupted. If both
drug delivery and the brief stimuli were removed, responding declined
even further. However, when the brief stimuli were then reinstated
without the drug, responding increased. Similar results have been found
in other studies including ones with intramuscular cocaine (Katz 1979).
Whether such rates would be maintained over long periods of time is
not known. In order to determine whether the stimuli used in second-
order schedules derive their ability to maintain responding from their
association with drug, Goldberg et al. (1979) compared the response
maintenance properties of drug-paired and unpaired stimuli. In this
study both intravenous cocaine and morphine maintained typical
responding under FI (FR) schedules in squirrel monkeys. Removing the
59
stimuli decreased rates and disrupted the pattern of responding. When
new stimuli were presented at the completion of the FR components
but never in association with the terminal ratio when drug was injected,
response rate also declined. Therefore, it is not the presentation of a
stimulus per se that maintains responding in these second-order schedules
but rather the response-contingent presentation of a stimulus associated
with the drug delivery. However, although Katz (1979) also showed that
the substitution of unpaired stimuli decreased responding, the magnitude
of the decrease was not so great as when stimuli were totally absent.
The fact that both the drug and the stimuli are determinants of the
rate of responding may explain the results when dose is manipulated
with this schedule. Although there is some tendency for rate to increase
with increases in dose, in general, dose-response functions are flat
relative to those generated by other schedules. Therefore, the strength
of cocaine’s ability to control responding does not seem to change with
its magnitude (dose) under second-order schedules. On the other hand,
since rates are often high under such schedules, there are limits to the
possible increases.
Two related procedures or schedules that have been used to compare
different doses of cocaine in the absence of any confounding influence
are concurrent schedules and preference procedures. In these procedures
responding on different levers is maintained by different doses and the
primary dependent variable is the relative frequency of occurrence of
the alternative responses. These procedures have also been used with
other reinforcers such as food and intracranial stimulation and have
been found to be sensitive to differences in reinforcer magnitude.
With concurrent schedules, responding is maintained by two or more
simultaneously operating schedules. In a study by Iglauer and Woods
(1974), responding was maintained in rhesus monkeys under a concurrent
two-lever VI schedule of cocaine injections with a 5-min time-out
following each injection. In this study, relative reinforcing efficacy was
evaluated by comparing relative response frequencies on the two levers.
A standard dose of cocaine (0.05 or 0.1 mg/kg) was available under a
variable interval 1-min schedule on one of two levers: the dose available
under an identical schedule on the second lever (variable-dose lever)
was varied to include both higher and lower doses of cocaine (0.013 to
0.8 mg/kg). The proportion of responses occurring on the variable-dose
lever increased as the dose available on that lever increased; in all
cases, the larger of the two doses presented for comparison was
preferred.
Another method designed to compare reinforcing properties involves the
use of discrete choice trials. In a study by Johanson and Schuster
(1975), rhesus monkeys were given an opportunity to choose between
two drug solutions, and injections were followed by a l5-min time-out
period. The number of trials during which one option rather than the
other one was selected was counted and used as the measure of
reinforcing efficacy. As in the Iglauer and Woods (1974) study, higher
doses of cocaine were preferred to lower doses. Similar results have
been found by Brady and Griffiths in baboons (1977).
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From this review two overall conclusions can be stressed. First of all,
cocaine self-administration occurs under a variety of experimental
situations and is not restricted to a narrow range of conditions.
Unfortunately it is impossible in the absence of direct comparisons to
conclude that the strength of cocaine’s reinforcing properties is unique
to cocaine. However, the ubiquitous use of cocaine in experimental
studies reflects not only an interest in this drug but as well the ease
of conditioning animals to self-administer it so that other variables can
then be studied. The second point is that the pattern of cocaine self-
administration and the circumstances under which it occurs are similar
to behavior controlled by nondrug reinforcers, such as food and water.
Although the direct or nonspecific actions of drugs can markedly affect
absolute rates of drug-maintained responding, by manipulating schedule
parameter values or using nonrate measures, dose-response functions
indicate that response strength increases with dose. Of particular
importance is the demonstration that persistent and excessive drug-
seeking behavior is determined by an interaction between the drug’s
schedule of presentation and its specific pharmacological properties.
This means that our general knowledge of how behavior is controlled
may be useful in understanding the mechanisms of cocaine self-
administration.
TOXICITY
Regardless of the nature of a drug’s reinforcing properties and predicted
dependence potential, there would be little public concern or action if
the use of cocaine at the levels determined by the organism did not
lead to toxicity. Deleterious consequences resulting from the drug self-
administration of any drug can range from death to subtle changes in
the ability of the person to cope with environmental demands. Any
drug can cause serious damage if given in excessive doses over extended
times, so the assessment of toxicity must include judgments of relative
risks. Clearly, in the case of recreational drugs where there is not
therapeutic justification, the safest option is to use no drug.
Despite the importance of toxicity studies, there have been only a few
studies in which the toxic consequences of cocaine self-administration
have been systematically evaluated (Deneau et al. 1969). Most of the
studies reviewed in the previous section examined cocaine self-
administration under conditions of limited access. Under these conditions
intake is remarkably well regulated and signs of drug toxicity are seldom
seen even when drug availability continues on a daily basis for years.
However, these conditions of access are determined by the experimenter,
not the organism. In contrast, in a study by Johanson et al. (1976),
access to drug was not limited; regulation disappeared and extreme and
somewhat unexpected toxicity was produced. More specifically, naive
untrained rhesus monkeys were exposed to continuous around-the-clock
access to one of a variety of psychomotor stimulant drugs in order to
simulate conditions of availability in humans. In addition to measuring
drug intake, food intake was monitored and behavioral observations were
made. For two monkeys, each lever press resulted in the infusion of
0.2 mg/kg cocaine. Both monkeys began taking drug the very first day
of its availablity and the number of infusions self-administered per day
ranged from 100 to 500 (a total of 20 to 100 mg/kg). However, both
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monkeys died following convulsions after 3 to 5 days of access. Food
intake was almost totally suppressed during this period and behavioral
changes including restlessness, stereotypic movements, dysmetria,
tremors, mydriasis, piloerection, and ataxia were observed. Similar
results were also noted with amphetamine and related drugs. Although
there were indications that some amphetamine-like drugs had less toxicity
than cocaine, the number of monkeys tested was too small to verify
this conclusion. Furthermore, in a similar study by Downs et al. (1979),
the authors claim that the toxicity of cocaine in amphetamine-
experienced monkeys was not as great (2 of 3 died) and was less than
that of methylphenidate (3 of 4 died). Unfortunately, except for weight
loss, the condition of the surviving monkey on cocaine was not described,
but its drug intake was low relative to the other monkeys. Taken as
a whole, despite minor differences, these studies would indicate that
under conditions where there are no outside restraints on drug
availability, animals can suddenly increase their drug-taking behavior to
the point of severe toxicity. In contrast, the intake of cocaine under
other conditions (i.e., limited access) is surprisingly regulated. These
differences may very well have implications for resolving the argument
between those who claim that cocaine is a safe recreational drug and
those who describe cases where users appear to “lose control” of their
drug taking. Some people may regulate their cocaine use either by
limiting their access or by a variety of other means and, like monkeys
maintained on cocaine for years, remain healthy. Others, however, for
reasons we do not understand, are described by clinicians as losing
control. The toxicity which is then produced can be extreme.
OTHER FACTORS CONTRIBUTING TO DEPENDENCE POTENTIAL
Factors which contribute to the loss of regulation in an individual could
either be internal (e.g., personality) or external. Although we may not
understand all these factors, two lines of experimental evidence give us
some clues. The first is that the reinforcing properties of cocaine,
despite qualitative similarity to other reinforcers, are relatively powerful.
The second is that some of the acute effects of cocaine in improving
performance are seductive. That this indirect effect may wane with
time and increased dose is not always appreciated.
In addition to the studies reviewed in the previous sections, there have
also been numerous studies designed to directly compare the strength
of the reinforcing properties of cocaine to other reinforcers, both drug
and nondrug. It is assumed that there is a direct relationship between
relative reinforcing properties and degree of dependence potential.
Therefore, if experimental studies demonstrate that the strength of
cocaine’s reinforcing properties is extreme, it may be concluded that
this property is one important factor contributing to its excessive illicit
use. While there is a good deal of evidence that would lead to this
conclusion, as will be described below, the assessment of relative
reinforcing properties is difficult and time-consuming and only a few
drugs have been evaluated. Many more studies would be required to
show that cocaine is a uniquely powerful reinforcer, relative to others,
particularly since it is unlikely that rankings are static. As emphasized
before, reinforcing properties are a result of a dynamic interaction
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between the drug and the environmental contingencies, and this is no
less true when comparisons across reinforcers are made.
Two types of procedures have been used with animals to measure the
reinforcing strength or efficacy of different drugs. One procedure which
has been used extensively to compare drugs, including cocaine, is the
progressive ratio schedule. In this schedule, responding is maintained by
a drug under a ratio schedule. After responding is well established, the
number of responses required for each drug infusion is systematically
increased until responding declines to below some criterion, i.e., animals
at these high ratios no longer continue to respond in order to get the
drug. The ratio value which leads to this cessation in responding is
called the breaking point. Although responding is maintained under a
ratio schedule, the breaking point, not rate of responding, is used as
the index of reinforcing efficacy. It does not matter how long an animal
takes to complete the ratio (within limits) but simply whether or not it
is finished. Using this procedure, Yanagita (1973) demonstrated that
breaking point was a direct function of the dose of cocaine. At the
highest dose of 0.48 mg/kg, animals continued responding even when
6,400 to 12,800 responses had to be made for each drug infusion.
Cocaine’s breaking point was 2 to 16 times higher than that for
methamphetamine and amphetamine. Similar results were found by
Bedford et al. (1978). Griffiths et al. (1975, 1978) determined that the
breaking point for cocaine was higher than for other stimulant or
anorec t ic  d rugs  inc lud ing  methy lphenida te ,  d ie thy lprop ion ,
chlorphentermine, and fenfluramine. However, secobarbital at the
highest dose tested showed reinforcing properties comparable to cocaine.
Studies using dogs have also demonstrated that cocaine sustains
responding at higher FR values than. d-amphetamine, mazindol,
fenfluramine (Risner and Silcox 1981), or nicotine (Risner and Goldberg
1983). It can be concluded from these studies that the reinforcing
strength of cocaine is high.
Similar results have been found using a choice procedure (Johanson and
Schuster 1975). In this procedure, described in a previous section, the
number of trials during which one option rather than the other one is
selected is used as the measure of reinforcing efficacy in much the
same way as breaking point is used in the progressive ratio procedures.
Similarly, this index is independent of rate of responding. It was found,
as might be expected, that higher doses of cocaine were preferred to
lower ones. In addition, while preference between cocaine and
methylphenidate was dose dependent (Johanson and Schuster 1975),
cocaine was generally preferred over diethylpropion (Johanson and
Schuster 1977) and procaine (Johanson and Aigner 1981). Interestingly,
in a choice procedure comparing cocaine to d,l-cathinone, these two
drugs had similar efficacy (Woolverton and Johanson 1984). Cathinone,
like cocaine, is the active alkaloid of a plant which is chewed
recreationally by inhabitants of Africa and the Middle East. In many
countries the chewing of the khat leaves has been a source of concern
for years. However, unlike coca leaves, khat leaves must be chewed
fresh, and the active alkaloid, cathinone, has only recently been isolated.
Given the similarities between cathinone and cocaine and the results of
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Woolverton and Johanson (1984), we would predict that cathinone, if it
became available, would also be extensively abused.
In addition to comparisons between cocaine and other drugs, there have
also been choice studies utilizing alternative nondrug reinforcers. For
instance, monkeys preferred even low doses of cocaine to the opportunity
to have visual contact with other monkeys (Woolverton, personal
communication). Even more compelling, monkeys given a choice between
food and cocaine preferred the latter and without experimenter
intervention might have starved (Aigner and Balster 1978). Although
clearly far more studies of this type are necessary, their implications
are profound. Cocaine may be such a powerful reinforcer that the
survival of the organism is threatened and therapeutic interventions
designed to develop alternative life-styles (i.e., reinforcers) will have
difficulty succeeding.
An alternative approach to assessing the strength of a reinforcer is to
determine its resistance to the effects of punishment. The effects of
punishment on behavior controlled by a variety of events other than
drugs have been studied extensively. Punishment is a process of reducing
the probability of a response as a consequence of: (1) the presentation of
a stimulus or (2) the removal of a stimulus contingent on the response.
In animal studies, the most frequently used punishing stimuli have been
electric shock delivery and time-out from positive reinforcement. The
degree of response suppression is dependent upon the intensity of the
punishing event and its schedule of presentation, as well as the time
delay between response and consequence. All else being equal, it could
be assumed that the greater the difficulty in decreasing the self-
administration of a particular drug, the greater is its reinforcing strength.
The effects of punishment of cocaine self-administration have been
demonstrated in several studies. Grove and Schuster (1974) examined
the ability of punishment to suppress responding maintained by cocaine
injections in monkeys under a FR 1 schedule during daily 3-hr sessions.
Punishment was accomplished by delivering a brief electric shock ranging
from 1 to 8 mA at the onset of each injection. Responding maintained
by both 0.1 and 0.2 mg/kg cocaine decreased as a function of the
intensity of the shock. However, the degree of suppression expressed as
a percent of control rates was the same for the two doses. That is,
increasing the magnitude of reinforcement did not seem to attenuate
the effects of punishment as might be expected if one assumes that
higher doses of cocaine have greater reinforcing efficacy. This finding,
however, is difficult to interpret because the baseline rates of responding
maintained by the different doses of cocaine were not the same. Because
responding was maintained under a ratio schedule, the rates maintained
by the higher dose were lower.
In a study by Bergman and Johanson (1981), responding was maintained
in rhesus monkeys by 0.1 mg/kg cocaine under a FR 10 schedule. During
single test sessions, the onset of each infusion was accompanied by the
delivery of electric shock. At intermediate intensity levels, the shock
initially reduced, but did not eliminate, cocaine-maintained responding.
Although test sessions with electric shock were separated by at least
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three nonpunished sessions, adaptation to the suppressant effects of the
shock occurred within five punishment test sessions for all monkeys.
On the other hand, adaptation did not occur with higher intensity levels
that had produced complete response suppression. This may imply that
for punishment to be effective, it must be severe enough to initially
eliminate all drug-taking behavior. It may also imply that cocaine self-
administration is difficult to punish.
Further evidence of this is also shown in a study by Johanson (1977)
using the discrete trial choice procedure previously described. Rhesus
monkeys were given a choice between two alternatives of intravenous
cocaine. These alternatives were initially equal in dose, but in subsequent
comparisons they differed in magnitude. Electric shock was delivered
at the onset of the delivery of one of the alternatives. When the two
doses were equal, the nonshocked alternative was chosen. For some
animals, the shocked alternative was preferred even when the dose of
this alternative was only twice as high. Other animals continued to
select the nonshocked alternative. However, as the dose of the shocked
alternative further increased, all animals preferred the higher dose. It
seems, therefore, that the effects of punishment can be overcome by
increasing magnitude of reinforcement, and for some animals the
necessary difference may be small.
The studies on the effects of punishment on cocaine self-administration
lead to the conclusion that cocaine has strong and robust reinforcing
properties. Unfortunately, comparable studies have not been done with
other drugs so it is impossible to make any statements about relative
strength in this context. While comparisons across drugs within the
same class may be useful in the assessment of relative dependence
potential, comparisons across drug classes may be difficult to interpret.
This is because some drugs, delivered noncontingently, have differential
effects on behavior that has been suppressed by punishment. For
instance, certain drugs such as the barbiturates attenuate the suppressant
effects of punishment, whereas other drugs such as the amphetamines
generally do not. It would be interesting to determine whether these
differential effects generalize to a situation where the drugs themselves
also function as reinforcers. One might predict that under similar
conditions, responding maintained by a barbiturate would be more
difficult to suppress with punishment than responding maintained by
cocaine.
Another demonstation that cocaine possesses strong positive reinforcing
properties emerges from studies of conditioned taste aversions. If certain
consequences (e.g., lithium chloride-induced illness) occur following the
presentation of a novel fluid or food (e.g., saccharin solution) to an
animal, the animal on subsequent presentations consumes less of that
substance. This response has been termed conditioned taste aversion or
gustatory avoidance conditioning. Initially, it was believed that only
agents that induce illness could produce a gustatory avoidance response.
However, subsequent studies have demonstrated that the administration
of psychoactive substances including psychomotor stimulants can also
induce this type of avoidance response (Cappell and LeBlanc 1978). Just
as the valence of the reinforcing properties of electric shock can be
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altered by environmental context (i.e., shock will maintain responding),
even drugs which are positive reinforcers can have aversive properties
under certain conditions (e.g., d-amphetamine). The effects of cocaine
in this paradigm have been inconsistent. Some investigators report a
weak efficacy (Booth et al. 1977; D’Mello et al. 1979; Goudie et al.
1978; Foltin et al. 1981; Foltin and Schuster 1982) while others report
that cocaine produces no avoidance responses (Cappell and LeBlanc 1978).
Although the reasons for the discrepancy are unclear, most investigators
would agree that cocaine is a weak agent, at best, in inducing a gustatory
avoidance response and its ability to do so is easily altered by minor
changes in procedure (Foltin and Schuster 1982). In contrast, other
drugs of abuse produce far greater aversions which are robust (Cappell
and LeBlanc 1978). It is conceivable that the inability to modulate the
positive reinforcing properties of cocaine may be another reason for its
extreme dependence potential.
The studies that have been reviewed to assess the dependence potential
of cocaine have evaluated the direct reinforcing properties of the drug.
But drugs may also have dependence potential because of their indirect
effects. For instance, if a drug improves performance necessary to the
well-being of a person, the desire to use the drug regardless of its other
effects may increase. A drug with both direct positive reinforcing
properties and indirect ones may have the greatest dependence potential
of all.
Since cocaine was first used experimentally, its ability to enhance
performance has been extolled (Freud 1884). There are many anecdotal
reports of enhancement, and the effects reported by cocaine users not
only include feelings of euphoria but also include claims of greater skills
across a variety of dimensions. Experimental evidence substantiating
these anecdotal claims is limited, but it does lend some support to the
hypothesis that “things go better with” cocaine. While many of these
studies are with humans (see Fischman, this volume), animal studies also
exist. In general, the effects of cocaine on operant performance are
similar to those of other psychomotor stimulants (Kelleher and Morse
1968). Regardless of the event maintaining responding the effects of
cocaine are rate-dependent, with low rates increased with low or
intermediate doses and high rates decreased in a dose-dependent manner
(Smith 1964; Spealman et al. 1977; Herling et al. 1979; Barrett 1976).
This is true even when the effects of cocaine are evaluated using a
self-administration paradigm (Spealman and Kelleher 1979). So although
high doses may eliminate responding, there are lower doses which at
least increase low-rate performance. Many other studies (e.g., Crow
1976; Schechel and Boff 1964; Torrelio and Izquierdo 1976) which have
claimed that cocaine specifically enhances performance can also be
interpreted within the context of rate dependency. Whether such
increases in rate of responding can be used as evidence of enhanced
performance is not clear. The use of other approaches not involving
rate measures has received little attention in the animal literature.
There is one report by Thompson (1977), however, showing that cocaine
can increase breaking point maintained by food in pigeons.
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Although the notion that cocaine enhances performance is widespread,
particularly among users, it is clear that there is little experimental
evidence in animals supporting it. To a large extent this is due to the
fact that little research has been done in this area either in animals
or humans (see Fischman, this volume). Additional studies will be
required in this area to determine cocaine’s effects on many types of
performances, e.g., learning, motor, sensory, etc. Even if these studies
were to demonstrate that acutely administered cocaine can improve
performance, great care should be made in interpreting such findings.
The effects of cocaine will always be dependent on dose and are likely
to change with repeated exposure to the drug. Even if improved
performance can be demonstrated with acutely administered cocaine, a
deterioration in performance may be seen either with higher doses or
when drug is repeatedly administered. But findings that acutely
administered cocaine can have positive effects is important in
understanding why humans use cocaine. That these enhancing effects
may be transitory or dose-dependent does not negate their influence in
producing subsequent drug use.
REFERENCES
Aigner, T.G., and Balster, R.L. Choice behavior in rhesus monkeys:
Cocaine versus food. Science, 201:534-535, 1978.
Altshuler, H.L., and Phillips, P.E. Intragastric self-administration of
drugs by the primate. In: Ho, B.T., Richards, D.W., and Chute, D.L.,
eds, Drug Discrimination and State-Dependent Learning. New York:
Academic Press, 1978. pp. 263-280.
Balster, R.L., and Schuster, C.R. A comparison of d-amphetamine, 1-
amphetamine, and methamphetamine self-administration in rhesus
monkeys. Pharmac Biochem Behav, 1:67-71, 1973a.
Balster, R.L., and Schuster, C.R. Fixed-interval schedule of cocaine
reinforcement: Effect of dose and infusion duration. J Exper Anal
Behav, 20:119-129, 1973b.
Barrett, J.E. Effects of alcohol, chlordiazepoxide, cocaine and
pentobarbital on responding maintained under fixed-interval schedules
of food or shock presentation. J Pharmacol Exp Ther, 196:605-615,
1976.
Bedford, J.A.; Baily, L.P.; and Wilson, M.C. Cocaine reinforced
progressive ratio performance in the rhesus monkey. Pharmac Biochem
Behav, 9:631-638, 1978.
Bergman. J., and Johanson. C.E. The effects of electric shock on
responding maintained by cocaine in rhesus monkeys. Pharmac Biochem
Behav, 14:423-426, 1981.
Booth, D.A.; Pilcher, C.W.T.; D’Mello, G.D.; and Stolerman, I.P.
Comparative potencies of amphetamine, fenfluramine and related
compounds in taste aversion experiments in rats. Br J Pharmac, 61:
669-677, 1977.
Brady, J.V., and Griffiths, R.R. Drug-maintained performance and the
analysis of stimulant reinforcing effects. In: Ellinwood, E.H.. and
Kilbey, M.M., eds. Cocaine and Other Stimulants. New York: Plenum
Press, 1977, pp. 599-613
67
Cappell, H., and LeBlanc, A.E. Gustatory avoidance conditioning by
drugs of abuse. In: Milgram, N.W.; Krane, K.; and Alloway, T.M.,
eds. Food Aversion Learning. New York: Plenum Press, 1978.
Crow, T.J. Enhancement by cocaine of intra-cranial self-stimulation in
the rat. Life Sciences, 9:375-381, 1970.
Deneau, G.A.; Yanagita, T.; and Seevers, M.H. Self-administration of
psychoactive substances by the monkey: A measure of psychological
dependence. Psychopharmacologia (Berl.), 16:30-48, 1969.
D’Mello, G.D.; Goldberg, D.M.; Goldberg, S.R.; and Stolerman, I.P.
Conditioned taste aversion and operant behavior in rats: Effects of
cocaine and a cocaine analogue (WIN 35,428). Neuropharmacology,
18:1009-1010, 1979.
Downs, D.A.; Harrigan, S.E.; Wiley, J.N.; Robinson, T.E.; and Labay, R.J.
Continuous stimulant self-administration in rhesus monkeys. Res
Comm Psycho1 Psychiat Behav, 4:39-49, 1979.
Downs, D.A., and Woods, J.H. Codeine- and cocaine-reinforced
responding in rhesus monkeys: Effects of dose on response rates under
a fixed-ratio schedule. J Pharmacol Exp Ther, 191:179-188, 1974.
Ferster, C.B., and Skinner, B.F. Schedules of Reinforcement. New York:
Appleton-Century-Crofts, 1957.
Foltin, R.W., and Schuster, C.R. The effects of cocaine in a gustatory
avoidance paradigm: A procedural analysis. Pharmac Biochem Behav,
16:347-352, 1982.
Foltin, R.W.; Preston, K.L.; Wagner, G.C.; and Schuster, C.R. The
aversive stimulus properties of repeated infusions of cocaine.
Pharmacol Biochem Behav, 15:71-74, 1981.
Freud, S. Uber coca. Zentbl. Ther., 2:289-314, 1884.
Goldberg, S.R. Comparable behavior maintained under fixed-ratio and
second-order schedules of food presentation, cocaine injection, or d-
amphetamine injection in the squirrel monkey. J Pharmacol Exp Ther
186:18-30, 1973.
Goldberg, S.R., and Kelleher, R.T. Behavior controlled by scheduled
injections of cocaine in squirrel and rhesus monkeys. J Exper Anal
Behav, 25:93-104, 1976.
Goldberg, S.R., and Kelleher, R.T. Reinforcement of behavior by cocaine
injections. In: Ellinwood, E.H., and Kilbey, M.M., eds. Cocaine and
Other Stimulants. New York: Plenum Press, 1977, pp. 523-544.
Goldberg, S.R.; Kelleher, R.T.; and Goldberg, D.M. Fixed-ratio
responding under second-order schedules of food presentation or
cocaine injection. J Pharmacol Exp Ther, 218:271-281, 1981.
Goldberg, S.R.; Kelleher, R.T.; and Morse, W.H. Second-order schedules
of drug injection. Fed Proc, 34:1771-1776, 1975.
Goldberg, S.R.; Morse, W.H.; and Goldberg, D.M. Behavior maintained
under a second-order schedule of intramuscular injection of morphine
or cocaine in rhesus monkeys. J Pharmacol Exp Ther, 199:278-286,
1976.
Goldberg, S.R.; Spealman, R.D.; and Kelleher, R.T. Enhancement of
drug-seeking behavior by environmental stimuli associated with cocaine
or morphine injections. Neuropharmacology 18:1015-1017, 1979.
Goudie, A.J.; Dickins, D.W.; and Thornton, E.W. Cocaine-induced
conditioned taste aversions in rats. Pharmac Biochem Behav, 8:757-
761, 1978.
68
Griffiths, R.R.; Findley, J.D.; Brady, J.V.; Dolan-Gutcher, K.; and
Robinson, W.W. Comparison of progressive-ratio performance
main ta ined  by  coca ine ,  methy lphenida te ,  and  secobarb i ta l .
Psychopharmacologia, 43:81-83, 1975.
Griffiths, R.R.; Bigelow, G.E.; and Henningfield, J.E. Similarities in
animal and human drug taking behavior. In: Mello, N.K., ed. Advances
in Substance Abuse: Behavioral and Biological Research. Greenwich,
Conn: JAI Press, 1980, pp. 1-90,
Griffiths, R.R.; Brady, J.V.; and Snell, J.D. Progressive ratio
performance maintained by drug infusions: Comparison of cocaine,
diethylpropion, chlorphentermine and fenfluramine.
Psychopharmacology, 56:5-13, 1978.
Grove, R.N., and Schuster, C.R. Suppression of cocaine self-
administration by extinction and punishment. Pharmac Biochem Behav,
2:199-208, 1974.
Herling, S.; Downs, D.A.; and Woods, J.H. Cocaine, d-amphetamine, and
pentobarbital effects on responding maintained by food or cocaine in
rhesus monkeys. Psychopharmacology, 64:261-269, 1979.
Iglauer, C., and Woods, J.H. Concurrent performances: Reinforcement
by different doses of intraveous cocaine in rhesus monkeys. J Exper
Anal Behav, 22:179-196, 1974.
Johanson, C.E. The effects of electric shock on responding maintained
by cocaine injections in a choice procedure in the rhesus monkey.
Psychopharmacology, 53:277-282, 1977.
Johanson, C.E., and Aigner, T. Comparison of the reinforcing properties
of cocaine and procaine in rhesus monkeys. Pharmac Biochem Behav,
15:49-53, 1981.
Johanson, C.E., and Balster, R.L. A summary of the results of a drug-
self-administration study using substitution procedures in rhesus
monkeys. Bull Narc, 30:43-54, 1978.
Johanson, C.E. Balster, R.L.; and Bonese, K. Self-administration of
psychomotor stimulant drugs: The effects of unlimited access.
Pharmac Biochem Behav, 4:45-51, 1976.
Johanson, C.E. Schuster, C.R. .A choice procedure for drug
reinforcers: Cocaine and methylphenidate in the rhesus monkey. J
Pharmacol Exp Ther, 193:676-688, 1975.
Johanson, C.E., and Schuster, C.R. A comparison of cocaine and
diethylpropion under two different schedules of drug presentation. In:
Ellinwood, E., and Kilbey, M.M., eds. Cocaine and Other Stimulants.
New York: Plenum Press, 1977, pp. 545-570.
Johanson, C.E., and Schuster, C.R. Animal models of drug self-
administration. In: Mello, N.K., ed. Advances in Substance Abuse:
Behavioral and Biological Research. Vol. II. Greenwich, Conn: JAI
Press, 1981, pp. 219-297.
Katz, J.L. A comparison of responding maintained under second-order
schedules of intramuscular cocaine injection or food presentation in
squirrel monkeys. J Exper Anal Behav, 32:419-431, 1979.
Katz, J.L. Second-order schedules of intramuscular cocaine injection
in the squirrel monkey: Comparisons with food presentation and effects
of d-amphetamine and promazine. J Pharmacol Exp Ther, 212:405-
411, 1980.
Kelleher, R.T. Conditioned reinforcement in second-order schedules. J
Exper Anal Behav, 9:475-485, 1966.
69
Kelleher, R.T. Characteristics of behavior controlled by scheduled
injections of drugs. Pharmacol Rev, 27:307-323, 1975.
Kelleher, R.T., and Goldberg, S.R. Fixed-interval responding under
second-order schedules of food presentation or cocaine injection. J
Exper Anal Behav, 28:221-231, 1977.
Kelleher, R.T., and Morse, W.H. Determinants of the specificity of
behavioral effects of drug. Ergebnisse der Physiologie, 60:1-56, 1968.
Pickens. R., and Thompson, T. Cocaine-remforced behavior in rats:
Effects of reinforcement magnitude and fixed-ratio size. J Pharmacol
Exp Ther, 161:122-129, 1968.
Risner, M.E., and Goldberg, S.R. A comparison of nicotine and cocaine
self-administration in the dog: Fixed-ratio and progressive-ratio
schedule of intravenous drug infusion. J Pharmacol Exp Ther, 224:
319-326, 1983.
Risner, M.E., and Jones, B.E. Self-administration of CNS stimulants by
dog. Psychopharmacologia, 43:207-213, 1975.
Risner, M.E., and Silcox, D.L. Psychostimulant self-administration by
beagle dogs in a progressive-ratio paradigm. Psychopharmacology, 75:
25-30, 1981.
Scheckel, C.L., and Boff, E. Behavioral effects of interacting imipramine
and other drugs with d-amphetamine, cocaine, and tetrabenazine.
Psychopharmacologia, 5:198-208, 1964.
Schuster, C.R.; Renault, P.E.; and Blaine, J. An analysis of the
relationship of psychopathology to non-medical drug use. In: Pickens,
R., and Heston, L.L., eds. Psychiatric Factors in Drug Abuse. New
York :  Grune  and  S t r a t t on ,  1979 ,  pp .  1 -19
Siegel, R.K.; Johnson, C.A.; Brewster, J.M.; and Jarvik, M.E. Cocaine
self-administration in monkeys by chewing and smoking. Pharmacol
Biochem Behav, 4:461-467, 1976.
Smith, C.B. Effects of d-amphetamine upon operant behavior of pigeons:
Enhancement by reserpine. J Pharmacol Exp Ther, 146:167-174, 1964.
Spealman, R.D.; Goldberg, S.R.; Kelleher, R.T.; Goldberg, D.M.; and
Charlton, J.P. Some effects of cocaine and two cocaine analogs on
schedule-controlled behavior of squirrel monkeys. J Pharmacol Exp
Ther, 202:500-509, 1977.
Spealman, R.D., and Kelleher, R.T. Behavioral effects of self-
administered cocaine: Responding maintained alternately by cocaine
and electric shock in squirrel monkeys. J Pharmacol Exp Ther, 210:
206-214, 1979.
Stretch, R. Discrete-trial control of cocaine self-injection behavior in
squirrel monkeys: Effects of morphine, naloxone, and chlorpromazine.
Canad J Physiol Pharmacol 55:778-790, 1977.
Thompson, D.M. Effects of cocaine and fenfluramine on progressive-
ratio performance. Pharmacol Biochem Behav, 7:555-558, 1977.
Thompson, T., and Unna, K., eds. Predicting Dependence Liability of
Stimulant and Depressant Drugs.
1 9 7 7 .  
Baltimore: University Park Press,
Torrelio, M., and Izquierdo, J.A. Pre-trial cocaine and performance in
rat. Psychopharmacologia, 45:283-285, 1976.
Weeks, J.R. Experimental morphine addiction: Method for automatic
intravenous injections in unrestrained rats. Science, 138:143-144, 1962.
70
Wilson, M.C., and Schuster, C.R. Interactions between atropine,
chlorpromazine and cocaine on food reinforced behavior. Pharmac
Biochem Behav, 3:363-375, 1975.
Wilson, M.C.; Hitomi, M.; and Schuster, C.R. Self-administration of
psycomotor stimulants as a function of unit dosage.
Psychopharmacologia (Berl.), 22:271-281, 1971.
Woods, J.H., and Schuster, C.R. Reinforcement properties of morphine,
cocaine, and SPA as a function of unit dose. Int J Addictions, 3:231-
237, 1968.
Woolverton, W.L., and Johanson, C.E. Preference in rhesus monkeys
given a choice between cocaine and d,l-cathinone. J Exp Anal Behav,
41:35-43, 1984.
Woolverton, W.L., and Schuster, C.R. Intragastric self-administration in
rhesus monkeys under limited access conditions: Methodological studies.
J Pharmacol Methods, 10:93-106, 1983.
Yanagita, T. An experimental framework for evaluation of dependence
liability in various types of drugs in monkeys. Bull Narc, 25:57-64,
1973.
Yanagita, T.; Deneau, G.A.; and Seevers, M.H. Evaluation of
pharmacologic agents in the monkev bv long-term intravenous self-
or programmed administration. Excerpta Med Int Congr Ser, 87:453-
457. 1965.
Young, A.M., and Woods, J.H. Behavior maintained by intravenous
injection of codeine, cocaine, and etorphine in the rhesus macaque
and the pigtail macaque. Psychopharmacology, 70:263-271, 1980.
ACKNOWLEDGEMENTS
The preparation of this manuscript was supported by grant DA 00250
from the National Institute on Drug Abuse.
AUTHOR
Chris E. Johanson, Ph.D.
The University of Chicago
Department of Psychiatry
950 East 59th Street
Chicago, IL 60637
71
The Behavioral Pharmacology of
Cocaine in Humans
Marian W. Fischman
In 1977, in response to a perceived rise in the use of
cocaine in this country, the National Institute on Drug
Abuse presented an "...attempt to summarize our
admittedly limited knowledge of cocaine through a series
of reports by leading workers in the cocaine area"
(Petersen and Stillman 1977, p. 1). One of the chapters
in that monograph was entitled, "What are the Effects of
Cocaine in Man?" (Byck and Van Dyke 1977). The most
striking aspect of the response to that question was how
little was actually known at that time. In fact, fewer
than 10 laboratory studies investigating the effects of
cocaine in humans were listed in the bibliography.
Since then, the topic has received considerably more
attention in several laboratories, allowing a more
complete description of the behavioral pharmacology of
cocaine in humans.
This paper reviews the available laboratory data on the
behavioral and physiological effects of cocaine in
humans. Since cocaine is self-administered via a number
of different routes, wherever possible the effects of
using this drug orally, intranasally, intravenously, and
by smoking are described. A major theme in the self-
reports of cocaine users is the insistence that they can
do anything better under the influence of cocaine. The
currently available data, reviewed in this paper, do not
support this idea. In addition, since cocaine and
amphetamine have very similar profiles of action, it is
appropriate to use the laboratory data on amphetamine's
effects to predict cocaine's effects. These, too, would
not lead us to believe that cocaine is a good
performance-enhancer. We would also predict that
cocaine would have toxic and disruptive effects similar
to those seen with amphetamine. Thus, the existence of
a cocaine psychosis after repeated cocaine use is
predictable on the basis of empirical laboratory
evidence showing the development of an amphetamine
psychosis after continuous amphetamine administration
(Griffith et al. 1972). Although questions about the
consequences of repeated cocaine use still remain, the
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research reviewed here has provided the foundation on
which these studies can be built.
ROUTES OF COCAINE ADMINISTRATION
Oral
Coca leaves have been harvested and chewed for more than
3000 years (Carroll 1977) by the Indians living in the
area of the Andes Mountains in South America. They chew
a combination of coca leaves and an alkaline substance
to release the cocaine from the leaves. Paly et al.
(1980a) measured plasma levels of cocaine in Peruvian
Indians who were allowed to chew measured amounts of
coca leaves under controlled laboratory conditions.
Plasma levels reaching 95 ng/mg peaked shortly after
cessation of chewing, and the levels achieved appeared
to be related to the amount of cocaine in the chewed
leaves. Despite elevated plasma levels, little "high"
was reported in these chewers (Byck et al. 1980),
perhaps due to the slow change in cocaine blood level.
It was suggested that absorption occurred through the
mucous membrane of the mouth as well as through the
lower gastrointestinal tract since saliva containing the
coca juice was swallowed as chewing continued. The
correlation between dose and plasma level was also found
by Holmstedt et al. (1978), who reported that the
stimulating or energizing effect of the coca seemed to
be well correlated with the rising concentrations of
cocaine in the blood.
The most complete series of studies with oral cocaine
was carried out by Sigmund Freud in the late 188Os, who
described in some detail the results of his self-
experimentation with pure cocaine. He described the
onset of action as occurring within 10-20 minutes, with
a stimulant effect which lasted for as long as 4-5
hours. Little has been added to his enthusiastic
description of the stimulant and euphorigenic qualities
of oral cocaine. Some of the other effects he
hypothesized, however, such as its substitution for
morphine, have not withstood the tests of time or
further experimentation.
In an attempt to eliminate buccal absorption and
determine whether or not cocaine was inactivated in the
gastrointestinal tract, Van Dyke et al. (1978)
administered cocaine-filled gelatin capsules. Under
these conditions, peak plasma concentrations were
reached at approximately 65 minutes after ingestion
(Wilkinson et al. 1980) and dissipated about as rapidly
as after intravenous administration.
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Intravenous
Cocaine was first isolated from coca leaves in 1860
(Mortimer 1901), and, once available in a pure and
considerably less cumbersome form, it was inevitable
that it would be used by other routes of administration.
The intravenous (i.v.) route of administration has
remained a popular one with "serious," and perhaps more
experienced drug users , since the drug goes rapidly to
the brain; and subjective effects, including an intense
"rush," are reported within 1 or 2 minutes (Resnick et
al. 1977; Javaid et al. 1978). Estimates of dose made
by laboratory subjects suggest that the average dose of
cocaine injected intravenously by users in a
recreational setting is approximately 16 mg/injection
(Fischman et al. 1976). Cocaine plasma levels are
correlated with dose of intravenous cocaine (Barnett et
al. 1981; Javaid et al. 1983), and plasma levels of
approximately 300 ng/ml have been recorded after single
32 mg doses (Javaid et al. 1978). It appears that the
elimination half-life of cocaine by this route is
approximately 40 minutes (Kogan et al. 1977; Javaid et
al. 1983) although it has been suggested that this value
is dose-related, increasing at very high doses (Barnett
et al. 1981).
Intranasal
The most common nonmedical method of cocaine self-
administration is "snorting," or inhaling. The
crystalline substance is inhaled in its hydrochloride
form, and is then absorbed through the nasal mucous
membranes. A "line" of powder (20-30mg) is laid out and
inhaled, and the user experiences approximately 20-40
minutes of stimulation, although no initial "rush."
Repeated intranasal use of cocaine has potentially
adverse physical consequences, including chronic
rhinitis and, rarely, a perforated nasal septum. Peak
plasma levels after intranasal crystalline cocaine occur
at 30-40 minutes subsequent to inhalation (Javaid et al.
1978; Wilkinson et al. 1980) and not until 60 minutes
after intranasal administration of the drug via cotton
soaked with cocaine solution (Van Dyck et al. 1976).
Peak plasma levels of 150-200 ng/ml are obtained after
inhalation of 96 mg crystalline cocaine (Javaid et al.
1978). The half-life for intranasal cocaine
administered as a powder or a 10% topically applied
solution is approximately the same as after intravenous
administration (Wilkinson et al. 1980; Javaid et al.
1983).
Smoked
The smoking of coca paste has been reported to be
widespread in Peru, Ecuador, Colombia, and Bolivia (Jeri
et al. 1980). The coca paste, containing solvents, is
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mixed with tobacco or marijuana and smoked. Subjects
tested in a research setting and allowed to smoke
controlled amounts of coca paste on tobacco cigarettes
showed peak plasma levels as high as 975 ng/ml within 5-
10 minutes after smoking 0.5 g paste (Paly et al.
1980b). Plasma half life of cocaine was similar to that
after other routes of administration. In subjects
allowed to smoke ad libitum for 90 minutes, blood levels
were fairly constant and similar during a second 90-
minute session (Paly et al. 1982), indicating excellent
dose regulation.
A more efficient method of self-administering cocaine
via the smoking route has emerged in recent years.
Cocaine is taken as the water-soluble hydrochloride when
self-administered orally, intravenously, and
intranasally. However, cocaine hydrochloride decomposes
at the high temperatures necessary for smoking. Cocaine
"free base," in which the cocaine alkaloid is "freed"
from the hydrochloride salt (see Siegel 1982 for a
review of this), has a melting point of 98°C and is
volatile at temperatures above 90° , therefore providing
an active drug for smoking. Extraction kits for
converting the hydrochloride to the base are
commercially available. Perez-Reyes et al. (1982)
allowed subjects to smoke 50 mg cocaine free base and
determined that no more than 32% could have been
inhaled. Users interviewed by Siegel (1982) indicated
that they generally began with approximately 81 mg of
the base, and increased the amount of each "hit" to as
high as 252 mg with the development of tolerance.
Although no pharmacokinetic or blood level studies have
been published, Siegel (1982) has reported that chronic
cocaine free base smokers have shown plasma levels of
800-900 ng/ml 3 hours after smoking.
PHYSIOLOGICAL EFFECTS
The primary physiological parameters measured after
cocaine administration have been cardiovascular
functions. When administered intravenously in doses
ranging from 8-32 mg, cocaine, like amphetamine,
produces a dose-related increase in heart rate and blood
pressure which begins 2-5 minutes after injection and
peaks approximately 6-8 minutes later regardless of dose
(Fischman et al. 1976; Resnick et al. 1977). These
effects appear to parallel plasma levels, peaking early
and showing decreases over the first 30 minutes after
injection (Javaid et al. 1978). Cocaine has not been
shown to have any effect on the electrocardiogram in
i.v. doses of 4-32 mg (Fischman et al. 1976) nor, in
doses of 10 and 25 mg, on respiratory rate and body
temperature (Resnick et al. 1977). Intranasal cocaine
administered in crystalline or in solution form has
similar effects excepting that onset is delayed. Peak
effects occur approximately 30 minutes after drug
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administration (Resnick et al. 1977; Javaid et al.
1978), and the cardiovascular changes dissipate within
the next 30 minutes, while blood levels are still
elevated. Oral doses of 30-200 mg/day given in divided
doses do not affect pulse, temperature, blood pressure,
or respiration (Post et al. 1974b). These oral doses
did, however, have a suppressive effect on both rapid
eye movement (REM) sleep and total sleep. The effect of
cocaine on REM sleep appears to be dose-related although
this could be an artifact of the number of days of use
as the drug was administered daily for 6 days in an
ascending series. Cocaine’s effects on sleep parallel
those seen after amphetamine (e.g., Rechtschaffen and
Maron 1964), an indication of the similarity of action
of these drugs.
SUBJECTIVE EFFECTS
Cocaine’s mood elevating properties were first described
almost 100 years ago (Freud, in Donoghue and Hillman
1963), and the drug still retains its reputation as the
euphoriant of choice among stimulant users. Experienced
drug users, however, often cannot differentiate among
cocaine, amphetamine, methamphetamine, and
methylphenidate (Martin et al. 1970; Fischman et al.
1976), all of which appear to have similar profiles of
action.
A consistent profile of cocaine’s effects generally
emerges when normal volunteers are administered the drug
and answer standard drug effects questionnaires. When
the Profile of Mood States (POMS), a five-point
adjective checklist, was administered after intravenous
cocaine, generally dose-related increases in a number of
scale scores were obtained. These were: Confusion,
Anxiety, Friendliness, Vigor, Elation, Arousal, and
Positive Mood (Fischman et al. 1983a; 1983b). Scores on
selected scales of the Addiction Research Center
Inventory (ARCI), a true-false test measuring drug
effects, have also consistently reflected the stimulant
properties of cocaine. Increases, generally dose-
related, were found in scores on the amphetamine (A)
scale (Fischman et al. 1976; Resnick et al. 1977) as
well as the morphine-benzedrine general scale (MBG,
thought to be a measure of a drug’s euphoric effects)
and benzedrine general (BG) scale. Decreases were found
on the pentobarbital-chlorpromazine-alcohol general
(PCAG) scale which measures sedative effects (Fischman
et al. 1976; 1983a; 1983b). Cocaine also resulted in
increased scores on scales of “pleasantness” (Resnick
et al. 1977), “high” (Fischman et al. 1983a; 1983b;
Resnick et al. 1977), and “stimulated” (Fischman et al.
1983a; 1983b) as well as decreased scores on ratings of
“hunger” (Resnick et al. 1977). Subjects who had
substantial histories of i.v. cocaine use generally
rated 16 mg i.v. cocaine as similar to the average dose
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that they were self-injecting outside of the laboratory,
and 24, 32, and 48 mg all as among the highest doses
they had ever experienced (Fischman et al. 1976; 1983a;
1983b). The "high" obtained from i.v. cocaine began as
an intense "rush," peaked approximately 3-5 minutes
after injection, and was dissipated within 30-40
minutes, when subjects indicated that they would like
another dose of drug (Javaid et al. 1978).
Subjects' reports of cocaine's effects after intranasal
administration were quite similar to those after
intravenous administration but less intense, slower in
onset and without the initial "rush." Doses of 25-100
mg were followed by increases in "high" (Resnick et al.
1977; Van Dyke et al. 1979) and "pleasantness" (Resnick
et al. 1977) scale scores, as well as the A (Resnick et
al. 1977; Fischman and Schuster 1980) and MBG (Fischman
and Schuster 1980) scales of the ARCI. Doses as high as
96 mg did not affect scores on any of the scales of the
POMS. When cocaine was administered as a solution, peak
"high" ratings occurred within 5-15 minutes and returned
to baseline values between 2 and 4 hours after drug
administration (Van Dyke et al. 1979). When the white
powder was inhaled, subjects reported that their maximum
"high" occurred 15-20 minutes after inhalation (Resnick
et al. 1977; Javaid et al. 1978) and returned to
baseline levels within 60-90 minutes (Javaid et al.
1978).
Cocaine given by the oral route appears to be effective
in producing an increase in "high" ratings (Van Dyke et
al. 1978). Subjects swallowed a gelatin capsule
containing 2 mg/kg cocaine, and reported a "high" which
peaked at 75 minutes and was dissipated approximately
three hours after swallowing the drug. This
effectiveness of cocaine via the oral route is expected
in view of the reported use patterns of the Andean
Indians since ancient times. Interestingly, until
recently textbooks of pharmacology have stated that
cocaine is rapidly hydrolyzed, and thereby rendered
ineffective in the gastrointestinal tract (e.g., Ritchie
and Cohen 1975). Clearly this is not so, although the
delay in effect might indicate that the drug is not well
absorbed until it reaches the small intestine.
When cocaine is smoked as the base, 37 mg of smoked base
and 20 mg of i.v. cocainehave approximately comparable
effects (Perez-Reyes et al. 1982) as measured by peak
scores and duration of effect on the POMS. ARCI and
"high" scales. Smoking caused significantly greater
effects on the Vigor scale of the POMS and the
"pleasantness" score. Degree of self-reported craving
for another dose of cocaine at 30 minutes was greater
after smoking the drug as compared with taking it
intravenously.
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The apparent acute stimulant and euphoriant properties
of cocaine led to examination of its potential as an
antidepressant in a group of depressed patients (Post et
al. 1974). Oral doses ranging from 5 mg/day to 100
mg/day had no consistent effects on mood of the
depressed patients studied. Intravenous doses of 2.5-25
mg often were effective in causing mood change, with
doses associated with marked physiological effects
usually resulting in intense mobilization of affect and
tearfulness. Milder changes in vital signs were usually
accompanied by more positive affective changes. Resnick
et al. (1977) reported that one subject who received 25
mg i.v. cocaine showed marked crying in response to the
drug. However, this subject had reported feeling
depressed at the start of the experimental session. It
thus seems that not all of cocaine's effects have been
described as euphoria-producing. The baseline affective
state of the subject may well play a role in the effect
of cocaine on observed mood and verbal report of its
effect.
Resnick et al. (1977) reported a biphasic response to
cocaine beginning with a stimulant effect followed 30-60
minutes after drug by a "crashing" effect,
"characterized by feelings of anxiety, depression,
fatigue, and wanting more cocaine." This cocaine
"crash" has been described by "street" users, but with
the exception of Resnick et al. (1977) generally has not
been described in laboratory studies. Fischman and
Schuster (1980) reported that between 4 and 8 hours
after intranasal self-administration of 96 mg, scores on
the PCAG scale (a sedative scale) of the ARCI were
substantially elevated and a composite stimulant score
(A + MBG + BG) was substantially lower than after
inhalation of placebo. This is somewhat longer than
might be expected for a "crash" effect based on the data
from) Resnick's laboratory.
TOLERANCE
There is anecdotal evidence that cocaine users can
increase their intake of cocaine to levels that might be
lethal to the cocaine-naive user. Although no long-term
repeated dose studies have been carried out with cocaine
in humans, Fischman et al. (in press) have demonstrated
the development of an acute tolerance to the
cardiovascular and subjective effects of intravenous
cocainewhen it is given 1 hour after a 96 mg intranasal
pretreatment as compared with the effects of the same
intravenous dose given after a placebo intranasal
pretreatment. In addition, when research subjects were
allowed to self-administer 16 or 32 mg cocaine
intravenously every 6-10 minutes for an hour, the
initial injections of drug exerted maximal
cardiovascular and subjective effects, with subsequent
repeated injections within an hour having smaller
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effects (Fischman and Schuster 1982). This apparent
tachyphylaxis does not appear to be dispositional
because blood levels rose at a rate consistent with the
dose being administered repeatedly.
EFFECTS ON LEARNING
Most research on drug-behavior interactions has
concentrated on studying the effects of drugs on
previously learned tasks (i.e., on performance rather
than on acquisition). However, behavior in transition
might be more sensitive to a drug’s effects than a well
learned response would be. Fischman (1978) described a
procedure adapted from the animal laboratory (Boren
1967; Thompson and Moersbacher 1979) for repeatedly
measuring acquisition of behavior in individual research
subjects.
Volunteer research subjects, working for points which
could be exchanged for money, were required to learn a
fixed sequence of 10 responses on 3 response keys. The
sequence of 10 correct responses was changed for each
10-minute session. Within 10 sessions subjects showed
stable acquisition curves from session to session as
indicated by consistent within-session response rates
and numbers of errors. This behavioral baseline on the
repeated acquisition task was used to assess the effects
of intravenous and intranasal cocaine. Seven subjects
were tested with two determinations at each dose of drug
(administered according to a modified Latin square
design). Repeated acquisition tests were given pre-
drug, in conjunction with drug administration, and 20
and 35 minutes after drug administration. Four
different repeated acquisition tasks were thus studied
within a 1-hour experimental session.
Response rate was generally unaffected by cocaine
regardless of the dose administered (figure 1). The
number of errors per 10-minute session, however,
increased in a dose-related fashion following both
intranasal and intravenous administration of cocaine and
was highest after 32 mg intravenous cocaine, the largest
i.v. dose administered. Verbal reports of cocaine’s
effects correlated with its other behavioral effects and
with peak plasma level. Scores on both the POMS and the
ARCI showed changes similar to those seen after
administration of cocaine in other experimental
situations (e.g., Fischman and Schuster 1980). Thus,
both learning and verbal report of drug effect were
maximally affected by intravenous cocaine immediately
after injection, and by intranasal cocaine 20 minutes
after inhalation. These data suggest that, at
sufficient doses, cocaine interferes with tasks
involving the acquisition of new behavior patterns, the
first time that a cocaine-induced disruption in an
operant task in humans has been demonstrated. This is
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Figure 1. Effects of cocaine on learning new behavior
patterns. Data collected during each pre-drug
repeated acquisition task were averaged across
subjects; the mean (± SEM indicated by broken
horizontal lines) is used as the baseline score.
Change from baseline is shown for number of errors and
response rate during each of the three 10-minute post-
drug tests. Cocaine was inhaled at doses of 4, 64,
and 96 mg, and 32 mg was injected intravenously. S
indicates an intravenous saline injection.
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important since cocaine clearly has central nervous
system effects as evidenced by the verbal reports of
subjects describing its mood-altering effects. Despite
such reliable effects on verbal report, it has been
difficult to show other behavioral effects of this drug
when it is administered in single doses in the dose
range taken for recreational purposes.
EFFECTS ON PERFORMANCE
It has been suggested that the Andean Indians chew coca
because it reduces hunger, produces a sensation of
warmth, and enhances working ability (Hanna 1971). In
fact, interviews with Indian coca-chewers yielded
statements reflecting the belief that chewing enabled
them to work harder: "Yes, I chew; I work hard.”
(Negrete and Murphy 1967, p. 14) In an initial study of
the response of coca chewers to exercise (Hanna 1970) it
was found that chewers, as compared to non-chewers,
showed a lower exercise and recovery heart rate after
using a bicycle ergometer, suggesting a slight advantage
for the chewers. However, a more careful examination of
the control group data indicated that the two groups
were not well matched, and a second study using a
bicycle ergometer and comparing matched groups of coca-
chewers and non-chewers found no differences between the
two groups in energy expenditure or efficiency over a
range of work levels. Thus, the belief that coca use
makes work easier was not supported.
There have been a number of suggestions that long-term
regular ingestion of cocaine through the chewing of coca
leaves causes deficits in such behaviors as attention,
speed of responding, accuracy on tests, etc. (Cagliotti
1980; Zapata-Ortiz 1970). In an effort to investigate
possible performance deficits of long-term coca chewers,
Negrete and Murphy (1967) compared their performance to
performance by a group of non-chewers using a battery of
“intelligence” tests, auditory and visual memory tests,
and attention tests. In general, controls scored better
than chewers, although the differences were not
substantial. A causal relationship between coca chewing
and lower test scores was not demonstrated, and the
results could have been due to variables other than coca
chewing since groups were not well matched and testing
was not blind. Further, the differences in test scores
between the two groups was not reflected in their
general social functioning or work behavior.
Cocaine users, as with coca chewers, frequently report
that the drug enhances performance, but, with few
exceptions this effect has never been investigated
experimentally. Freud's self-experimentation led him to
conclude that cocaine enhanced physical and mental
capacity and restored the fatigued person to maximal
alertness (in Donoghue and Hillman 1963). Resnick et al.
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(1980), however, reported that neither 10 nor 25 mg
cocaine administered intravenously or intranasally had
an effect on hand-grip strength. Inhalation of 96 mg
cocaine also had no effect on performance of a reaction
time task in rested subjects (Fischman and Schuster
1980). However, when subjects were deprived of sleep
for 24-48 hours, which resulted in a fatigue-induced
decrement in performance, inhalation of 96 mg cocaine
reversed (after 24 hours) or partially reversed (after
48 hours) the decrement. Freud also indicated that his
cocaine-induced increase in physical capacity as
measured by performance on a dynamometer was greatest
when his condition was poor. No other research has been
carried out investigating the effects of cocaine on
performance in humans. Substantial data do exist,
however, indicating that, in general, the amphetamines
have minimal effects on performance in the non-sleep-
deprived subject (see reviews by Weiss and Laties 1962;
Weiss 1968) but are generally successful in returning to
its pre-deprivation level performance which has
deteriorated due to fatigue (Kornetsky et al. 1959).
Laties and Weiss (1981) have recently pointed out,
however, that the small changes induced by amphetamines
can result in the one or two percent improvement which
can make the difference in a close athletic competition.
Such data are not available for cocaine, but its short
duration of action argues against the usefulness of such
an effect.
SELF-ADMINISTRATION
As indicated by another article in this monograph (see
Johanson), cocaine is a potent reinforcer, readily self-
administered by laboratory animals and often used as the
training drug for drug-naive animals. In addition,
reports of illicit cocaine use indicate substantial
increases during the past 5 to 10 years, both in the
drug-taking population as a whole and particularly in
young adults (Richards 1981). Cocaine-related emergency
room visits have also increased as indicated by the
DAWN1 survey data.
Only limited data are available describing cocaine self-
administration by humans under controlled laboratory
conditions (see Fischman and Schuster 1982). Subjects
given a choice between injections of i.v. cocaine or
saline approximately once every 6 minutes for 1 hour
consistently chose cocaine (16 or 32 mg). As with
laboratory animals, drug injections were fairly
regularly spaced and intravenous cocaine intake reached
224 mg, with plasma levels of approximately 1200 ng/ml.
This kind of regulation in intake was also seen with
subjects allowed to smoke cocaine paste during a 90-
minute limited access procedure (Paly et al. 1982).
Subjects self-administering i.v. cocaine indicated that
they felt high, stimulated, "weird; and anorexic for 2-3
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hours after these sessions; several subjects indicated
that they had difficulty sleeping 8-14 hours later.
Cocaine, therefore, has been shown to serve as a
positive reinforcer in humans and can maintain drug-
taking behavior under limited access conditions daily
for a two-week period.
SYNTHETIC LOCAL ANESTHETICS
Although the reinforcing properties of cocaine have been
documented in the laboratory for both human and non-
human research subjects, it is only recently that other
local anesthetics have been similarly studied (Ford and
Balster 1977; Hammerbeck and Mitchell 1978; Woolverton
and Balster 1979; Johanson 1980). Drugs such as
procaine, chloroprocaine, and dimethocaine are self-
administered by rhesus monkeys, while lidocaine,
proparacaine, and procainamide do not appear to serve as
positive reinforcers in those animals. These data have
been puzzling, since, in general, drugs which serve as
reinforcers in animals do so in humans (Johanson and
Balster 1978), and it is assumed that this property is
an important factor in their dependence potential.
Despite these reports of local anesthetic self-
administration in non-humans, however, none of the drugs
mentioned above appear to be commonly abused by humans.
A traditional approach to the evaluation of a drug's
dependence potential is to compare its spectrum of
action to that of a known drug of abuse (Fischman 1977;
Jasinski 1977). Similarity to the prototype along
several dimensions is then used to predict possible
abuse liability. Two recently published studies have
investigated the cardiovascular and subjective effects
of synthetic local anesthetics using such an approach
(Fischman et al. 1983a, 1983b). In both studies
volunteer subjects were tested with a range of
intravenous doses of cocaine and matched intravenous
doses of either procaine or lidocaine. The effects of
the two local anesthetics on verbal report of drug
effect (as measured by the POMS, the ARCI, a series of
visual analog scales evaluating drug effects, and a drug
identification question), and measures of heart rate and
blood pressure were compared to the effects of cocaine
using the same measures.
In the preceding comparative studies, only cocaine had
significant effects on heart rate and blood pressure,
similar to those previously reported for this drug after
intravenous administration. When the effects of 16, 32,
and 48 mg cocaine on verbal report were compared with
those of placebo, there was a dose-related increase in
stimulant scale scores on the ARCI, POMS and Visual
Analog Rating Scales. In contrast, matched doses of
lidocaine or procaine did not produce any effects
different from placebo except on the "high" and
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"stimulated" scales of the Visual Analog Scale. The
only measurable effect was a small but significant
increase in "high" and "stimulated" scores after 96 mg
procaine as compared with placebo. Subjects identified
both 48 and 96 mg procaine as cocaine and were accurate
in identifying saline as placebo and cocaine as cocaine.
All doses of lidocaine and 16 and 32 mg procaine were
identified as placebo.
There has, however, been one report of subjects giving
similar ratings of "high" to cocaine and lidocaine when
these two drugs were topically administered in solution
intranasally in matched doses of 0.19, 0.38 and 0.75
mg/kg (Van Dyck et al. 1979). However, statistical tests
were not applied to the data, making interpretation
difficult. It seems likely that the two lower doses of
cocaine were not discriminable from placebo. Although
cocaine plasma levels were not reported by Van Dyck et
al. in this study, levels after 1.5 mg/kg delivered by
the same route in another study resulted in peak plasma
levels of 130-165 ng/ml (Van Dyck et al. 1976).
Extrapolating from this dose, we would expect 0.75 mg/kg
to yield a peak plasma level of 65-80 ng/ml, with slow
onset, and the lower doses to yield correspondingly
lower plasma levels. Fischman et al. (unpublished) have
found that doses of inhaled crystalline cocaine yielding
peak plasma levels below 50-55 ng/ml do not appear to
produce a response of "high" in volunteer subjects.
Thus, the report of similar subjective effects of
cocaine and lidocaine may be due to the very low doses
of cocaine used.
The data from Fischman et al. (1983b) indicate that
procaine and cocaine share some stimulus properties
(i.e., procaine was identified as cocaine), and at the
highest dose tested procaine caused increases in "high"
and "stimulated" scores. To the extent that shared
stimulus properties predict shared reinforcing
properties, the obvious implication is that procaine
might be expected to be a reinforcer in humans. In
fact, preliminary data indicate that this is true
(Fischman and Schuster, unpublished). Procaine,
however, is not thought to be abused by humans. This
descrepancy could be due to several factors. First of
all, it may well be thatwhatpasses for cocaine "on the
street" is, in fact, another local anesthetic such as
procaine. Procaine is commonly misrepresented as
cocaine or mixed with illegally sold cocaine, providing
a less expensive substitute or filler in the sale of
cocaine. Perhaps the "filler" is, in this case, not
inactive but is being used for its own properties.
Another factor to be considered in evaluating the abuse
potential of procaine is its very short half-life.
Procaine has been estimated to have a 7.7 minute
elimination half-life in humans (Seifen et al. 1979),
and that of cocaine is approximately 40 minutes after
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intravenous injection (Javaid et al. 1978). Frequent
injections of drug would thus be necessary to maintain
intoxication. This is precisely what is seen with
rhesus monkeys who self-administer large numbers of
procaine injections rapidly (Ford and Balster 1977;
Johanson 1980), but would generally be inconvenient for
humans to arrange. Potency differences are also
relevant. There appears to be a 6-to-10-fold potency
difference between cocaine and procaine when the animal
self-administration and discriminative stimulus property
data are examined (Woolverton and Balster 1982). In
rats, for example, cocaine was found to be 9 times more
potent as a discriminative stimulus than procaine.
Since 8 mg of i.v. cocaine has been found to be a strong
reinforcer in humans, we would expect that 96 mg
procaine should be a sufficient dose to be a reinforcer.
Thus, the necessity of both frequent injections and
substantial amounts of a drug might well be sufficient
reason for its lack of "street" popularity except,
perhaps, as an adjunct and component of cocaine
mixtures.
TOXICITY
No laboratory studies have been carried out to
investigate high-dose or repeated-dose cocaine toxicity.
On the other hand, an increasing number of clinical
reports have described the deleterious effects of
repeated cocaine use via various routes of
administration. Regardless of the route, the effects
are similarly debilitating (Rappolt et al. 1978;
Carbajal 1980; Siegel 1982). Gay et al. (1975) have
described the "Advanced Stimulation 'Caine' Reactions"
as divisible into three categories: (1) Early
Stimulation is accompanied by excitement, apprehension,
nausea, vomiting, and twitching of voluntary muscles; (2)
Advanced Stimulation is characterized by hyperkinesis,
convulsions, increases in pulse and blood pressure, and
irregular respiration; and (3) Depression is accompanied
by loss of reflexes, unconsciousness, circulatory and
respiratory failure, and perhaps death. Siegel (1982)
has pointed out that heavy chronic cocaine smokers often
exhibit hallucinations and persecutory delusions and are
generally incapable of regulating their drug intake. A
recent report of iatrogenous cocaine psychosis (Lesko et
al. 1983) described similar symptomatology in a young
man given a topical anesthetic solution of dyclonine
hydrochloride and cocaine which he was allowed to apply
to the inside of his mouth as needed for pain due to
oral ulcers. The hallucinations, paranoid ideation,
hyperactivity, and repetitive behavior patterns
disappeared within 60 hours of cessation of the cocaine.
These symptom descriptions appear to be
indistinguishable from the toxic syndrome produced by
the amphetamines. This latter effect has been produced
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in human research subjects under controlled laboratory
conditions (Angrist and Gershon 1969; Griffith et al.
1972) and indicates that in sufficient doses a toxic
psychosis can develop in anyone regardless of pre-drug
psychiatric status. Because of the similarity in action
between cocaine and the amphetamines, there is no reason
to believe that cocaine toxicity will be any less severe
or general than that seen after amphetamine. The fact
that the cocaine toxic psychosis has not been
demonstrated under controlled laboratory conditions
should not be taken to mean that it does not exist.
This is a situation in which all of the other available
data indicate that the similarities between cocaine and
amphetamine are far more striking than their
differences, and we can readily predict similar toxic
effects. Clinical reports support this prediction.
CONCLUSION
Laboratory studies with human research subjects have
indicated that cocaine's cardiovascular and subjective
effects mimic those reported for other stimulant drugs
such as the amphetamines, diethylpropion, and
methylphenidate. Differences observed reside primarily
in factors related to dosing regimens, duration of
action, etc. Furthermore, these effects generally
increase with increases in cocaine plasma level. In
addition, as with nonhuman research subjects, cocaine
clearly functions as a positive reinforcer.
When given concurrent alternative substances to self-
administer (e.g., saline versus cocaine), subjects
generally chose cocaine over saline and showed
predictable increases in heart rate as well as verbal
report of its stimulant effects early in the session.
However, there does appear to be an acute tolerance to
its effects.
The data collected in the laboratory have all been
collected under limited access conditions. It has been
pointed out in another paper in this monograph
(Johanson) that rhesus monkeys allowed to self-
administer cocaine under limited access conditions do so
with well-regulated intake and few signs of toxicity.
However, results from unlimited access procedures
indicate substantial toxicity including convulsions and
death. It is possible that with a less restricted drug-
taking schedule for humans, other toxic effects would
also emerge. The data indicating development of an
amphetamine toxic psychosis provide the clues for what
this toxicity might be, and point out the potentially
serious consequences of repeated cocaine use.
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FOOTNOTE
lDAWN, the Drug Abuse Warning Network, monitors drug-
related emergency room visits and deaths. Now funded by
the National Institute on Drug Abuse, it was funded
jointly by NIDA and the Drug Enforcement Administration
(DEA) from 1972 to 1980.
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Changing Patterns of Cocaine
Use: Longitudinal Observations,
Consequences, and Treatment
Ronald K. Siegel
INTRODUCTION
In 1858 the Austrian frigate Novara was sent to South America on
a most unusual mission. The Novara was named after the city in
which the Austrians had defeated the Italians, thereby stopping a
threatening cultural and political renaissance. On board the
Novara was a trade expert, Doctor Scherzer, who was intrigued by
another Italian “renaissance” started by Milan neurolgist Paola
Mantegazza. Mantegazza had published an 1857 paper proclaiming
the medical importance of coca that he had chewed while a
resident of Peru (Mantegazza 1857). The paper was the newest
curiosity of the European medical community which even awarded
Mantegazza a prize for this work in 1859 (Mortimer 1901). The
Novara stopped in Peru and Scherzer took a quantity of coca
leaves back to the great chemist Wohler at the University of
Gottingen in Germany. Wohler’s assistant, Albert Nieman, named
the isolated alkaloid “cocaine” in 1859/1860 (Phillips and Wynne
1980). The isolation and naming of the alkaloid signalled the
start of 125 years of changing patterns of cocaine use. Prior to
that time, only coca products were available, and the patterns of
their use had not changed substantially in over 4700 years.
For most of its early history, cocaine remained hidden and
unidentified in the protective envelope of the coca leaf. The
coca plant (Erthroxylum spp.) produces at least 14 different
alkaloids as defensive agents to ward off foraging animals. The
bitterness, numbing, and psychoactive properties of these
alkaloids perform this defensive function effectively, teaching
animals to avoid the plant and thus contributing to its
evolutionary survival. Interestingly, compared with other
tropical American crops, coca is relatively pest free.
Herbivorous insects are rarely observed on plants and damage to
the leaves is relatively minor.
Accidental encounters with ingestion of coca exposed early man to
the effects of its alkaloids. From 3000 B.C. to the middle of
the 16th century, coca was used by the indigenous peoples of
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South America in religious, magical, medical, and recreational
contexts. Little information is available on the psychopharma-
cological consequences of this use, but patterns changed very
little during this period. The leaves were chewed whole or in
powdered form , smoked with or without tobacco, or else swallowed
in various infusions.
In 1580 coca was introduced to Europe, where it eventually, by
the middle of the 19th century, found its way into widespread
medical use. Coca products included preparations of leaves,
extracts, wines, liquors, cordials, lozenges, cigars, cigarettes,
and chewing gum,  among many other forms. Patterns of use were
largely confined to medical applications, although sane
nonmedical uses were also reported.
After the isolation of cocaine in 1859/1860 by Nieman (a crude
alkaloid, named “erythroxylon,” was isolated by Gaedecke in
1855), early experimentation revealed stimulant and local
anesthetic properties (Siegel and Hirscham 1983). The medical
community became enthusiastic about this new wonder drug, the
patent medicine manufacturers exploited it, and the nonmedical
use of cocaine for pleasure began to grow rapidly. Fostered by
glowing reports from the patent medicine advertisements,
encouraged by the research and writings of Sigmund Freud (who was
strongly influenced by Mantegazza), and pushed by the
euphoria-enhancing techniques of intranasal and intravenous
administration, the pattern of use began to change.
In addition to the numerous coca products, cocaine itself started
to appear in flake crystals, tablets/ solutions for inject ion,
ointments, and nasal sprays. Both coca and cocaine were also
used in a variety of soft drinks and tonics, the most famous
being Coca-Cola. Indeed, “during the seventeen years Coca-Cola
contained cocaine [until 1903], the drink and drug became so
closely identified that ‘dope,’ as in ‘let’s have a dope’ became
the established, common term for Coca-Cola” (Ashley 1975, p. 49).
Observations on these patterns of use were made in both the
medical and lay press during the early 20th century. Many of
these articles suggested that cocaine was associated with
uncontrollable addiction, physical and psychological
deterioration, demoralization, and criminal violence. Federal
legislation, beginning with the Pure Food and Drug Act of 1906
and the Harrison Act of 1914, effectively launched a period of
cocaine prohibition by restricting and controlling all aspects of
its manufacture, possession, sale, distribution, and use. Both
the medical and nonmedical use of cocaine gradually declined, and
general interest in the drug all but disappeared between 1930 and
the late 1960s.
Cocaine continued to be used, albeit by relatively few users,
during this period of prohibition. The primary route of
ministration was intranasal, although the intravenous route was
also employed. In the early 197Os, cocaine was “rediscovered” as
a recreational drug of choice. As with its initial introduction
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a century before, contemporary users began to experiment with new
preparations and patterns of use.
SHORT-TERM OBSERVATIONS OF USERS (1970-1983)
A number of studies have provided observations of contemporary
patterns of cocaine use in the period 1970 to 1983. These
studies have concentrated on selected populations of users that
were seen at only a single point of time during this period.
When reviewed chronologically, these observations suggest that
patterns of cocaine use were changing rapidly throughout the
period 1970 to 1983 and in particular for long-term users. For
individuals engaged in continued use this change was
characterized by increased dosage and frequency of use resulting
in decreasing positive effects and increasing negative reactions
including physical and psychological dysfunction. This changing
pattern is also examined (see following sections) in a series of
longitudinal observations made on a sample of users studied at
multiple points of time during this sane period.
Users entered the 1970s with attitudes that supported their
beliefs that cocaine was a "safe recreational drug." Gay and
Inaba (1976) suggested that the rediscovery of cocaine in the
1970s was inevitable because its effect of euphoria and
stimulation "reinforces and boosts what we recognize as the
highest aspirations of American initiative, energy, frenetic
achievement, and ebullient optimism" (p. 251).
Phillips and Wynne (1980) interviewed and observed a group of
cocaine users and dealers in 1975 in a study of user beliefs and
myths regarding cocaine. among the myths endorsed by users were:
cocaine is an aphrodisiac; cocaine increases creative and
physical performance; there are no bad effects associated with
cocaine use; the cost of cocaine is related to its purity; and a
cold shower is an antidote for cocaine intoxication. Widespread
belief in these "street" myths appeared to support continued use
of cocaine.
Gottlieb (1976) also interviewed and observed a number of cocaine
users who expressed similar beliefs: cocaine is an aphrodisiac;
cocaine facilitates the learning process; cocaine improves
physical activity; and cocaine "is not addictive." While users
preferred the intranasal route of administration, Gottlieb
reported the growing experimentation with intrabuccal and
sublingual routes of administration, the rediscovery of drinking
cocaine in alcoholic beverges such as cordials, and the smoking
of cocaine hydrochloride alone or in combination with marijuana
or tobacco.
The consequences of this early use were repotted by Ashley (1975)
who interviewed and observed 81 cocaine users, all of whom
reported experiencing euphoria, sexual stimulation, increased
energy, and reduced fatigue and appetite. His respondents also
reported a wide range of other positive effects including
increased mental lucidity and muscular strength. Not
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surprisingly, these users agreed “that cocaine was a ‘good’ drug,
and virtually all were certain it should be used in moderation”
(p. 156). Reports of adverse effects were more variable and
appeared to be dependent on the pattern of use. In this regard,
Ashley observed three patterns of use: moderate, chronic
moderate, and heavy. Sixty of his respondents were moderate
users (0.25-0.50 grams/day for “a few” days) who reported minor
adverse reactions such as lassitude. Fourteen were chronic
moderate users (0.25-0.50 grams/day for prolonged periods) who
reported mild insomnia, occasional impotency, irritability, and
personality changes. The remaining four heavy users (chronic use
of 2.0-4.0 grams/day) reported insomnia, impotency, irritability,
personality changes, and paranoia. Importantly, Ashley’s
respondents noted a tendency to escalate dosages which resulted
in increased adverse reactions. Consequently, they reported
adjusting dosages or abstaining for brief periods in order to
control use. Lassitude was the only withdrawal symptom noted by
these users.
Using a more careful interview and questionnaire study, Resnick
and Schuyten-Resnick (1976) described five profiles of typical
cocaine-using behavior, based on the patterns of drug use
established by the National Commission on Marihuana and Drug
Abuse. These patterns included experimental (short-term and
nonpatterned); recreational (use in social settings among
friends); circumstantial (use for specific effect); intensified
(daily use); and compulsive (high frequency and intensity).
These researchers described intensified users as using from 3 to
20 times a day. Compulsive users were characterized as having a
high degree of psychological dependence: “The most striking
feature of this pattern is that the drug use dominates the
individual’s life and precludes other social functioning” (p.
221).
As Ashley had predicted, consequences of adverse reactions
appeared dependent on the pattern of use. Users following the
more intensified and compulsive patterns of use started to show
up in treatment centers seeking clinical attention. Gay and
Inaba (1976) traced an increase in cocaine users seekity clinical
attention beginning in the middle of 1970. Chronic cocaine abuse
was marked by psychological dependence, a withdrawal depression,
and sleep disturbances.
In an interview study of 17 recreational users, Grinspoon and
Bakalar (1976) found that even intranasal users experienced
common psychological problems including insomnia, irritability,
and anxiety. Physical problems included rhinitis and weight
loss. Toxic eftects, psychosis, and loss of psychomotor control
were considered rare reactions for these users.
However, with intravenous patterns of use, the problems appeared
to escalate. In a series of in-depth case studies, Spotts and
Shontz (1976, 1980) examined the lifestyles of nine American
cocaine users. The users in their studies were primarily
intravenous users with an average of 5 to 9 years of experience
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with cocaine. They concluded that low levels of usage were
associated with use of cocaine to enhance sensory pleasures, to
make the real world seem like an imaginary paradise, and to help
the user compensate for inability or unwillingness to accept
responsibilities. Relatively higher levels of usage were
associated with use of cocaine to provide necessary support for
the self-concept, as a means to provide the drive and energy
needed to succeed, or as a way of inducing a state of blissful
oblivion to overwhelming life problems. These researchers found
that at high levels of use the sensory pleasure is often
counterbalanced by adverse react ions including tension, anxiety ,
paranoia, hallucinations, and fear of overdose and subsequent
death. Interestingly, following completion of the study, Spotts
and Shontz report that of the nine respondents “two of them are
now dead, one is in prison, and one has been convicted of a
felony involving cocaine. These chilling statistics highlight
the danger and volatile nature of the world of the heavy cocaine
user” (1980, p. 492).
Siegel (1979) cited the growing popularity of smoking cocaine
free base and a concanitant increase in negative reactions:
Free base parties have became increasingly popular, and
the practice has spread, . . .Unlike intranasal users,
cocaine smokers do not appear to titrate or adjust
dosage. Consequently, both frequency and quantity of
dosages escalate rapidly.. . This pattern of use is
similar to that found with intravenous heroin and
cocaine and has an associated high potential for
dependency and overdose. (p. 373)
User beliefs, however, strongly supported the smoking of cocaine
free base with attitudes that it was “the ultimate high,” “the
greatest thing since sex,” “gives you the ecstatic illusion of a
synthetic heaven,” and is capable of producing mind-expanding
experiences (Anvil 1979; Raye 1980; Davidson 1981). Smoking of
cocaine free base continued throughout this period. Siegel
(1982) studied 32 users seeking clinical attention for problems
related to cocaine free base. Of the 32 users studied, 20
engaged exclusively in individual compulsive patterns of smoking,
seven engaged in exclusively social compulsive patterns (usually
with a single smoking partner), and five engaged equally often in
both individual and social smoking. All users reporting initial
periods of intensified use started with one gram per day (range
0.5-3.0) and escalated over the course of the intensified period
to an average of 7.0 grams per day (range 2.0-28.0). All the
users were diagnosed as having a Cocaine Smoking Disorder, an
organic mental disorder with associated features of euphoria,
dysphoria, and schizophreniform psychosis.
While these studies were being conducted on cocaine users in the
United States, a series of reports began to emerge on abuse of
coca paste in Peru and other countries in South America (Aramayo
and Sanchez 1980; Jeri et al. 1978, 1980; Noya 1978; Valladolid
1979). Taken together, these reports suggested that the chronic
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smoking of coca paste was associated with successive stages of
psychopatholgy: euphoria, dysphoria, hallucinosis, and
psychosis. Jeri and colleagues (1978) reported a characteristic
profile of these coca paste users. Users experienced an initial
euphoria followed almost immediately by compulsive anxiety to
smoke more paste, depression, irritability, suspiciousness,
paranoid thinking, excitement, and visual, auditory, and tactile
hallucinations. In addition to toxic effects (e.g., convulsions
and seizures) resulting from chronic or high dose usage,
psychosocial dysfunction as well as psychological impairment was
commonly reported.
Cocaine smokers were not the only users reporting such adverse
reactions. As both the dosages and chronicity of cocaine use
escalated, these adverse consequences became ubiquitous among all
classes of users. Helfrich and coworkers (1983) found a profile
similar to the coca paste users after examining a group of
cocaine users who sought treatment. Examination of these
patients revealed impairment in several areas: psychological,
interpersonal, financial, physical, and vocational. The
dysfunction appeared to be independent of the route of
administration. This latter finding was consistent with a
telephone interview study of users seeking help for
cocaine-related problems (McConnell 1983). In the telephone
study, users reported an average use of 8 grans per day, 6 days
per week, with 56 percent reporting such use for 2 years.
Symptoms included nosebleeds, exhaustion, headaches, seizures,
paranoia, panic attacks, and violence towards others.
LONG-TERM OBSERVATIONS AND CHANGING LEGAL STATUS (1970-1983)
The period 1970 to 1983 was marked by a steady increase in
virtually all aspects of cocaine use (Siegel 1982). Importation
of cocaine, paraphernalia sales, cocaine-related stories in the
media, samples of cocaine submitted by users for analysis,
hospital and treatment center admissions for cocaine, cocaine-
related deaths, seizures of illicit cocaine, cocaine-related
crimes and arrests, among many other parameters, increased
dramatically.
The changing patterns of cocaine use, as well as changing
attitudes, have been reflected in the nature of legal defenses
raised in cocaine-related crimes during 1970 to 1983 (Siegel
1983). Initially, cocaine was viewed as a "non-addictive" and
non-narcotic recreational drug that was not as dangerous as the
law maintained. The first evidentiary hearings on the scientific
and medical nature of cocaine were held in Commonwealth v. Miller
(366 Mass. 387,318 N.E.2d 909[D.Ct.1976]) in 1976. Here the
constitutionality of cocaine's classification as a "narcotic" was
successfully challenged and the judge issued 125 findings of fact
regarding the state of knowledge about cocaine as a relatively
safe drug in typical patterns of social-recreational use.
Defenses from 1976 to 1981 attempted to educate the trier of fact
about these opinions and thus, hopefully, to temper the judgment
and disposition of the cases. These defenses met with
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considerable success in lower courts, but higher courts have held
that it is valid to classify cocaine as a narcotic for purposes
of punishment. As cocaine use spread and effects of toxicity and
dependency became recognized, defenses based on cocaine- induced
diminished capacity or insanity started to emerge in courts. The
effects of cocaine on criminal responsibility, on credibility of
witnesses, and as a causative factor in accidental deaths or
homicides were raised as mitigating factors in guilt or penalty
phases of criminal trials. By 1983, cocaine appeared to be
replacing phencyclidine as the novel drug defense of the decade.
The forensic issue that most clearly illustrates the changing
patterns of cocaine use is the quantity necessary for charges of
possession and sales. Some courts, particularly Federal courts,
have permitted an inference of intent to sell to be drawn from
the fact that a large quantity of a drug was involved, despite
the absence of a statutory presumption. Thus, in the early 1970s
possession of more than a gram of cocaine was often viewed as
possession for sale. As users escalated their patterns and
dosages, particularly with smoking cocaine free base, possession
of larger amounts for personal use became more common. It was
not unusual to find that intranasal users might possess a week’s
supply of several grams or a cocaine smoker might use as much as
1 ounce or more. Consequently, by 1980 many jurisdictions viewed
1 ounce of cocaine or less as simple possession for personal use.
One aspect of a changing pattern in cocaine use was clear: there
were more users in general, more intensified and compulsive users
in particular, and more cocaine-related psychological, physical,
and legal problems. Another aspect of this changing pattern was
less clear: did individual long-term users manifest parallel
changing patterns of cocaine use? In other words, do the
recreational and circumstantial users cited in the above studies
escalate use to more intensified and compulsive patterns of use?
Does increased use of cocaine increase the incidence of negative
and toxic effects? Is long-term use of cocaine inevitably
associated with an escalating dependency marked by more frequent
use? If not, what factors control and maintain stable patterns
of chronic use? A longitudinal study of a small sample of users
was begun in 1975 to provide information on these questions as
well as the consequences of long-term use dur iry this period.
Preliminary findings from the first 4 years of this study have
been reported elsewhere (Siegel 1977, 1980). Only those results
relevant to the question of changing patterns of use will be
discussed below.
LONGITUDINAL STUDY OF USERS (1975-83)
Methods
A total of 118 cocaine users were recruited for study in 1974.
Of these, 19 were selected for interview and questionnaire study
while 99 (85 males, 14 females) were selected for a more
comprehensive longitudinal study. All 99 users (18-38 years old)
were social-recreational users who met the initial requirement of
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having used a minimum of 1 gram of cocaine per month for 12
months (range 1-4 grams). The majority of users were students
(73 percent,) while others listed their occupations as
housewives, business people, writers, attorneys, physicians,
secretaries, teachers, or unemployed. Exaninations and tests
were performed on each subject at 6-month intervals for 4 years
(1975, 1976, 1977, 1978) and then at approximately 18-month
intervals for another 5 years. Examination procedures included a
personal history questionnaire, drug history questionnaire,
subjective drug effects questionnaire, mental status exanination,
the Minnesota Multiphasic Personality Inventory (MMPI), the
Experiential World Inventory (EWI), in-depth interviews, and
physical examinations (for most subjects). In addition, assays
were performed on samples of cocaine used by these subjects. An
important caveat is that a number of users dropped out of the
study throughout the years or could not be located for followup
examinations. Several followup examinations in the last 5 years
of the study were conducted via telephone, and these were
restricted to questionnaires and interviews. Nevertheless, a
total of 61 users participated in all phases of the first 4 years
of study and 50 users were available for followup in 1983. Eight
additional users who refused followup examinations reported that
they had stopped all cocaine use.
Preparations and Purity
All subjects used cocaine hydrochloride available through illicit
markets. The average purity of their samples fluctuated
throughout the years of the study: 43.2% in 1975; 56.2% in 1976;
52.1% in 1977; 60.8% in 1978; 25.0% in 1979; 13.9% in 1980; 48.7%
in 1981: 58.0% in 1982; and 75.0% in 1983. When cocaine free
base was prepared, the average purity of the final product was
95.0%. The most common adulterants and diluents were mannitol,
lactose, inositol, lidocaine, and phenylpropanolanine.
Routes of Administration
All subjects employed the intranasal route at the start of the
study period. By the end of the first year, 14 percent had
experimented with smoking cocaine hydrochloride on tobacco or
marijuana cigarettes. By 1978, 39 percent of the users had
smoked cocaine as the hydrochloride or free base and 10 percent
classifed themselves as primarily cocaine free base smokers. For
the last 5 years of study, there were two distinct populations of
users: intranasal users (90 percent) and cocaine free base
smokers (10 percent). Throughout the study, users experimented
with other routes including injection (n=5) and oral (n=ll).
Dosages and Dose Regimes
Intranasal users administered cocaine in amounts (uncorrected for
purity) of 20 g per &ministration if a "cokespoon" was employed
or 50 g if “lines” were used. Throughout 1975-1978, intranasal
users averaged between 1 and 4 grams (uncorrected weight) per
month. From 1978 to 1983, intranasal users, approximately 90
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percent of the sample, averaged between 1 and 3 grams per week.
Cocaine free base smokers, approximately 10 percent of the
sample, used approximately 100 mg of free base per “hit” or
inhalation. Throughout 1975-1978, smokers averaged 1 gram per
day during periods of use. From 1978 to 1983, smokers averaged
1.5 grams per day. The temporal spacing of hits and the total
duration of a smoking episode varied considerably . Inhalations
were repeated as often as every 5 minutes during binges ranging
from 30 minutes to 96 hours. Individual consumption ranged from
1 gram to 30 grams per 24-hour period, although some users
reported smoking up to 150 grams in 72 hours. Smoking episodes
continued until supplies of cocaine were depleted or users became
exhausted and fell asleep.
Patterns of Use
All 99 users were classified initially as social-recreational
users, since use generally occurred in social settings among
friends or acquaintances who wished to share an experience
perceived by them as acceptable and pleasurable. Such use was
primarily motivated by social factors and did not tend to
escalate to more individually oriented patterns of use. Use
tended to occur in weekly or biweekly episodes. From 1975 to
1978, 75 percent (n=46) of the users still in the study (N=61)
engaged in episodes of more frequent use (see below) but remained
primarily social users. From 1978 to 1983, 50 percent (n=25) of
the users still in the study (N=50) remained social-recreational
(with continuing episodes of increased use), 32 percent (n=16) of
the users became primarily circumstantial-situational users, 8
percent (n=4) became intensified users, and 10 percent (n=5)
became compulsive users. Importantly, this latter compulsive
group consisted entirely of cocaine free base smokers.
An important caveat is that all users had episodes of decreased
use or abstinence interposed between periods of use in their
normal patterns. Thus, users reported abstaining from cocaine
for periods ranging from a few days to several months. For
example, from 1978 to 1983, four social-recreational users
reported no use for 2 years. During this same period, all
compulsive users reported periods of social use as well as brief
periods of abstinence. And most users in all categories reported
that supplies of cocaine were often unavailable, thus resulting
in regular periods of nonuse. However abstinence also occurred
during periods of cocaine availability.
Thus, 25 social-recreational users at the beginning of the study
remained in this pattern of use after 9 years. Throughout this
period, these users continued to report positive effects of
intoxication including euphoria and stimulation, although they
also reported negative effects including nasal problems,
restlessness, and attentional difficulties. By restrictiting
themselves to social patterns of use, they reported the ability
to titrate their doses and thereby minimize these negative
effects. Reliefs in cocaine as an “ideal safe drug” which
facilitated social behavior, the economics of supply, and the
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legal risks of use all seemed to contribute to maintaining stable
patterns of use which did not change substantially for these
people. The incompatibility of cocaine use with other activities
(e.g., work) also served as controlling determinants.
Circumstantial-situational use was defined as a task-specific,
self-limited use which was variably patterned, differing in
frequency, intensity, and duration. This use was motivated by a
perceived need or desire to achieve a known and anticipated drug
effect deemed desirable to cope with a specific condition or
situation, Use tended to occur in four or five episodes per
week. Sixteen of the social-recreational users adopted this
pattern of use by 1983. The major motivations cited by users
were to increase energy or performance at work and to enhance
mood during periods of boredom or depression.
Four users became classified as intensified cocaine users by
1983. Intensified use is characterized by long-term patterned
use at least once a day. Such use was motivated chiefly by a
perceived need to achieve relief from a persistent problem or
stressful situation or a desire to maintain a certain self-
prescribed level of performance. While sane social - recreational
users referred to their periods of intensified use as short-term
runs or binges, these four users reported that they were on
repeated runs of several months’ duration and did not return to
social pat terns of use.
Compulsive use is characterized by high frequency and high
intensity levels of relatively long duration, producing sane
degree of dependence. The dependence is such that the individual
user does not discontinue such use without experiencing
physiological discanfort or psychological disruption. The five
compulsive users found here were all cocaine free base snokers.
Use tended to occur in episodes of continuous smoking for periods
of several hours to 96 hours. These users were characterized by
significantly reduced individual and social functioning. The
motivation to continue compulsive levels of use was primarily
related to a need to elicit the euphoria and stimulation of
cocaine in the wake of increasing tolerance. Compulsive users
were also motivated by the desire to avoid the discomfort and
depression of withdrawal. Consequently, compulsive users were
preoccupied with obtaining adequate and sufficient amounts of
cocaine in order to forestall an abstinence-like syndrome. When
compulsive users were sufficiently well supplied so that
preoccupation with obtaining cocaine did not occur, it was common
to find an equally intense preoccupation with using such
supplies.
Acute and Chronic Effects
Users reported that a variety of acute intoxication effects were
perceived as positive. These included: euphoria, stimulation,
reduced fatigue, diminished appetite, garrulousness, sexual
stimulation, increased mental ability, and increased sociability.
Other acute effects were experienced as negative: restlessness,
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anxiety, hyperexcitability, irritability, and paranoia. During
1975-1978 all users reported experiencing some positive effects
in all intoxications and negative effects in only 3 percent of
the intoxications. However, during 1979-1983 all users, except
compulsive users, reported positive effects in all intoxications
but negative effects in approximately 40 percent of the
intoxications. Compulsive users reported the absence of positive
effects in 15 percent of the intoxications and negative effects
in 82 percent of the intoxications. The acute and chronic
effects reported by these compulsive users, all of whan were
smoking cocaine free base, did not differ substantially from
those seeking clinical attention. These are discussed elsewhere
(Siegel 1982).
Several positive and negative chronic effects were reported by
users. The positive effects included: a generalized feeling of
increased energy, increased sensitivity to cocaine, general mood
elevation, and weight loss. Negative effects included restless-
ness or irritability, attentional or perceptual disturbances,
nasal problems, and fatigue or lassitude. During 1975-1978,
users reported a gradual reduction in the frequency of these
chronic positive effects and a concomitant increase in the
frequency of chronic negative effects such as fatigue (Siegel
1980, table 2). From 1979 to 1983, there appeared to be no
further changes in the relative frequency of positive and
negative effects for social-recreational users. Overall, these
social users reported some chronic positive effects in all
intoxications while negative effects were experienced in 11
percent of the intoxications. Conversely, the ratio of chronic
positive to negative effects appeared to decrease with patterns
of increased use. Thus, circumstantial users reported percentage
ratios of 74 percent (positive effects) to 25 percent (negative
effects) and intensified users reported 56 percent (postive
effects) to 32 percent (negative effects). Compulsive users
reported chronic positve effects in all intoxications and
negative effects in 71 percent of the intoxications.
Toxic Crisis Reactions
In addition to the negative effects described above, users
reported adverse physical and psychological toxic reactions.
Toxic physical reactions were defined as acute crises consisting
of at least one of the following symptoms: myoclonic jerking,
chest pains, nausea or vomiting, respiration difficulties or
failure, seizures or convulsions, or unconsciousness. More
commonly experienced physical symptoms such as blurred vision,
nasal problems, or insomnia were not classified as crisis
reactions. Toxic psychological reactions were defined as acute
crises with at least one of the following symptoms:
hallucinations with delusions, violent loss of impulse control,
or attempted suicide. More commonly experienced psychological
symptoms such as psychomotor agitation, depression, paranoia, or
situational impotency were not classified as crisis reactions
here.
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During 1975-1978, users reported no toxic physical or psycho-
logical crisis react ions. From 1979-1983, the social-recreational
users continued to report no toxic physical or psychological
crises. Also during 1979-1983, 18 percent of the circumstantial
users reported an average of four physical crises and one
psychological crisis, all instances of impulse dyscontrol. All
intensified users reported an average of two physical crises and
one psychological crisis. All compulsive users also reported
experiencing adverse crises during this latter period. The
incidence of these reactions was so frequent that canpulsive
users could not accurately estimate their number. However, they
reported that both physical and psychological crises developed in
approximately 10 percent of their intoxications. The nature of
these toxic crises for compulsive users has been discussed
elsewhere (Siegel 1982).
Personality Profiles
During 1975-1978, retesting with the MMPI detected no
pathological deviations from normal T-score means for adults.
However, a slight but insignificant elevation in D scales
(Depression) and Pa scales (Paranoia) was noted for 7 percent of
the users on at least one retest during this period. Also during
this period, the EWI retesting indicated that 38 percent of the
users displayed elevated Euphoria scales. This suggests
increased happiness and contentment with life. Concomitantly, 5
percent showed increased suspiciousness or paranoia, but this was
usually directed at concern over their own bodies
(hypochondriacal complaints, perceptual disturbances, rhinit is)
rather than paranoid ideation concerning others.
From 1979 to 1983, retesting continued only with the EWI. The
social-recreational and circumstantial-situational users showed
no significant abnormal scores during this period. Most
displayed elevated euphoria scales but these were not
significant. The four intensified users did not show abnormal
T-scores but all showed elevated scores on scales suggesting
concern centering around their bodies, egocentricity, and
disturbances in social adjustment and comnunication. The five
compulsive users displayed marked elevations in almost all
T-scores. The typical configuration of these scores suggested a
paranoid profile with features of depression, reduced frustration
tolerance, problems of social adjustment and communication,
disturbances in sleep-wake rhythms, and difficulties in impulse
regulation.
Multiple Drug Use
At the beginning of the study, all subjects had past and current
(1975) histories of multiple drug use. Prior to their cocaine
use, they reported experience with alcohol (100%), marijuana
(100%), amphetamines (27%), barbiturates (20%), hallucinogens
(10%), diazepam (10%), methaqualone (2%), and opiates (2%).
During 1975-1978, the average percentage of subjects using other
drugs were: alcohol-85%; marijuana-66%; amphetanines-8%;
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hallucinogens-5%; diazepam-4%; opiates-4%; and methaqualone-4%.
During 1978-1983, the following distribution was reported:
alcohol-70%; methaqalone-30%; marijuana-24%; hallucinogens-18%;
diazepam-13%; opiates-10%; and amphetanines-2.5%. An important
caveat is that these drugs were not necessarily coadministered
with cocaine. Many of these drugs were used to treat the
hyperexcitability and stimulation produced during periods of
excessive cocaine use.
Treatment
Since all users were monitored on a regular basis, few sought
independent treatment for cocaine-related problems. Nonetheless,
a number were given referrals for specific complaints: two users
developed perforated septums; two developed skin problems
associated with cocaine smoking: and six became involved in legal
problems associated with possession of cocaine. Following toxic
crisis reactions, two users summoned paramedics and one user want
to the emergency room of a local hospital. One intensified and
one compulsive user chose to enter a formal clinical treatment
program.
Most users initiated self-control strategies in order to treat
their own negative effects and crisis reactions. The most common
strategy was to titrate or restrict the amount of cocaine used in
a given period of time. This was usually accomplished by
purchasing or carrying a limited anount of cocaine at a time.
Social-recreational users reported success in this method. A few
users attempted to control use by combining supplies of cocaine
with cocaine substitutes, commercial products containing local
anesthetics and stimulants that mimic the effects of cocaine.
Other users initiated strategies whereby they periodically
abstained from cocaine in an effort to “detoxify” and/or “recover
from cocaine effects” for periods ranging from a few days to a
few months. The most common negative effects prompting
abstinence were nasal problems and irritability. Three major
strategies were employed. In avoidance strategies, users
attempted to avoid all contact with cocaine, cocaine
paraphernalia, and cocaine users. Some users reported that it
was effective simply to avoid dealers or other social users.
Others engaged in destruction of paraphernalia, and still others
employed physical constraints by taking a vacation. In aversion
strategies, users sought out and embraced information and stories
containing aversive stimuli. Perhaps the most common stories
were those that circulated about individuals suffering toxic
reactions. These folklore stories told of frequent incidents of
bizarre behavior, economic distress, casualties in the
criminaljustice system, and toxic overdoses. The stories
appeared to generate much concern and anxiety, prompting at least
one intensified user to seek counseling and encouraging many
others to return for periodic followup examinations throughout
the study. In these exams, users would ask for verification of
the folklore as well as explanations for cocaine-related effects.
In self-initiated contingency contracting, which differs from
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clinical models (Anker and Crowley 1982), users made a public
pledge to family or peers and asked for support in maintaining
abstinence. This support took the form of denial of cocaine
supplies, tight controls over financial resources, and careful
monitoring of behavior. Surprisingly, pledges were often made to
dealers so that they would no longer supply cocaine, and many
users reported such contracts were honored by their dealers.
However, since the contracts were initiated and maintained
verbally, they were easily broken after periods ranging from 1
week to 6 months.
Discussion
Considering the escalating toxicity and dependency associated
with long-term use of stimulant drugs, the most apparent aspect
of these findings is that many of the social-recreational cocaine
users do not change their long-term pattern of use and do not
appear to develop toxic crisis reactions that may warrant
clinical attention. Thus, this population of users differs
substantially from those "abusers" who experience physical or
psychological dysfunction and seek clinical treatment (Helfrich
et al. 1983; Kleber, this volume; Siegel 1982).
Fully 50 percent of the social users available for followup in
1983 retained this pattern of use from 1975-1983. One common
factor cited for such controlled recreational use is the
rate-limiting effect of cocaine's high financial cost. Fourteen
of these users were students in 1975 and, throughout the study
period, graduated and entered higher income levels. Yet only
three escalated use from the initial social patterns. Two users,
who were law students and became attorneys, developed
circumstantial-situational patterns: the third, a medical student
who became a physician, became a compulsive user. The 12
ex-students who remained social users, as well as the other users
in this category, all reported stable patterns of cocaine use
independent of increased income available for the drug. Thus,
the notion that cocaine use is exclusively limited by cost is not
supported in this group.
Surprisingly, social-recreational users maintained relatively
stable patterns of use when supplies were available and when they
were not purposely abstaining. These users ranked cocaine as
their recreational drug of choice. It was viewed by users as a
social drug which facilitated social behavior. When restricted
to social situations, users reported that cocaine was "ideal" in
terms of convenience of use, minimal bulk, rapid onset of
effects, minimal duration of action with few side effects, a high
degree of safety, and minimal after effects. Users reported that
this set and setting were the major factors controlling the
pattern of use. In addition, they reported that the inconsistent
quality of street cocaine, together with a rapidly developing
tolerance to the euphoric effects, contributed to controlled use.
Legal risks, supply, and cost were cited as minor factors.
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The intranasal cocaine users averaged between 1 and 4 grams per
month during 1975 to 1978. From 1979 to 1983, these users
increased use to an average between 1 and 3 grams per week. The
hypothesis that increased dosayes result in increased risks of
negative effects and toxicity is partially supported by findings
here. Social-recreational users averaged 1 gram per week during
1979-1983 and manifested significant increases in acute and
chronic negative effects despite the absence of crisis reactions.
Circumstantial-situational users averaged 2 grams per week during
1979-1983 and displayed increased chronic negative effects in 25
percent of the intoxications as well as Some crisis reactions.
Three of these users reported an average of four physical crises
and one psychological crisis. Intensified users averaged 3 grams
per week during the some period and reported chronic negative
effects in 32 percent of the intoxications along with an average
of two physical and one psychological crises. The relative
reduction of crises in the intensified users may be partially
related to behavioral tolerance that could be associated with
daily patterns of use. Tolerance may also explain the reduction
in positive effects reported by both circumstantial-situational
and intensified users. However, such tolerance seems to have
been easily overshadowed by the escalating dosages of compulsive
use. Indeed, compulsive users, all of whom smoked cocaine free
base, reported experiencing chronic positive effects in all
intoxications, negative effects in 71 percent of the
intoxications, and crises in 10 percent of the intoxications.
Compulsive users also manifested profiles of a paranoid disorder,
while most other users only displayed profiles of heightened
euphoria.
The hypothesis that long-term use of cocaine is inevitably
associated with an escalating dependency marked by more frequent
patterns of use is not supported by these findings. While little
is known about the 41 users who dropped out of the study at sane
time during the 9 years, 8 social-recreational users who refused
to report for followup examinations after 1979 explained that
they had stopped all use of cocaine. During 1979-1983, several
users reported abstaining for periods ranging from a few days to
several months. Four social-recreational users stopped all use
for 2 years in the middle of the study. Even compulsive users
reported periods of social use or brief periods of abstinence.
Thus, users periodically attempted to treat themselves with
strategies of controlled use, forced abstinence, or even multiple
drug use.
OVERVIEW
The year 1970 began with an increase in the nonmedical use of
cocaine. Most users began as experimental users engaged in
short-term, nonpatterned trials of cocaine with varying
intensity. These users were primarily motivated by curiosity
about cocaine and a desire to experience the anticipated drug
effects of euphoria, stimulation, and enhanced sexual desire
(Siegel 1977). Some users experienced little or no drug effect,
which supported their belief that cocaine was a subtle,
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over-priced drug undeserviry of continued use. Other users who
experienced a “kick” or "rush" expressed a desire to continue
use.
From 1970 to 1983 these users separated into various patterns of
use and abuse. Short-term observations of these users suggested
that intensified and compulsive patterns of use resulted in
physical and psychological problems. Observations of users
seeking clinical attention confirmed the presence of serious
dependency, dysfunction, and toxicity. Longitudinal observations
confirmed many of these findings but revealed that many users who
adopt social-recreational patterns appear to control use with no
escalation to more individual-oriented patterns, thus
circumventing toxic crises.
Taken together, however, the increased frequency of negative
effects and crisis reactions, the escalation of some users to
canpulsive smoking of cocaine free base, the rising psychosocial
and financial and legal costs, all indicate that the last 13
years of changing patterns of cocaine use have been the most
unlucky of its 125 year history. Given the promise of cocaine as
a "renaissance" of the 185Os, the "medical miracle" of the 187Os,
and the "safe recreational drug" of the 197Os, these 13 years
have also been disillusioning. As Mantegazza, who may have
started it all, might have commented, as he did upon recovering
from a coca intoxication full of blissful and fantastic images
only to realize that they were mere hallucinations:
One sighs deeply or laughs madly.
(Mantegazza 1859, p. 39)
SUMMARY
The literature describing contemporary cocaine use from 1970 to
1983 has been reviewed. Short-term studies published on users
observed an initial period of social-recreational use supported
by the belief that cocaine was safe. By the end of this period,
both dosages and chronicity of cocaine use showed an escalation
marked by increased adverse reactions. A longitudinal study
tracked 99 social-recreational users from 1975 to 1983. By 1983,
41 users had dropped out of the study while eight others had
stopped all use. Of the 50 continuing users still in the study
in 1983, 25 remained primarily social users with few negative
effects and no toxic physical or psychological crises. The
remaining 25 users, while engaged in some social use, were more
frequently involved in other patterns. Sixteen users frequently
escalated to circumstantial-situational patterns marked by some
toxic physical effects but no psychological crises. Four users
developed intensified (daily) patterns of use with episodes of
both physical and psychological crisis reactions. Five users
became compulsive users, smoking cocaine free base, and
experienced crisis reactions in approximately 10 percent of their
intoxications. The majority of users attempted to treat the
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hyperexcitability and stimulation of excessive cocaine use with
multiple drug use or self-initiated strategies of controlled use
or short-term abstinence. It is concluded that many of the
social users are capable of controlling use with no escalation to
more individual-oriented patterns. Others, by escalating
patterns of use, increase the risks of dependency and toxicity.
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Cocaine Abuse: A Review of
Current and Experimental
Treatments
Herbert D. Kleber and Frank H. Gawin
Cocaine abuse is a rececntly revived drug problem that is again generating great
popular concern. Unfortunately, scientitic evaluation of cocaine abuse
treatment has been surprisingly sparse kind no consensus exists regarding
optimal treatment strategies. This review summarizes current treatment issues
and regimens. as well as preliminary data on new, approaches to cocaine abuse
treatment.
Since this chapter  will deal  with treatment of the cocaine abuser, it is important
from the outset to define what is meant by that term. Although in some settings
any use of ilegal drugs equals abuse. such a definition is more legal than
medical and  will not he used here. Instead. the definition of drug abuse found
elswhere in the field will be employed. namely...“the nonprescription use of
psychoactive chemicals by an individual to alter his her psychological state in a
situation in which the individiual or society incurs some harm” (Kleber 1974).
The great majority of cocaine users applying for treatment fit into this
definition. The most common exception is the individual who defines his use as
recreational. controlled and nonharmful. but is brought to treatment by
another (e.g. spouse, parent),  while the significant other views the cocaine use
as harmful and needing to be stopped at once. It can be argued. of course. that
the existence of such a dispute is in itself evidence that “harm” is occurring.
Alternatively, it may be argued that the legal definition is being imposed in such
cases. These issues lead to the question of who “needs” treatment? A broad
answer is: any cocaine user who finds that be cannot stop or significantly cut
back his use in spite of the presence of problems arising from the use.
The above definitions approximate the DSM-III criteria for cocaine abuse: “a
pattern of pathological use. impairment in social or occupational functioning
due to cocaine use, and duration of disturbance of at least one month,“but are
broader in their locus on the individual’s self-perception of harm.
It should also he noted that the studies and impressions reviewed here are based
only on patients who appear for treatment. It is probable that some cocaine
abusers, like some alcohol and nicotine abusers, are able to stop use without
treatment. No data is available indicating what proportion of those who want to
cease cocaine use are able to do so without treatment. Similarly, the strategies
employed and difficulties experienced by those who cease use without
treatment have not been systematically studied. although Siegel has described
longitudinal use patterns  which include cessation and abstinence (this volume).
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COCAINE, ABUSE AND CONCURRENT  DISORDERS: DIAGNOSIS
Our clinical experience and the literature agree that individuals who abuse
cocaine arc not a homogenous class. Distinctions in characterization of cocaine
abusers with clear treatment relevance exist primarily along dimensions of
psychiatric symptoms and behavioral-psychosocial disruption.
Greater variation in severity of use may exist in patients seeking treatment for
cocaine abuse than in patients seeking treatment for abuse of other substances
(Gawin and Kleber 1983a, Gold 1983). The typical cocaine user probably,
begins his her use in a similar way to the typical marijuana user. albeit at a later
age. Like marijuana. cocaine has been labelled by popular culture as
“recreational," and most who try it do so with the firm belief that they will have
no difficulty in controlling their consumption. Many people are successful in
such an endeavor; some, however, increase their use and appear for treatment.
The point at which treatment is sought can vary dramatically. Because
of cocaine’s expense, significant psychosocial disruption leading to treatment
can often occur without extreme abuse. The actual abuse in such cases is
similar to that occurring with substances such as nicotine and mari-
juana. At the other end of the cocaine abuse spectrum lies very heavy intra-
venous (Gawin and Kleber 1983a) or freebase cocaine abuse (Siegel 1982),
which is continuous for prolonged periods, in a pattern very similar to that
observed in intravenous methamphetamine addicts (Kramer et al. 1967) over a
decade ago. Treatment needs within this diverse population vary based on
severity. Flexibility is therefore necessary in designing treatments for cocaine
abusers.
Route of administration has been used as an indication of the probability that
disruptive use patterns will develop. This has prompted recent controversy
(Helfrich et al. 1983). Severe cocaine abuse has been considered a sequel of
administration by routes that provide very rapid changes in plasma stimulant
levels, such as intravenous use or cocaine freebase smoking (Siegel 1982;
Van Dyke and Bach 1982). Intranasal use has been popularly considered
comparatively mild abuse of a “nonaddicting,” “safe” stimulant (Grinspoon
and Bakalar 1976). Preliminary evaluations of patients appearing for treatment
contradict the assumption that intranasal administration is not associated with
severe cocaine abuse. Route of administration is not significantly related to
psychosocial disruption (Gawin and Kleber 1983a: Helfrich et al. 1983),
neuroendocrine abnormalities (Gawin and Kleber 1983b), or psychiatric
diagnoses (Gawin and Kleber 1983a; Weiss et al. 1983). These data support the
impression that severe cocaine abuse can develop with any route of
administration. However. our experience and that of others is also that
intravenous abusers or cocaine freebase smokers are more likely to develop
significant distress requiring treatment. Epidemiologic study comparing
distress and the need for treatment with mode of administration in the general
population of cocaine users has not been done and should be extremely difficult
to implement. Since severity of cocaine abuse cannot be determined simply on
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the basis of route of administration, other factors, such as dosage. pattern and
duration of use, degree of psychosocial disruption and impulse control, and
medical and psychiatric characteristics. also require evaluation in assessing
severity of cocaine usage and treatment needs. No research clearly: demarcating
the contribution of each of these factors or of others to “severity” has been
done; therefore. assessments remain based, at present. on clinical impressions
and evaluation.
Variations also exist in the psychiatric characterization of cocaine abusers.
Detailed modern psychiatric descriptions are limited. Past attempts have
focused on nondiagnostic characterization using instruments such as the
MMPI (Helfrich et al. 1983; Siegel 1977) or have focused on personality
attributes or psychoanalytic formulations of cocaine abusers (Khantzian 1979;
Wieder and Kaplan 1969; Wurmser 1974). and the relevance of such work to
treatment decisions is unclear. Drug abusers, in general, have been observed to
self-regulate painful feelings and psychiatric symptoms via their drug use
(Khantzian 1981; Rounsaville et al. 1982). If cocaine use occurs as self-
medication. conventional treatments modulating self-medicated
symptoms would be indicated. The most important and clearly treatable
disorders of this type correspond to DSM-III axis I categories. Only two
studies of DSM-III axis I symptomatology in cocaine abusers exist. Weiss et
al. (1983) recently presented DSM-III diagnostic data for 30 hospitalized
cocaine abusers, and Gawin and Kleber (1983a) reported Axis 1 data on 17
outpatient cocaine abusers. These independent studies generated very similar
results, with depressive disorders (Major depression, Dysthymic disorder.
Atypical depression) appearing in 30 percent and bipolar disorders (including
Cyclothymic disorder) in 20 percent of each sample. Also, a smaller hut
possibly important sub-group of patients with Attention Deficit Disorder-
Residual Type (ADD) existed in each sample. Thus a large proportion of
cocaine abusers could be self-medicating. Since more and larger studies have
not yet been done and methodologic problems require clarification (Gawin and
Kleber 1983a). the actual prevalence, and therapeutic relevance. of Axis l-like
psychiatric disorder in cocaine abusers requires further examination.
Accurate psychiatric and behavioral characterization of the cocaine abuser is
important because symptomatology appearing during abstinence could
theoretically provide important guides both to when and what pharmacological
adjuncts are indicated (Gawin and Kleber 1983c). However, the meaning and
importance of such symptoms are at present based only on the self-medication
hypothesis. Two further issues confuse the interpretation of symptoms in
cocaine abuse. First. definitive diagnoses of psychiatric illness other than
substance abuse are difficult to make in the context of active drug abuse
because symptoms may arise secondarily from the drug use itself, rather than
preceding the drug abuse. Second, clarification between the acute depressive
symptomatology occurring immediately after an episode of cocaine use (the
post-cocaine “crash”) and more enduring symptomatology independent of
specific use episodes is also difficult. Thus investigators in the studies thus far
have attempted to circumvent these issues by gathering extensive historical and
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corroborating family history data, and by repeated longitudinal evaluations
isolated from periods of acute cocaine use and post-cocaine symptomatology
However, these "diagnostic" studies must be considered tentative in the
absence of prospective study or more elaborate investigation because
exclusinoary criteria based on substance abuse could not be applied
The “diagnoses” in the studies cited may nonetheless be useful as simple
descriptions of the clinical state of cocaine abusers. Since symptoms in the
cocaine abuser could indicate the presence of enduring cocaine-induced
disorders which mimic psychiatric syndromes, or subclinical susceptibility
to psychopathology aggravated by cocaine abuse. and both of these potential
consequences of cocaine use could be responsive to conventional therapies, it is
possible that distinctions between antecedent or consequent symptomatology
would not determine initial pharmacological treatment choice. Such
distinctions could. however, still affect issues such as duration of treatment or
prophylactic treatment and require evaluation.
Two groups of pilot efforts that reflect diagnosis in the context of cocaine abuse
treatment have been reported. These studies are all non-blind, non-placebo
preliminary examinations. The first group consists of descriptions of a total of
seven cocaine abusers with diagnoses of ADD by Khantzian et al. (1983a.
l983b) and Weiss et al. (1983). Six responded to appropriate stimulant
medications. The second study consists of a structured open trial of lithium and
desipramine (Gawin and Kleber 1983c) in which lithium administration was
associated with cessation of cocaine abuse and diminished cocaine craving in
several cyclothymic patients,  while non-cyclothymic cocaine abusers did not
appear to benefit from lithium. Desipramine also appeared beneficial. but
independently of diagnosis. This treatment is discussed more fully in the
discussion of pharmacotherapy below. In all, these reports indicate that ADD-
Residual  Type and cyclothymic disorder bipolar disorder may comprise
subgroups of cocaine abusers with distinct treatment needs. More definitive
research is obviously needed to substantiate these studies. Future research
would benefit from uniform attention to diagnostic issues and to non-
homogeneity among cocaine abusers.
Treatment of thc acute complications sometimes associated with cocaine abuse
is based on clinical experience rather than rigorous comparisons. Medical
complications of acute cocaine use and their treatment are reviewed elsewhere
(Gay 1982). Acute psychiatric complications occur in three areas. These
include dysphoric agitation, psychotic symptoms,  and acute, severe post-use
depression. Gay (1982) and Rappolt et al. (1977) employ, diazepam for
transient agitation and desribe dramatic amelioration of symptoms with
addition of propranolol for more persistent cases. Neuroleptics are routinely
used for brief  periods for severe cocaine-associated psychotic symptoms. The
present authors employ chlorpromazine because of its sedative properties and
because  evidence from primate studies indicates that a potential interaction
between cocaine’s epileptogenic effects and decreased seizure threshold
associated with neuroleplics does not occur. Instead chlorpromazine
substantially antagonizes epileptogenic and lethal effects of cocaine (Guinn et
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al. 1980). It should be noted that the same study reported increased seizure
susceptibility and decreased mean lethal cocaine dose with propranolol. but the
clinical significance of this is unclear, since Gay et al. (1982) have administered
propranolol in several hundred cases without major untoward effects. Finally,
suicidal ideation and other depressive symptomatology often occur during the
post-cocaine “crash.” Such symptoms are usually transient, require no acute
treatment other than close observation, and resolve following sleep
normalization (Gawin and Kleber 1983a). Prolonged severe depression was
discussed earlier. Also, psychotic symptoms may be short-lived in cocaine
abuse and usually remit following sleep normalization.
COCAINE ABUSE TREATMENT STRATEGIES
Strategies devised to treat cocaine abuse have existed since its intractable lure
for some first became obvious almost a century ago. During this period no
generally accepted or successful treatment has emerged. Chronic cocaine abuse
has been assumed to cause no physiologic withdrawal state on discontinuation
because of insufficient evidence for an abstinence syndrome of major
physiological changes. like the classic sort characterizing sedative or opiate
withdrawal (Glatt 1974; Grinspoon and Bakalar 1980; Woods and Downs
1973). Cocaine abuse has thus been assumed to be a “psychological
dependence” rather than one involving neurophysiological adaptations, and
currently used treatments consist of psychological strategies aimed at
modifying addictive behaviors. Issues related to current psychological
strategies will be discussed first, followed by a summary of evidence indicating
cocaine abuse may cause neuroadaptation. The latter includes a review of
pharmacological strategies, aimed at reversal of such adaptation, which may
hold future potential as adjuncts in cocaine abuse treatment.
Current Treatments
Only two comprehensive efforts at cocaine abuse treatment are described in the
modern literature. Both are nonpharmacological, but each involves a very
different approach to treatment. Anker and Crowley (1982) have adapted the
behavioral method of contingency contracting (Boudin 1972; Ross and Jones
1973) for cocaine abuse. The contract involves such contingencies as the
therapist’s holding letters of notification of cocaine abuse or resignation of
professional licenses, written by the patient with content chosen specifically
because of severe irrevocable personal effects, and mailing them to drug
enforcement authorities, employers, or licensing boards upon finding evidence
of cocaine use in urinalysis or after missed urinalysis. Such treatment appears
to effectively induce abstinence in those willing to take part. Anker and
Crowley report 48% of their sample were willing to engage in this treatment,
with over 90% cocaine abstinence during the duration of the “contract." Over
half of these patients relapsed following completion of the "contract”(Crowley
1982), however, even though the sample was a presumably well motivated and
well educated group. The patients declining “contracts” (52%) were treated
with supportive psychotherapy which was also used as an additional
intervention in those accepting contracts. All noncontract patients nonetheless
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dropped out and or resumed cocaine abuse within 2 to 4 weeks. In this case, the
consequences used with the behavioral treatment technique may have been
unnecessarily punitive and may reduce the clients’ willingness to become
involved in treatment. Anker and Crowley present no comparisons of severity
of cocaine use and thus ignore the likely possibility that cocaine abusers with
severe craving and problems of control recognize their inability to comply and
consequently avoid what for them would simply become destructive treatment.
In addition to problems of long-term efficacy and possible inapplicability to
more severe cocaine abuse, obvious ethical problems exist in those cases where
the procedure could have been based on positive reinforcement or on less
aversive techniques. That is, when negative rather than positive reinforcement
procedures arc applied, an obligation to use the least deleterious technique
exists. Variations in “contract” design, such as employing contingencies
graduated in severity. or a top contingency level with less drastic consequences,
or applying positive contingencies for abstinence (e.g.. starting with a sum of
money from the patient and giving part back each week for clean urines) could
also circumvent the problems noted. Some cases might optimally need a
combination of both positive and negative reinforcement. These variations
have not yet been examined in cocaine abuse treatment. Thus, optimal ways of
applying the promising approach of contingency contracting will become clear
only after further investigation. Broader behavioral intervention techniques
have been widely applied and studied in treatment of diverse forms of drug
abuse (Grabowski et al. 1984) but other behavioral techniques have not been
subject to outcome studies in cocaine abuse. Cocaine abusers are usually
treated with more conventional psychotherapies. Except for one description,
however. such treatments and their orientations have not been reported in the
literature. In the one study reported, Siegel (1982) describes a treatment
approach using frequent supportive psychotherapy sessions, self-control
strategies, “exercise therapy,” and liberal hospitalization during initial
“detoxification." This treatment aims at initially separating the user from the
use-fostering environment via external controls, and then gradually facilitating
internalization of controls through psychotherapy. Half of Siegel’s sample of
32 heavy cocaine smokers dropped out, but 80% of those remaining were
cocaine-free at 9-month followup.
Almost all psychotherapeutic treatment of cocaine abusers can be organized
around three dimensions (Rounsaville et al. 1983). These are: (1) To help the
abuser recognize deleterious effects of cocaine use and accept the need to stop
it. Anker et al.‘s treatment approach emphasizes this area. (2) To help the
abuser manage impulsive behavior in general. and cocaine use in particular; for
example, exploring ways to disassociate the abuser from cocaine use situations
and cocaine sources. Such supportive functions are emphasized in Siegel’s
treatment approach. (3) To bring the abuser to an understanding of the
functions that cocaine has played in his life and to help him serve these
functions without drugs. For example. cocaine can serve narcissistic needs
through the glamor associated with its use (or by direct pharmacological
effects). needs for identity via the social networks and drug-using subculture
associated with it. and anaclitic needs via possible facilitation of intimate
interpersonal interactions. among many others. These three dimensions are
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present, in varying degrees. in virtually all cocaine abuse treatment programs.
They correspond closely to behavioral, supportive, and psychodynamic
orientations to psychotherapy. The authors feel all three orientations are
necessary in the treatment of cocaine abusers, but their admixture is best
determined by taking into account the needs of the individual cocaine abuser at
the time of seeking treatment. rather than by simple program structure. For
example, patients in Anker and Crowley’s (1982) study who refused
contingency contracts could be approached from psychodynamic or supportive
perspectives. The authors’ clinical impression is that severe cocaine abusers
acutely attemptingabstinencedo not respond to psychodynamic interventions.
while moderate abusers may be more readily able to utilize them. Hence choice
of primary therapeutic orientation might shift from behavioral to psy-
chodynamic to supportive as severity increases, The authors’approach to the
psychotherapy of cocaine abusers is described more fully elsewhere
(Rounsaville et al. 1983). These notions have not as yet received any empirical
testing.
Whether inpatient or outpatient treatment is indicated, and for whom, is also
somewhat controversial. Siegel’s study and earlier work in stimulant abuse
(AMA Council 1978; Connell 1970) both strongly advocate hospitaliration for
initial detoxification. However, in Anker and Crowley’s (1982) study and
Gawin and Kleber’s (1983c) study using pharmacological adjuncts,
hositaliration was usually not indicated. It is likely that this also reflects
severity. Siegel’s subjects were very heavy cocaine smokers who were minimally
treated with adjunctive pharmacotherapy and may have been incapable of
combating cocaine craving without hospitalization and seclusion from cocaine
sources. These circumstances can require hospitalization, as can the existence
of severe acute depressive or psychotic symptoms, multiple drug dependence
especially involving sedative drugs, and previous failure(s) of the outpatient
approach. The question needs to be raised, however, of whether inpatient
treatment for the initial treatment of cocaine abuse is not too uniformly
employed. It is known that relapse following hospitalization is quite high. This
is consistent with studies of animal behavior (Goldberg et al. 1979; Spealman et
al. 1977) and clinical work (Maddux and Desmond 1982; Wikler 1973) with
drug abusers that point out the importance of environment and conditioning in
drug-taking behavior. Cocaine abusers ultimately have to maintain abstinence
within the general setting where abuse developed. and our impression is that a
period of abstinence within the context of everyday stimuli and stressors, akin
to a period of “extinction,” is a necessary prerequisite to consistent long-term
reductions in craving. Hospitalization in many cases may thus simply delay
confrontation with fundamental issues determining long-term outcome. Also,
since many subjects in Gawin and Kleber’s study were also severe abusers but
did not require hospitalization, severity alone may not be an index of need for
inpatient treatment. This area requires further attention and clarification. The
current almost ubiquitous presence of cocaine in many areas of American life
makes it unlikely that the former user will simply be able to avoid temptation.
Like the former cigarette smoker or alcoholic, the person attempting to give up
cocaine must make the drug “psychologically unavailable” since it is so hard to
make it physically unavailable.
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A final psychological approach to cocaine abuse is the self-help group modeled
after A.A. Some former abusers have reported significant help either from
A.A. or N.A. (Narcotics Anonymous). Structure. group support, a religious
tenor, and availability of an around-the-clock helping network have been of
important assistance for some abusers. Some inpatient programs combine the
confrontation groups long in use at residential therapeutic communities for
narcotic addicts such as Daytop Village with heavy N.A. emphasis. No
outcome studies of these programs for cocaine abusers have been reported.
Treatment of chronic cocaine abuse as currently practiced is vaguely defined
and difficult to evaluate. The more structured treatments of Anker and
Crowley (1982) and Siegel (1982), which are both intensive efforts, can claim
long-term effectiveness in 25% and 40% of the total number of patients initially
seeking treatment. Most other cocaine abuse treatment presently heing
conducted has received no systematic evaluation. is based on nonspecific
psychological treatments for general substance misuse with no particular
attention to the specific difficulties of cocaine abuse, and appears to be even less
effective than the treatments reviewed above. Such treatment, focused on
simple abstinence and psychotherapeutic management., has been recently
characterized as “ineffective and idealistic” (Van Dyke and Byck, in press).
Treatment strategies for abusers of other stimulants, such as amphetamine
(AMA Council 1978; Connell 1970) have been similar to the treatment
described by Siegel and provide no additional knowledge applicable to cocaine
abuse treatment. There thus appears to be a substantial need for new and
effective treatments of cocaine abuse.
Potential New Directions in Treatment
Despite the past assumption that cocaine abuse is a “psychological addiction,”
it is plausible that chronic cocaine abuse could lead to neurophysiologic
adaptations which require more than psychological intervention. Cocaine
exerts its effects neurochemically. The nervous system’s usual response to
persistent neurochemicat perturbation is compensatory adaptation. It is
illogical to assume that this does not occur or is unimportant in cocaine abuse.
This does not rnean a classic abstinence syndrome and tolerence uniformly
occur; rather chronic high dose use may generate sustained neurophysiological
modification whose clinical expression is psychological.
Neuroadaptation following extensive chronic cocaine use is suggested by
presence of persistent post-cocaine symptomatology (Blum 1976; Ellinwood
1977; Jaffe 1980; Siegel 1982). evidence that enduring neurophysiologic
changes occur in animals following chronic cocaine administration (Banerjee
et al. 1979; Borison et al. 1979; Chanda et al. 1979; Pert et al. 1979; Taylor et
at. 1979). preliminary data indicating neuroendocrine abnormalities may be
associated with cocaine ”withdrawal”(Gawin and Kleber 1983b). and reports
that pharmacologic interventions (Cronson and Flemenbaum 1978; Ellinwood
1977; Gold and Byck 1978; Mandell and Knapp 1976; Resnick et al. 1977;
Smith and Wesson 1980) may facilitate cocaine abstinence. Pharmacologic
interventions in cocaine abuse could thus be useful, but pharmacotherapy
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aimed at correcting presumably cocaine-altered neurophysiologic states has
not been systematically examined.
The following review outlines evidence indicating that desipramine, lithium.
and methylphenidate could each facilitate cocaine abstinence, by different
mechanisms. Although these are the same treatments discussed earlier in
relationship to diagnosis, we wish to make clear that the following discussion
pertains to the possible use of these agents as general treatments, irrespective of
distinctions in symptomatology. Some points at which “diagnosis” may
interact with general treatments will. however, be noted.
Tricyclic Antidepressants (TCAs)
Animal research on neurotransmitter and receptor changes following chronic
cocaine suggests long-term effects possibly reversible by treatment with TCAs.
Studies of receptor changes in animals, measured by radioligand binding,
report increased beta-adrenergic (Banerjee et al. 1979; Chanda et al. 1979; Pert
et al. 1979), alpha-adrenergic (Pert et al. 1979), and dopaminergic (Borison et
al. 1979; Taylor et al. 1979) receptor binding. Receptor supersensitivity (beta-
adrenergic or dopaminergic) could be a neurochemical substrate for post-
cocaine dysphoria or craving.
One study (Gawin and Kleber 1983b) also shows some human cocaine abusers
have elevated plasma growth hormone and decreased plasma prolactin,
findings that are consistent with the adrenergic and dopaminergic receptor
changes in animals. Beta-adrenergic supersensitivity has been hypothesized to
be a cause of depressive illness, and beta-adrenergic subsensitivity, which can
be induced by different types of antidepressant treatments may explain
antidepressant effectiveness (Charney et al. 1981; Maggi et al. 1980; Sulser et
al. 1978). Dopaminergic receptor changes following antidepressant treatment
(Koide and Matshushita 1981; Naber et al. 1980) also are in the opposite
direction from those occurring following chronic cocaine use, and could be
even more important, since dopamine may mediate acute cocaine euphoria
(Wise 1980), and craving or dysphoria after chronic cocaine could be based on
adaptations within dopaminergic systems (Gawin and Kleber 1983c).
Additional support comes from studies done on amphetamine. Evidence from
acute experiments in humans (Fischman et al. 1976), observations of the
post-use state (Cassems et al. 198 I; Kosman and Unna 1968; Leith and Barrett
1976; Schildkraut et al. 1971; Watson et al. 1972) as well as animal behavioral
(Colpaert et al. 1979; Leith and Barrett 1976; Leith and Barrett 1981),
electrophysiological (Colpaert et al. 1979; Kokinidis and Zacharko 1980; Leith
and Barrett 1976; Leith and Barrett 1981; Simpson 1974; Simpson and Annau
1977), and neurochemical studies (Post et al. 1976; Schildkraut et al. 1971;
Watson et al. 1972) indicate that generalization to cocaine from amphetamine
data is appropriate. Reports indicate that treatment with TCAs reverses
chronic amphetamine-induced decreases in self-stimulation (Simpson 1974), a
possible model for stimulant craving and its treatment. TCAs also appear to
have effects opposite to those of cocaine on urinary MHPG (Cobbin et al. 1979;
Goodwin et al. 1975: Perry et al. 1981).
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These data lend neurochemical plausibility to the clinical observation that
TCA therapy can be helpful in treating the cocaine abuser (Blum 1976;
Ellinwood 1977; Siegel 1982; Smith and Wesson 1980). However, little
systematic evaluation of TCA treatment of cocaine abusers has been done.
Tennant and Rawson (1983) reported anecdotal data that desipramine
facilitated abstinence in 14 cocaine abusers, but their study was based on a
rationale involving acute desipramine-induced decreases in noradrenalin
reuptake rather than receptor changes, and consequently 11 of their subjects
received desipramine less than 7 days. The other 3 subjects were not described.
Also. several methodologic shortcomings (Gawin and Kleber 1983c) and
limited followup make the meaning of this report unclear. Gawin and Kleber
(1983c) report prolonged desipramine treatment in 6 subjects, systematically
evaluating cocaine use, craving, and psychosocial function. All 6 demonstrated
prolonged abstinence (> 12 weeks). and craving decrease followed a delayed
time course consistent with desipramine’s time course for neuroreceptor
changes and its known clinical characteristics in depression. Unlike Tennant
and Rawson’s (1983) results, half of the patients continued cocaine use
throughout the first week and until the third week of treatment. Two of the
subjects had diagnoses of major depressive disorder, but the remainder did not,
and displayed desipramine-associated craving decreases and abstinence-
facilitating effects despite lack of neurovgetative symptoms and prior
treatment failures. Although the above results are encouraging, the reports
cited were both non-blind and uncontrolled. Further more rigorous studies
with larger sample size are needed before any conclusions arc drawn regarding
desipramine use in cocaine abuse treatment.
Lithium Carbonate
Lithium carbonate treatment has been advocated for stimulant abuse
(Buchsbaum et al. 1977; Flemenbaum 1974; Gold and Byck 1978; Knapp and
Mandell 1975; Mandell and Knapp 1976; Resnick et al. 1977; VanKammen and
Murphy 1975) based on lithium’s antagonism of multiple acute stimulant
effects including euphoria. Lithium blocks behavioral (Berggren et al. 1978;
Cox et al. 1971; Davies et al. 1974; Furukawa et al. 1975; Lal and Sourkes 1972;
Poitou et al. l975), electrophysiologic (Cassems et al. 1973; Colpaert et al.
1979). and neurochemical (Cobbin et al. 1979; Scheel-Kruger et al. 1977;
Simpson and Annau 1977) effects of acute cocaine and amphetamine. Case
studies report blockade of amphetamine euphoria by lithium (Flemenbaum
1974), as does one doubleblind placebo-controlled study of 11 depressed
patients (VanKammen and Murphy 1975). Lithium had more variable results
on amphetamine euphoria in 8 patients with personality disorders (Angrist and
Gershon 1979). In several case studies (Cronson and Flemenbaum 1978; Gold
and Byck 1978; Mandell and Knapp 1976) lithium attenuated cocaine-induced
euphoria. Decreasing cocaine usage during the lithium treatment was also
reported. Lithium did not block i.v. cocaine euphoria in an experiment done on
6 methadone-treated opiate addicts with significant cocaine abuse (Resnick et
al. 1977). In the latter study (not a direct treatment evaluation). lithium
administration was associated with decreases in cocaine abuse. despite lack of
euphoria-attenuating effects. Studies of other stimulants (Huey et al. 1981;
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Jarbe 1978; Wald et al. 1978) report similar results. In both studies of
stimulants reporting no lithium blockade (Resnick et al. 1977; Wald et al. 1978)
the agents were administered intravenously in relatively large boluses. Studies
using other routes of administration do report blockade. Lithium effects may
thus be competitively antagonized by large abrupt increases in stimulant blood
levels. Since much street cocaine use is intranasal, the practical impact of this
possibility on treatment is unclear and merits examination.
Overall, neurochemical evidence clearly indicates lithium has multiple acute
effects which counteract those of cocaine. Clinical evidence further indicates
that such properties may be useful in the treatment of stimulant abusers;
however placebo-controlled studies do not exist. In the study by Gawin and
Kleber (1983c) cited in the discussion of diagnosis, the responding cyclothymic
subjects did not use cocaine to test euphoria-blocking effects, but the
nonresponding patients reported cocaine euphoria was unchanged in intensity.
Some suggestion of decreased duration of euphoria was noted, but this did not
appear to be therapeutically useful.
Although the theoretical focus in lithium treatment of cocaine abuse has been
on blockade, another potential mechanism of action exists. Lithium is reported
to modulate fluctuations in functional receptor activity (Bunney and Garland
1983). Lithium’s effectiveness in bipolar patients could be due to damping of
abnormal oscillations of select neuroreceptor populations (Bunney et al. 1977).
Lithium might reverse cocaine-induced neurophysiologic changes in a manner
similar to that postulated for desipramine. Further, if cocaine causes receptor
changes, bipolar or cyclothymic patients might be more sensitive to both such
cocaine effects and to opposite lithium effects. This could explain any
diagnostic specificity found in lithium treatment of cocaine abuse. In all,
lithium’s efficacy, diagnostic specificity, and possible mechanisms of action in
cocaine abuse treatment all require further study.
Methylphenidate (MPH)
There is experimental evidence logically supporting possible clinical usefulness
of MPH as a general treatment for severe cocaine abuse. Stimulant “high” in
humans appears to be related to both plasma stimulant level prior to an
additive increment and to the characteristics of plasma level changes, rather
than to simple absolute plasma level (Van Dyke et al. 1982; Zahler et al. 1982).
Increases of plasma stimulant level in subjects with preexistent stimulant
concentrations may correspond to less euphoric effect than identical increases
in plasma level in subjects with a stimulant-free baseline. Similarly, increases
occurring slowly may correspond to less subjective euphoria than increases
occurring more rapidly. Self-administration data in animals also support this
phenomenon (Balster and Schuster 1973; Brady and Griffiths 1977) which has
been called “acute tolerance.”
Since methylphenidate produces euphoria indistinguishable from amph-
etamine (Brown et al. 1978) and, presumably, cocaine, MPH could produce
consistent tolerance-sustaining effects. Through such an acute “cross tolerance,”
a given dose of cocaine might be less euphorigenic and have less abuse liability.
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This is similar to high dose methadone maintenance causing Longer term
tolerance to opiates, thereby reducing heroin euphoria and abuse. Unlike
methadone, however, MPH tolerance would end sooner, requiring more
frequent administration, due to its shorter half life.
Although MPH is an abusable euphorigen, it has advantages parallel to
methadone administration. The advantages of medical dispensation include
controlled dosage, decreased legal risk, economic stabilization, and a breaking
of “street” associations and secondary abuse reinforcers. In preliminary use,
cocaine abusers considered MPH far less desirable than cocaine, decreasing
compliance. Attenuated cocaine effects and decreased abuse were reported
when compliance occurred (Gawin and Kleber 1983d) in three pilot non-ADD
patients treated by the authors; but abstinence from cocaine was not sustained,
and it is unclear whether methylphenidate has practical utility as a general
treatment. In all, methylphenidate may be similar to lithium, with treatment
response in the few reports available occurring only in one diagnostic subgroup
(ADD-residual type) and not in other cocaine abusers.
The potential pharmacotherapies described simply represent the treatment
rationales available given the state of current theory and research. Much is
unknown, and other possibilities also exist.
Conclusions
Single focus approaches are generally ineffective in drug abuse treatment. A
number of approaches to cocaine abuse are in current use and a number of
issues require resolution. Preliminary data on pharmacologic treatments are
beginning to appear and pharmacologic adjuncts may show promise in the
future. However, it currently appears no more likely that any unimodal
approach to cocaine abuse treatment will arise than it has for opiate abusers.
Integration of various approaches based on the needs of the patients seems
indicated instead. A possible schema illustrating this and utilizing the
impressions and preliminary studies reviewed here is presented in figure I.
Before any such schema is used in clinical practice, however, detailed
comprehensive research will be needed.
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FIGURE 1
Possible Future Guidelines for Cocaine Abuse Treatment
Cocaine Abuse Psychotherapeutic Pharmacotherapeutic
Seveity Approach Approach
Mild Behavioral with or None
without Psychodynamic
Moderate Supportive and Only if psychiatric
Psychodynamic with or diagnosis is present.
without Behavioral Choice of agent based on
sysptoms. If no treatble
diagnosis exists, general
treatment (desipramine)
may be usefully tried in
difficult cases.
Severe Supportive, with or General treatment
without hospitalization (desipramine) indicated
for acute phase; then as unless diagnosis dictates
in "moderate" another treatment choice
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